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ABSTRACT 
 
SANDRA McCOY: HIV Testing and Linkage to Care in North Carolina:  
Early Diagnosis, Late Diagnosis, and Delayed Presentation to Care  
(Under the direction of William C. Miller) 
 
 
Persons with unrecognized HIV infection forgo timely clinical intervention and may 
unknowingly transmit HIV to partners. In North Carolina (NC), unrecognized infection and 
late diagnosis are common. To understand more about the individual and structural factors 
associated with HIV diagnosis and presentation to care, this dissertation examined three 
sources of data from HIV-positive patients in NC. We analyzed data from 75 patients with 
acute HIV infection identified through the Screening and Tracing Active Transmission 
(STAT) program to understand more about motivations for testing during early infection. We 
found that nearly one-third of patients had a sexually transmitted co-infection at the time of 
HIV diagnosis. The prevalence of co-infection was highest in women compared to 
heterosexual men (PR=0.67, 95% CI 0.31, 1.45) and men who have sex with men 
(PR=0.34, 95% CI 0.15, 0.76). To understand the effect of perceived social support on late 
presentation to medical care, we examined data from the University of North Carolina 
Infectious Disease Clinic Clinical and Socio-Demographic Survey. We analyzed data from 
216 HIV positive patients and quantified the four functional domains of social support with a 
modified Medical Outcomes Study Social Support Scale. We found the median delay 
between diagnosis and entry to primary care was 5.9 months. Only positive social 
interaction support was associated with delayed presentation in adjusted models. The effect 
of low perceived positive social interaction on delayed presentation differed by history of a 
drinking problem (history of alcoholism HR=0.71, 95% confidence interval (CI): 0.40, 1.28;
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no alcoholism HR=1.43, 95% CI: 0.88, 2.34). Finally, we conducted a qualitative interview 
study of 24 HIV positive patients entering care at the UNC ID clinic with moderate to 
advanced immunosuppression to describe attitudes and beliefs about HIV testing and care. 
The primary barrier to HIV testing prior to diagnosis was perception of risk; consequently, 
most participants were diagnosed after the onset of clinical symptoms. While patients were 
anxious to initiate care rapidly after diagnosis, some felt frustrated by the passive process of 
connecting to specialty care. The first visit with an HIV care provider was identified as critical 
in the coping process.  
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For the people living with HIV who courageously agreed to share their stories with me. 
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 CHAPTER ONE: SPECIFIC AIMS 
 
 
Highly active antiretroviral therapy has been the cornerstone of HIV care in the 
United States since its widespread adoption in the late 1990’s. However, its benefit is best 
realized in conjunction with timely access to medical care. Early presentation for medical 
care among HIV infected persons can improve the length and quality of life by providing 
access to antiretroviral drugs and prophylactic treatment for opportunistic infections.1 
Further, HIV testing and counseling and knowledge of one’s serostatus has been shown to 
reduce high-risk behavior, thereby reducing transmission to others.2, 3 Early entry into care 
can also optimize personal and healthcare system planning.4, 5 Despite these benefits, many 
adults enter care late in the course of HIV infection, countering the benefits of timely access 
to HIV services and missing opportunities for risk reduction.6-8 Consequently, linking HIV 
positive persons to high-quality care and prevention services has been identified as a 
priority of the U.S. Centers for Disease Control and Prevention (CDC).9  
The process of an HIV-infected individual presenting to primary care can be divided 
into two meaningful time periods: 1) the time between acquisition of infection and testing; 
and 2) the time between testing and presentation to care. The time between HIV acquisition 
and testing is a function of risk perception, access to testing services and testing history, 
demographic factors, health insurance, education, and prison status.6, 7, 10-16 However, some 
individuals are diagnosed with HIV in the first few weeks of infection, known as the acute 
phase, and their reasons for testing are less well understood. For some, co-infection with 
sexually transmitted infections (STI) may prompt HIV testing during the acute phase.
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Although the synergistic relationship between HIV and STIs with respect to transmission and 
acquisition is well-described, the possible impact of concurrent STIs on HIV testing warrants 
greater attention.17, 18 
Factors affecting the time period between HIV diagnosis and presentation to care are 
less well characterized. Demographics, health insurance status, injection drug use, and 
testing and counseling history are associated with delayed presentation, but the role of 
psychosocial factors, such as perceived social support, on care-seeking behavior has not 
been rigorously evaluated.11, 14, 19, 20 Social support consists of factors such as belonging to a 
social network, perceived satisfaction with support, emotional support, information, and 
tangible assistance.21 Social support improves coping with HIV, quality of life, and has been 
demonstrated to improve adherence among patients on highly active antiretroviral therapy 
(HAART).22-26 Given the positive role of social support on adherence, it is feasible that HIV 
positive individuals with higher levels of perceived social support may seek medical care 
earlier than those with less perceived social support.  
In this dissertation, we examined the structural and individual factors that influence 
HIV testing and care-seeking behavior in North Carolina. We undertook a multidimensional 
approach, relying on data from diverse sources and utilizing different methods of data 
collection. We relied on acute HIV surveillance data, psychosocial factors from clinic 
interviews, and in-depth qualitative data. This multifaceted approach provides new 
knowledge about HIV testing and care-seeking that is directly applicable to North Carolina. 
  
Specific Aim 1. a. Describe the prevalence and types of sexually transmitted 
infections (STI) among individuals acutely infected with HIV at the time of testing in 
North Carolina. 
Hypothesis: STIs are common among individuals with acute HIV. 
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b. Evaluate variation in the time from HIV acquisition to testing among individuals 
with acute HIV infection by the presence of STI at the time of HIV testing and testing 
site type. 
Hypotheses:  
1.  Persons diagnosed with acute HIV and a concurrent STI will be diagnosed earlier 
than those without a concurrent STI.  
2.  Persons diagnosed with acute HIV at STD testing sites will be diagnosed earlier than 
those diagnosed at non-STD testing site types. 
 
c. Determine differences in median serum viral load (copies/ml) by the presence of 
STIs at the time of HIV testing and testing site type. 
Hypothesis: Among persons with acute HIV infection, the HIV viral load will be higher in 
persons with an STI than in persons without an STI. 
 
Overview: We utilized information on patients with acute HIV infection identified through the 
North Carolina Screening and Tracing Active Transmission (STAT) Program to determine 
the prevalence of STI co-infection and factors associated with co-infection. We determined 
the effect of STI co-infection and testing site type on the time between HIV acquisition and 
HIV testing. We also evaluated differences in baseline serum HIV RNA, and examined 
factors associated with testing before and after peak HIV viremia.  
 
Specific Aim 2.  Describe the effect of perceived social support on late presentation to 
medical care among HIV positive persons receiving care at the UNC Infectious 
Disease (ID) Clinic. 
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 Hypothesis: The presence of a strong social support system will reduce the time between 
testing HIV positive and initial presentation to HIV care. 
 
Overview: Using the Clinical and Socio-Demographic Survey from the Center for AIDS 
Research Clinical Core at UNC, we examined the effect of social support on the time from 
the first positive HIV test to the initial presentation for primary medical care. We conducted a 
validation substudy to examine the reliability of self-reported first positive HIV test by 
comparing to state HIV/AIDS morbidity records. Social support was quantified with the 
modified Medical Outcomes Study (MOS) Social Support Survey Scale and entered into a 
Cox proportional hazards model.27 
 
Specific Aim 3.  Describe attitudes and beliefs about HIV testing and care among HIV 
infected persons attending the UNC ID clinic who presented with clinically advanced 
illness. 
Overview: We conducted semi-structured qualitative interviews of HIV-infected persons who 
presented to care with moderate to advanced immunosuppression, defined as an indication 
for HAART therapy (CD4+ T-lymphocyte cell count <350 cells/mm3 28). Data collection was 
guided by the achievement of theme saturation and consisted of 24 interviews. The 
conceptual framework and interview instrument was developed with constructs from the 
Health Belief Model (HBM) and the Information-Motivation-Behavioral skills (IMB) model.29, 30  
 CHAPTER TWO: BACKGROUND AND SIGNIFICANCE 
 
 
Epidemiology of HIV/AIDS in the Southern United States 
The southern region of the U.S. includes 16 states and the District of Columbia and 
represented 36% of the U.S. population in 2005.31, 32 By the end of 2005, 40% of the 
425,910 persons living with AIDS in the U.S. resided in the southern U.S., and from 2001 to 
2005, the number of deaths from AIDS increased in the region, while other regions of the 
U.S. experienced declines.33 An analysis of AIDS case reports since 1981 found that being a 
southern state was independently associated with a 4.3% higher AIDS growth rate 
compared to other states.34  
The reasons for the HIV/AIDS burden in the U.S. South are multidimensional and 
complex. The South performs poorly on a variety of health indicators including death rate 
(the states with the 11 highest death rates are located in the South), diabetes rate, heart 
disease, and stroke.35 The South also has high rates of the uninsured, which increased from 
18.2 percent in 2004 to 18.6 percent in 2005.36 The South has the highest proportion of 
people living below the poverty line – 14%, compared to 11% in the Northeast and Midwest 
and 13% in the West.36 In addition, the high proportion of the population living in rural areas 
may undermine an already weak health infrastructure by adding additional obstacles to HIV 
care such as transportation issues and lack of specialty health care providers.31  
There are other important factors that influence the HIV/AIDS epidemic in the South. 
The demographic makeup includes a large proportion of the U.S. African American 
population, a group that is disproportionately affected by the epidemic. High rates of
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sexually transmitted diseases play a role by increasing the likelihood of HIV acquisition, 
transmission, or both.37 Social factors also play a role facilitating the spread of HIV in the 
South. Incarceration, stigma, trust in providers, marriage rates, and non-injecting drug use 
have been shown to be associated with the epidemic.37, 38 Further, examination of sexual 
network patterns has suggested that levels of disassortative mixing and concurrent 
relationships may be higher in the South.39 
Thus, these factors demonstrate the need to improve our understanding of the 
epidemiology of the HIV/AIDS epidemic in the South with the goal to reduce new infections 
and ensure high-quality care for persons living with HIV/AIDS. 
 
Unrecognized HIV Infection 
HIV counseling and testing has been the predominant HIV prevention paradigm since the 
1980s. Each year, approximately 16 to 22 million people are tested for HIV, a number that 
has remained the same for the past decade.40 This translates to roughly 38% of the 
population having ever had an HIV test in their lifetime. However, there is room for 
substantial improvement: it is estimated that approximately 25% of all adults living with 
HIV/AIDS in the U.S. do not know their status.8, 40  
Unrecognized HIV infection has important public health consequences. In addition to 
limiting the benefits of early medical care including antiretroviral therapy and prophylaxis for 
opportunistic infections, persons with unrecognized infection may unknowingly transmit HIV 
to partners.41, 42 The prevalence of unrecognized infection varies by group. A national study 
of young men who have sex with men (MSM) found that 77% of those with HIV infection 
were unaware of their infection, ranging from 91% of black MSM to 60% of white MSM.43 
Most with unrecognized infection perceived themselves to be at low risk for being infected. 
An inner city emergency department found 29% of all HIV infections to be unrecognized and 
among STD clinics, approximately 40% of infections were unrecognized.44, 45 These results 
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underscore the barrier that unrecognized infection, and consequently, late diagnosis, poses 
to HIV prevention and care efforts. 
HIV testing recommendations in the past have focused on targeted testing to high-
risk groups or areas of high HIV prevalence.46, 47 However, as the HIV/AIDS epidemic in the 
United States evolved to include greater numbers of women, minorities, and heterosexuals, 
persons <20 years, and those who reside outside of major metropolitan areas, targeted 
testing became less effective.48, 49 Several studies demonstrated these gaps in HIV 
prevention efforts. An anonymous HIV serosurvey of 52,260 patients found that those who 
were not voluntarily tested were more likely to be HIV infected than those who were tested, 
regardless of demographic characteristics, risk group, or STD diagnoses.45 Similarly, among 
young MSM, 72% of those with unrecognized HIV infection had a regular source of health 
care, suggesting missed opportunities for diagnosis.43 Of those with HIV infection in a large 
health care plan, 21% denied having risk factors in the five years prior to diagnosis.50 Some 
argued that time restraints precluded incorporation of the traditional HIV counseling and 
testing model into routine medical care, resulting in missed opportunities to identify those 
with unrecognized infection.51  
In response to the changing epidemiology of HIV in the United States, the Centers 
for Disease Control and Prevention (CDC) launched the Advancing HIV Prevention Initiative 
in 2003. The Initiative promoted the adoption of simpler testing procedures without pretest 
counseling and the expansion of testing recommendations to include those with risk factors 
in low prevalence clinical settings.52 The Initiative was followed in 2006 by revised testing 
recommendations for the adoption of routine, voluntary HIV screening for patients in all 
health care settings.49 An explicit goal of the new screening guidelines is to foster earlier 
detection of HIV infection and identify those with unrecognized infection. It is expected that 
the incorporation of HIV testing into routine medical care will increase the numbers of people 
tested, de-stigmatize the testing process, and improve access to HIV care after diagnosis.49 
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The availability of over the counter home based HIV testing kits may remove some 
barriers to HIV testing. Since 1996, home-based specimen collection kits have been 
available (Home Access HIV-1 Test System) but users are required to call a toll-free number 
for results after mailing in dried blood spots. In 2005, the FDA began hearings for the first 
home HIV testing system (OraQuick ADVANCE 1/2).53, 54 It is unclear if a completely 
anonymous home based HIV test can increase the number of HIV positive U.S. residents 
who are aware of their serostatus. Home testers must be able to afford the test (currently US 
$44) and are likely to be the “worried well,” new couples confirming HIV status, people 
seeking confirmation of positive tests received elsewhere, and persons with recent high-risk 
exposures who may be in the window period before antibody detection is possible.53 In the 
latter case, false negative results during acute infection may lead to increased transmission 
during one of the most infectious periods of HIV infection. In addition, monitoring outcomes 
such as linkage to care will be impossible, and false positive results may cause unnecessary 
distress.53, 55 However, home based tests offer convenience, privacy, and the timely receipt 
of results.56 While the value of increasing access to HIV testing is unquestioned, the ability 
of home tests to affect the U.S. HIV epidemic in a meaningful way will be determined in the 
coming years. 
 
Delays in Presentation for Medical Care 
From a clinical perspective, timely access to HIV care can improve the length and quality of 
life by providing access to antiretroviral drugs and prophylactic treatment for opportunistic 
infections. Current treatment guidelines recommend the initiation of highly active 
antiretroviral therapy (HAART) once the CD4+ T-lymphocyte cell count falls below 350 
cells/mm3.28 The CD4 count is an important prognostic marker and is strongly associated 
with survival.57 The survival benefit of HAART declines as the baseline CD4+ cell count at 
the initiation of therapy falls below the treatment threshold of 350 cells/mm3 – individuals 
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initiating therapy <200 cells/mm3 have at least a three times greater risk of death than those 
whose levels were above 200 cells/mm3.1 Individuals who delay seeking medical care, 
knowingly or unknowingly, forgo these benefits. 
In addition to the clinical benefits of early HIV care, HIV testing and counseling and 
knowledge of one’s serostatus has been shown to reduce high-risk behavior, thereby 
reducing transmission to others.2, 3, 58, 59 A meta-analysis of 11 studies from 1998-2003 in the 
U.S. found that the prevalence of unprotected anal or vaginal intercourse was an average of 
53% lower in the population aware of their HIV positive status compared to those who were 
HIV positive but unaware of their status.41 Similarly, the transmission rate (number of new 
infections per year divided by the number of persons living with HIV/AIDS in a year) among 
those unaware of their HIV infection is more than six times greater than those aware of their 
status (10.8% vs. 1.7%, respectively).60 In additional to the potential for behavior change, 
the reduction in plasma viral load achieved by antiretroviral therapy may decrease the 
transmission probability to partners.61 Taken together, these studies suggest that prevention 
counseling and medical care among newly diagnosed individuals can reduce, but not 
eliminate, transmission to at-risk partners.  
Despite these benefits, late entry to care is common among HIV infected adults. In 
the United States, 40% of those tested in 2004 were diagnosed with AIDS less than one 
year after the initial HIV diagnosis, a figure that has remained relatively stable since 1994.33, 
62 Further, Samet et al. estimated that the median delay from HIV acquisition to medical 
presentation in two clinics in Massachusetts and Rhode Island was eight years. The 
situation in the South is more concerning. In North Carolina, Gay et al. found that in the 
University of North Carolina HIV outpatient clinic, 75% of patients had an indication for 
antiretroviral therapy at their first clinic visit, and 50% had a CD4+ T-cell count less than 200 
cells/mm3.12 In Birmingham, Alabama, 41% of patients presenting to an HIV/AIDS outpatient 
clinic had progressed to CDC-defined AIDS.63 These findings and the knowledge of the 
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unique HIV epidemic in the South raise special concerns about access to testing and 
medical services in the region.64 
The process of an HIV-infected individual presenting to primary care can be divided 
into two meaningful time periods: 1) the time between acquisition of infection and testing; 
and 2) the time between testing and presentation to care (Figure 2.1).7 The summation of 
the time between HIV acquisition and testing (period T3 in the Figure) and the time period 
between HIV diagnosis and presentation to care (T4) comprise the overall delay between 
acquisition and presentation to medical care (T5).  
Methodologically, considering the two time periods (T3 and T4) as distinct outcomes 
with separate, but overlapping “etiologies” is necessary to prevent mixing the effects of 
“delayed testing” with “delayed care.” Studies that consider only the outcome at the time of 
entry to care, such as “presentation with an AIDS defining illness”, treat barriers to testing 
the same as barriers to seeking care. The validity of this assumption has not been resolved. 
For example, a study in a southern HIV/AIDS clinic found that presentation within six months 
of diagnosis and presentation more than five years after diagnosis were associated with 
AIDS at the initial clinic visit among whites – this finding suggests that some people test 
early and then delay care, and that some people test late and only present to care once they 
experience clinical symptoms.63 Studying these two time points as methodologically distinct 
is therefore necessary to understand the process of awareness, testing, and entering care. 
Because the date of HIV acquisition is typically unknown, most efforts to improve 
patient outcomes after diagnosis have focused on promoting testing programs, increasing 
the numbers of “early testers”. Although HIV testing and counseling is the cornerstone of 
HIV prevention efforts, focusing on testing behavior alone will not universally improve 
access to quality HIV care and positive health outcomes. The time period between 
acquisition and testing may account for the majority of the medical care delay on a 
population level, but some individuals delay care even after testing positive. A 
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comprehensive understanding of both the barriers to testing and seeking care is necessary 
to optimize health outcomes for newly diagnosed HIV positive individuals. 
 
Delayed presentation to care due to late diagnosis. Many people do not present to medical 
care until they are symptomatic or have an AIDS-defining illness, and only then do they find 
out they are HIV positive. Other people test positive before the development of symptoms 
but many years after they acquired the infection. This phenomenon, known as delayed 
testing, is common in the United States. In the Birmingham clinic, 54% of those who 
presented for initial care with CDC-defined AIDS had been diagnosed in the year preceding 
their entry to care.63 Similarly, a study of 7,200 HIV infected persons found that 42% sought 
testing because of illness.52 Delayed testers miss out of the benefits of early medical care 
and may unknowingly transmit the infection to others.  
Factors associated with less HIV testing include age, being non-White, having less 
education, living in a non-metropolitan area or the Midwest, using recreational drugs, and 
being exposed to HIV through heterosexual contact.62, 65, 66 Experiencing symptoms is an 
important determinant of testing behavior - most people who delay testing (65%) eventually 
receive HIV testing because of illness.62 In addition, accurately perceiving HIV risk can act 
as a facilitator or barrier to HIV testing – either by increasing awareness and thus the 
likelihood of testing or by increasing fear of testing positive.65-67 For example, in New 
England, only 66% of HIV positive participants were aware of their HIV risk before testing, 
and of those unaware of their risk, 42% were eventually tested by either a physician 
recommendation or hospitalization.7 Structural level factors are also related to testing such 
as contact with the health care system and incarceration.68 
Delayed testing poses a significant barrier to HIV prevention efforts, and many are 
hopeful that the new CDC testing guidelines will have an impact on reducing the numbers of 
individuals who first test positive late in the course of disease. 
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Delayed presentation to care due to delay after diagnosis. Less common than late testing is 
the phenomenon of delaying the initiation of medical care after testing positive. Median 
delays from HIV diagnosis to presentation for care range from 30 days to over a year.14, 19, 20, 
63, 69 A study of HIV-infected women in New York City found that roughly one quarter delayed 
more than six months after diagnosis to see a physician.70 Delayed initiation of care may 
become more of a problem as new HIV testing guidelines recommending routine HIV 
screening in all health care settings take effect.49 Screening for HIV without successful 
linkage into HIV care undermines the positive benefit of the screening program, as the 
maximum advantage of HAART and prophylaxis for opportunistic infections is realized when 
the patient enters care early in the course of disease.49 Even recently infected patients for 
whom treatment is not recommended can benefit from risk-reduction counseling, social 
services, and case management.  
Race is often found to be associated with delay seeking medical care after HIV 
diagnosis. African Americans and Hispanics tend to delay longer or in greater numbers than 
Whites,14, 20, 70 although no effect of race was found in 2 studies.19, 71 One study found that 
Hispanics enrolled into care earlier than Whites, with no difference between Whites and 
African Americans observed.72 In addition to race, sex is also associated with delayed care. 
Men have been found to delay care longer than women after diagnosis in some studies,14, 20, 
72 but not all.20, 71 Intravenous drug use has been associated with delay after diagnosis in 
most but not all studies.14, 19, 20, 71, 72 
The data on insurance status and delayed medical care after diagnosis are mixed. 
Having any insurance has been shown to decrease the likelihood of delay in some 
studies.14, 71 However, health insurance at the time of diagnosis was not found to have an 
effect on care delay in a study of 2 urban hospitals in New England as well as among clients 
to California’s Early Intervention Program.19, 72 Turner et al. found that that Medicaid was 
associated with shorter delays after diagnosis.20 In contrast, a study of HIV positive patients 
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from STD clinics nationwide found that none of the patients who had delayed care for at 
least six months cited lack of money as a primary reason for not making a clinic visit.59 
The site of the HIV test or the counseling, notification, or referral method may be 
associated with delays. Turner et al. found that delays were equally as common among 
private testing sites, clinics, anonymous testing sites, and hospitals, but testing at “other” 
testing sites improved linkage to care.20 The authors postulate the “other” sites may be 
research studies or other programs. Samet et al. reported that not being notified of HIV 
status in person (e.g. mail or telephone) was associated with a 2.5 years longer delay before 
entering care.19 Longer delays have been reported for individuals referred from prison, 
another HIV/AIDS organization, or from family or friends.14, 72 Additional factors, such as 
competing care giving responsibilities, HIV risk awareness at testing, and having a usual 
source of care may also be important issues.19, 20, 72, 73 A qualitative study of women found 
that the main barriers to seeking care were psychological and not socioeconomic, and that 
the trauma of discovering one’s HIV status often led to a state of denial about their status or 
the seriousness of their disease.69 
There is little information about the effect of social support on delays seeking medical 
care, and the inconsistency of measurement precludes any definitive conclusions. Samet et 
al. found that not having a living mother and not having a spouse or partner was associated 
with delay after diagnosis.19 In the California study, family size of 2 or more was associated 
with shorter delays (124 vs. 142 days, respectively), although this finding was not confirmed 
in the multivariable analysis.72 In an urban hospital, perceived support was not correlated 
with the time since diagnosis, although the time since diagnosis was self-reported and the 
sample size was only 114 patients.74 More research is needed to understand the role that 
support from others may play in the decision making-process to seek HIV care. 
Although these findings provide important preliminary insight into individuals who 
delay medical care, many other factors that may be associated with delay have not been 
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examined. For example, mistrust of the medical establishment, religion/spirituality, financial 
resources, and transportation may be important influences. To date, only a handful of 
studies have been explicitly designed to improve our understanding of delayed medical care 
by interviewing patients for the reasons they delay medical care in their own words. What 
can be concluded is that HIV testing services perform a critical public health function by 
linking newly diagnosed patients into care, and the success of this linking function requires 
rigorous evaluation to determine if improvement is needed. 
 
Theoretical Considerations about Access to HIV Care  
We can anticipate that antiretroviral drugs will continue to improve and the life expectancy of 
those diagnosed with HIV will extend past 24 years in the future.75 Despite these advances, 
we still do not have an adequate understanding of the process of testing positive and 
seeking medical care from the patient’s perspective. Unfortunately, most of the HIV/AIDS 
research in this area has focused on describing characteristics of individuals who present 
late in the disease course from ubiquitous patient databases – limiting the findings to basic 
demographics correlated with delayed care. Causal inference requires more in-depth 
information from that which can be found in medical records, highlighting the need for 
focused, in-depth studies on the linkage process from testing site to health care provider. In 
addition, looking to research on other chronic diseases and theories of access to medical 
care may provide valuable insight as HIV/AIDS is increasingly considered a chronic medical 
condition. 
An ecological perspective of HIV care suggests that we consider individual 
characteristics and contextual factors such as the availability of services and the policy 
environment in which individuals seek medical care. Aday and Andersen published a 
framework for the study of access to medical care in 1974 which illustrates the multiple 
levels of influence on access to care (Figure 2.2).76 Characteristics of the health care 
 15 
 
  
delivery system include the volume and distribution of resources as well as the structural 
organization and method of entry. Characteristics of the population at risk include 
predisposing characteristics which influence utilization of services (e.g. demographics, 
beliefs, attitudes, and values), enabling factors which relate to the means of an individual to 
seek care, and the need component, which refers to illness level.76 The utilization of health 
services and consumer satisfaction constructs reflect the outcomes of movement through 
the health care system.  
In the context of HIV testing and care, most research on delayed testing and entry to 
care has focused on identifying characteristics of the population at risk, with a tendency to 
identify immutable factors that are associated with delay (e.g., age, race, sex). There are 
other unknown descriptors of the population at risk, such as barriers to care, views about 
personal susceptibility and severity of the disease, and beliefs about the benefits of medical 
care that have yet to be described. At the next level of the framework, evaluation of the 
impact of health insurance and socioeconomic status begins to address structural factors 
that influence care seeking (“Characteristics of the Health Care Delivery System,” Figure 
2.2). However, there remains much to be evaluated in terms of the availability of services, 
the ease at which persons utilize the services, the barriers to utilizing services, and the 
personal belief systems which influence the decision-making process. We do not have a 
comprehensive understanding of the barriers and facilitators to seeking HIV testing and 
medical care, and improving our knowledge can only help to improve the delivery of 
HIV/AIDS health care services in the U.S. 
The breast cancer model of care can be viewed as similar to that of HIV/AIDS – 
women are screened for abnormalities and referred to specialty care when necessary. 
Women who delay screening or medical care frequently present to care in the advanced 
stage of disease. Lannin et al. examined factors associated with a late tumor stage at the 
initial breast cancer diagnosis in eastern North Carolina.77 Factors associated with advanced 
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disease stage at presentation included being African American, low income, lacking private 
health insurance, and never having been married. In addition to these findings, they 
examined the role of culturally derived folk beliefs, religious beliefs, and fatalism on delayed 
medical care. 
Formative research from qualitative interviews with women in the same study 
highlighted the importance of understanding the cultural belief system with which patients 
understand their disease and negotiate the health care system.78 Almost all of the women 
believed at some point during their diagnosis period that their lumps were a result of “bad 
blood” and impurities in the body which were best left alone if they were asymptomatic. 
Many women thought that surgery and other medical care would exacerbate the problem. 
Medical decisions were made cautiously, juxtaposing an indigenous model of disease with 
the biomedical model of their caregivers.78  
As a result of measuring folk beliefs in their study, the effect of race on presentation 
with advanced stage disease diminished from OR=3.0 to 1.2 when socioeconomics and 
cultural beliefs were added to the model.77 These findings illustrate that although many of 
the demographic factors associated with delayed diagnosis or delayed medical care are 
similar for breast cancer and HIV/AIDS, a deeper understanding of the attitudes, beliefs, and 
knowledge are necessary to accurately interpret the findings.  
 
Health Behavior Models. One relevant model to consider is the Health Belief Model (HBM). 
The HBM was developed in the early 1950’s to explore the reasons that many people did 
not participate in programs by the U.S. Public Health Service to prevent and detect disease. 
The model consists of five main dimensions which explain preventative health behavior 
(Table 2.1).29 Perceived susceptibility refers to beliefs that a person is susceptible to a 
condition. Perceived severity refers to beliefs that the condition has serious consequences. 
Perceived benefits and barriers refer to the costs and benefits of taking action for a 
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particular condition.  Cues to action are factors that stimulate a person to action, such as 
health promotional materials or television advertisements.79 The Health Belief Model has 
been used in previous HIV research examining the barriers to condom use, medication 
adherence, and predictors of HIV testing.80-82 
Table 2.1 also presents the potential HIV care factors that relate to each construct in 
the HBM. For example, perceived susceptibility is related to awareness of HIV risk and how 
this influences HIV testing – awareness of risk is generally a precursor to seeking HIV 
testing. Further, belief in a folk model of disease may influence if a person who has tested 
HIV positive believes that he/she is at risk for symptoms or complications as the disease 
progresses. The HBM is a useful theoretical model which extends beyond simply assessing 
individual barriers to seeking care by understanding additional societal, contextual, and 
cultural factors which influence the utilization of health care services. 
A second model relevant to this work is the Information-Motivation-Behavioral Skills 
(IMB) Model.30 This model was developed to facilitate the development of interventions to 
reduce HIV/AIDS risk behavior. The model postulates three determinants of risk reduction: 
1) basic information about HIV transmission and prevention, 2) motivation to act on one’s 
knowledge about HIV transmission and prevention, and 3) behavioral skills for performing 
specific HIV preventative acts.30 The model is novel in that information and motivation are 
independent, such that highly knowledgeable individuals may not be motivated to change 
their HIV risk behavior, and highly motivated individuals may not be necessarily well 
informed about HIV transmission and prevention. The IMB model is directly applicable to the 
decision to be tested for HIV as well as health seeking behavior after an HIV diagnosis.  
In summary, the availability of thoughtful theoretical models and related work in other 
fields warrants increased attention to the issue of delayed medical care, with a goal to 
elucidate meaningful factors beyond demographics that are associated with delayed care. 
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Acute HIV and Sexually Transmitted Infections (STI) 
Acute HIV-1 infection is the interval in the HIV disease course when the virus can be 
detected in the blood serum and plasma before the body has created antibodies against the 
virus. During the acute phase the virus rapidly and widely disseminates to cellular reservoirs 
throughout the body, typically lasting approximately 4-6 weeks after the initial exposure to 
the HIV virus.83 During this period, infected persons experience a dramatic increase in 
plasma viral load and viral shedding from the genital tract.84, 85 Over time, the body’s virus-
specific immune responses are mounted, resulting in reduction of plasma viral load and 
shedding, and the beginning of the long clinical latency period.86 
The period of acute HIV infection has been identified as a key intervention period to 
interrupt transmission.87-89 Because viral load is a predictor of the probability of sexual 
transmission of HIV, the peak viremia characteristic of the acute phase dramatically 
increases the likelihood of sexual transmission during this period.61 The average probability 
of male to female transmission of HIV-1 in a single unprotected coital act has been 
estimated to be between 1 in 2000 to 1 in 328 coital acts during established (non-acute) HIV 
infection.85, 90, 91 However, during acute infection, the probability of transmission has been 
estimated to be approximately 1 in 200 coital acts.84, 85 Population modeling has indicated 
that this short state of hyper-infectiousness may disproportionately contribute to the 
propagation of the epidemic.92-94 
Understanding the testing behavior of those with acute HIV is important as this is the 
earliest possible time point for clinical and public health benefit. Individuals who are treated 
with antiretroviral medications (ARV) during acute infection may experience clinical benefit. 
Individuals who begin ARV therapy during acute infection appear to have a lower viral set 
point, which is correlated with survival. They may also have a lesser degree of viral 
diversification, which could make these individuals less susceptible to developing resistance 
to antiretroviral drugs.83, 95, 96 Further, early treatment may reduce the levels of latently HIV-
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infected CD4+ T-lymphocytes and preserve host HIV-specific immune function.97-100 
Regardless of the outcome of the current debate on when best to start treatment, individuals 
with acute HIV can benefit from the case management and social support services of routine 
medical care.  
In addition to the potential for individual clinical benefits of early diagnosis and 
treatment, the public health implications of acute HIV are tremendous.  In addition to the 
ability to generate accurate incidence rates of HIV infection, acute HIV detection offers new 
insights into the real-time dynamics of an epidemic. Detection of acute infections can be 
used to identify outbreaks of disease or sexual networks at high risk.101, 102 Further, the 
identification of geographic regions of high HIV transmission can allow for more effective 
targeting of limited public health resources to the areas of highest risk. Detection of acutely 
infected persons also provides the opportunity for more effective partner notification, 
counseling, and testing services.89, 103 North Carolina has established itself as a leader in 
detecting acute HIV via a novel pooling strategy utilized at all publicly funded testing sites.103 
 
Detection of Acute HIV Infection. Although the detection of HIV during the acute phase could 
be viewed as a chance occurrence, there are some factors that might influence testing 
during this brief but critical time period. Roughly half of all people with acute HIV will develop 
symptoms of acute retroviral syndrome, a nonspecific flu-like illness including fever, rash, 
fatigue, nausea and vomiting, and night sweats.103-105 The symptoms may be severe enough 
to prompt medical care, and often astute physicians will consider HIV testing. Anecdotal 
evidence in North Carolina suggests that health promotion materials about acute HIV 
infection have led to several individuals with acute HIV infection requesting acute (RNA) 
testing on their own behalf after experiencing symptoms (unpublished data). In North 
Carolina, most individuals with acute HIV requested an HIV test directly (64%), whereas 
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other common reasons for testing included STD related testing, provider referral, and testing 
for drug treatment related reasons (McCoy SI, unpublished data).  
In terms of demographics, individuals with acute HIV tend to parallel the HIV infected 
population. In North Carolina, 73% of men with acute HIV reported a history of sex with 
men, 22% of all acutely infected persons were recently released from prison, and 22% had 
engaged in transactional sex.103 In San Francisco and Los Angeles, acute or primary 
infection was associated with MSM and having a known HIV positive partner.105, 106 Co-
infection with sexually transmitted infections is also common in individuals with acute 
infection.103, 104 Little is known about the testing frequency, cues for testing, and risk 
awareness of those with acute HIV. Since these individuals represent the earliest possible 
time point for entry to the medical system and public health intervention, a thorough 
understanding of the testing behavior during this time is warranted. 
While the role of acute HIV in the HIV epidemic has garnered recent attention, little 
attention has been given to how sexually transmitted infections (STIs) may interact with 
acute HIV. STIs have a well-established synergistic relationship with chronic HIV infection. 
Co-infection with HIV and an STI can increase the probability of HIV transmission to an 
uninfected partner by increasing HIV concentrations in genital lesions, semen, or both.90, 107 
STI infection can also increase the likelihood of HIV acquisition by reducing physical and 
mechanical barriers, increasing the concentration of HIV receptor cells, and, in the case of 
women, changing the vaginal environment to favor HIV infection.17, 108-110 In the case of 
acute HIV, STI co-infection appears to be common. A study in a Malawi sexually transmitted 
disease (STD) clinic found that 17 of 23 persons with acute HIV infection had an STD 
detected.104 In North Carolina, eight of 23 (35%) persons identified in the first year of the 
Screening and Tracing Active Transmission (STAT) program had symptoms consistent with 
an STD.103 No additional studies have described the prevalence of STIs among individuals 
with acute HIV in the United States. 
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In addition to understanding the types and prevalence of STIs most commonly 
associated with acute HIV, an improved understanding of the way that STI co-infection 
impacts testing behavior is also necessary. Individuals with symptomatic STIs may seek 
medical care at STD clinics and consequently be tested for HIV earlier than those without 
STD co-infection. Further, STD clinics may be more likely to incorporate routine HIV testing 
and therefore identify individuals earlier in the course of HIV infection than other types of 
testing sites. Understanding how STIs impact testing behavior may have important 
implications for testing protocols as well as the adoption and design of RNA testing 
programs to detect acute HIV (e.g., targeted testing, pooling algorithms). 
 
Social Support and Health 
Social support is a combination of the different types of support received from friends, 
family, and acquaintances. Social support can be defined as the existence or quantity of 
social relationships and the resources provided by other persons.21, 111 Social support can be 
subdivided into structural aspects of support and functional aspects of support. Structural 
aspects of support include an objective assessment of the size, type, contact, and density of 
social networks and ties.112 Functional support assesses whether the interpersonal 
relationships fulfill particular functions, such as provide affection, a sense of belonging, or 
material aid (Table 2.2).111 Functional support can be subdivided into four support 
components – emotional, informational, tangible, and belonging (or appraisal). Emotional 
support includes expressions of comfort and sharing. Informational support consists of 
sharing advice, information, and guidance. Tangible support includes the provision of 
material aid, such as transportation, money, or childcare. Finally, belonging support includes 
belonging to a social network with which to engage in social activities.112 Together, structural 
and functional support describe the types of resources we receive from other people.  
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Social relationships have a well-established relationship to health. Most studies that 
evaluate the role of either structural or functional support find that the level of support is 
inversely related to all-cause mortality.112 The impact of social support on specific conditions 
is less clear, although the findings are compelling. In one study of Mexican Americans, 
mortality following myocardial infarction was 3.4 times more likely among those with low 
levels of social support compared to those with higher levels of social support, even after 
controlling for a battery of cardiovascular disease risk factors.113 This finding has been 
validated by at least one other study.112 A landmark study of weekly group therapy and 
breast cancer survival in 1989 showed a significant effect on survival, although treatment 
improvements since then may have diminished the effect.114-116  
The mechanism by which social support exerts its effect on health is not clear. Social 
support could act as a main effect and have a causal effect on health outcomes through 
psychological-physiological pathways which influence immune or neuroendocrine 
functioning.111 Social support could also act as a main effect by influencing the adoption of 
healthy (or unhealthy) behaviors (e.g. smoking, seatbelt use, medical care seeking).  
Alternatively, social support may act as a “buffer” between stress and negative health 
outcomes.117 The buffering hypothesis posits that social support reduces the perception that 
an event is stressful and/or facilitates healthful behaviors after the event.117 While the 
mechanism of social support’s action on health may be unknown, the field of social support 
and HIV/AIDS has been inadequately explored. 
  
Social Support and HIV/AIDS. The relationship of social support on HIV/AIDS outcomes has 
not been well explored and therefore no firm conclusions are possible. There is, however, 
some evidence that social support may have an influence on positive health outcomes for 
individuals with HIV/AIDS. 
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Social support may improve positive coping with an HIV diagnosis. Coping includes all 
individual efforts to mediate stressful situations and the negative emotions that arise with 
these situations.118 Social support may affect coping by the evaluation of an event or stimuli 
as stressful and then individual coping with the event if it is deemed to be stressful.118 One 
study of social support and coping among HIV positive gay or bisexual men found that men 
with higher levels of perceived social support reported greater use of positive action coping 
(e.g., ‘formed a plan of action’) and seeking social support. Men with lower levels of social 
support reported more self-destructive coping (e.g., ‘reducing tension by drinking’).22 
 
Social support has been found to improve adherence in most studies. Adherence to ARVs 
optimizes treatment benefit, as even small declines in adherence have been shown to have 
effects on plasma HIV-1 RNA suppression and the development of drug resistant 
mutations.119-121 In general, most studies that evaluate some type of social support find it to 
be associated with improved adherence.25, 26, 81, 122, 123 Kalichman et al. found that individuals 
with less social support were more likely to be nonadherent in the past two days compared 
to those with higher levels of support (OR=2.0), but this effect disappeared in the 
multivariable analysis when education and health literacy were included - suggesting the 
possible overlap of these two constructs.124 A study in the southeastern U.S. found that an 
unmet need for a support group was independently associated with not currently taking any 
HIV medications, even after adjusting for CD4+ cell count, symptom status, and 
demographics.125 
 
Social support might improve quality of life after an HIV diagnosis. One study in Spain 
evaluated the role of social support on health related quality of life (HRQOL) and found 
social support to be positively associated with both the physical and mental health indexes 
of quality of life on the HRQOL scale.24 
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Social support may also affect the care-seeking behavior of newly diagnosed 
individuals. As described above, social support can influence health independently of other 
stressors by influencing the adoption of healthy (or unhealthy) behaviors or activities and 
adherence to social norms.111 In addition, social support can influence health indirectly by 
buffering the pathogenic effects of stressful events through the process of perceiving the 
event as stressful and/or coping with the stress.117 Both of these mechanisms could 
potentially impact the care seeking behavior of newly diagnosed individuals. To date, there 
is only one paper that has explicitly examined the role of social support on the time to seek 
medical care after an HIV diagnosis, and it did not find any correlation.74  
However, there is some evidence from related areas that suggests that social 
support plays an important role in the acceptance and readiness to address a new HIV 
diagnosis, which may translate to care-seeking behavior. McClure et al. found that the 
presence of higher levels of social support was significantly associated with attending at 
least one clinic visit in the first six months after a patient’s initial appointment.126 Another 
study found that HIV infected, pregnant women participating in a qualitative study cited lack 
of social support as a barrier to seeking adequate prenatal care.127 Another qualitative study 
of HIV infected women found that the main barriers to seeking care were psychological and 
focused on the trauma of discovery, lifestyle circumstances, and limited knowledge about 
the availability and success of newer treatments.69 Factors related to financial circumstances 
or health insurance were cited, but much less commonly than the psychosocial factors, 
suggesting that  supportive services to help women come to terms with their infection may 
reduce delays to seeking medical care.69 
The presence of functional social support, especially informational and tangible 
support, may be instrumental in encouraging newly diagnosed individuals to seek care. For 
example, a social network may help to overcome the previously identified barriers to care, 
such as fear of drug side effects, lack of transportation, or a fatalistic attitude. Further, 
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individuals with larger networks or more familial responsibility may believe that they have 
‘someone to live for’ and may be more willing to seek care, even if it falls outside of their 
traditional belief system. Social support may also help to overcome fears about HIV-related 
stigma in the healthcare system. Thus, evaluation of the role of social support on HIV care-
seeking behavior would bring value to programs who seek to improve linkage to medical 
services after an HIV diagnosis. 
 
Bridging Case Management. If social support is an important determinant of seeking care 
among HIV positive individuals, “bridging case management” programs – specialized case 
management interventions designed to link newly diagnosed individuals into routine HIV 
care – may provide needed support services after an HIV diagnosis. In a multi-site study in 
four large U.S. cities, more bridging case management participants visited a physician at 
least twice within 12 months compared to those that received passive referral, the current 
standard of care (RR=1.41, P<0.01).128 In California, a similar program identified individuals 
who were out-of-care and successfully linked 29% to care.129 These findings suggest that 
programs to increase social support after diagnosis with particular attention to the emotional, 
informational, and tangible types of support, may improve the efficiency at which we 
currently link patients to care. 
 
Summary 
Ensuring timely access to HIV care remains a challenge in the southeastern U.S. despite 
the availability of safe and effective antiretroviral therapy and programs to link newly positive 
persons into care. It is anticipated that findings from this dissertation will have an impact on 
HIV care in North Carolina by broadening our understanding of the testing and care-seeking 
behavior among those with HIV. 
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FIGURE 2.1. Conceptual framework describing the steps between acquiring HIV infection 
and establishing primary medical care. The specific phases are labeled as time periods 1-6. 
Adapted from Samet et al.7  
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FIGURE 2.2. Conceptual framework describing access to medical care. Reproduced with 
permission from Wiley-Blackwell Publishing.76  
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TABLE 2.1. Constructs of the Health Belief Model.29, 79 
 
 
CONCEPT DEFINITION RELEVANT HIV CARE FACTORS 
 
Perceived susceptibility 
 
Beliefs about personal 
vulnerability to a condition 
 
Awareness of personal HIV risk 
Beliefs in folk/indigenous disease model
Perceived severity Beliefs about the seriousness of 
a condition and its 
consequences 
Knowledge of HIV/AIDS 
Fatalistic attitude 
Perceived benefits Beliefs about the effectiveness 
of taking action 
Confidence in medical establishment 
Knowledge of ARV benefits 
Control of symptoms 
Perceived barriers Beliefs about the negative 
material and psychological costs 
of taking action 
Distrust of medical establishment 
Health insurance/financial concerns 
Transportation 
Availability and knowledge of 
     testing/care facilities 
Stigma 
Lack of perceived social support 
Fear of side effects of treatment 
Fear of testing positive 
Cues to action Stimulus to trigger the 
decision-making process 
Presence of symptoms 
Health promotion materials 
Concurrent sexually transmitted disease
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TABLE 2.2. Definition and examples of different support functions.112 
 
TYPE OF 
SUPPORT DEFINITION EXAMPLE 
 
Emotional 
 
Expressions of comfort and 
caring 
 
Someone who makes you feel better 
because they listen to your problems 
 
Informational 
 
Provision of advice and guidance 
 
A person who can give you trusted 
advice and guidance on an issue 
 
Tangible 
 
Provision of material aid 
 
A family member who could give you a 
personal financial loan 
 
Belonging 
 
Shared social activities, sense of 
social belonging 
 
A friend with whom you enjoy just 
“hanging out” 
 CHAPTER THREE: DESCRIPTION OF DATA SOURCES 
 
 
The Screening and Tracing Active Transmission Program 
Since the advent of the Screening and Tracing Active Transmission (STAT) program in 
North Carolina in November of 2002, all antibody negative HIV tests performed in publicly 
funded clinics are tested for viral RNA to detect patients in the acute phase of HIV infection 
using a novel pooling algorithm.103, 130 The STAT program is led by Dr. Peter Leone at the 
University of North Carolina at Chapel Hill (UNC-CH) in close collaboration with the North 
Carolina Department of Health and Human Services (NC DHHS). 
The STAT program is evidence of one of the many successful partnerships between 
UNC-CH and the NC DHHS. Since the program’s inception in 2002, the STAT program has 
successfully tested all antibody negative samples for HIV-1 RNA, over 500,000 tests. Figure 
3.1 presents the algorithm of the procedures of the NC DHHS for HIV testing, notification, 
and surveillance. In the first twelve months of the program, the use of nucleic acid 
amplification tests increased the rate of HIV identification by 3.9% over standard antibody 
testing alone, translating to 23 new case-patients and a prevalence of 0.2 per 1,000.103 
In addition to the success of the partnership between UNC-CH and the NC DHHS, 
the STAT program is also successful at linking individuals who are detected with acute HIV-
1 infection to medical care. The STAT program provides a complimentary first visit to all 
acutely infected persons in North Carolina, at which time they receive individualized care 
guidance from a specialist and are connected with a variety of social services. In the first 3
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years of the program, 80% of the reported acute cases were evaluated by an HIV specialist, 
65% within 30 days of their first positive test.131 Since records were maintained, 88% of all 
persons with acute HIV infection identified via the STAT system have decided to stay in 
medical care.132  
 
The University of North Carolina Center for AIDS Research (CFAR) Clinical Cohort 
The UNC CFAR is based at UNC-CH and is a collaboration of three productive and 
successful institutions in the field of HIV research: UNC-Chapel Hill, Research Triangle 
Institute, and Family Health International. The UNC CFAR is designed to provide 
infrastructure to support four approaches to understanding and combating the global 
HIV/AIDS epidemic: clinical, behavioral, and molecular research, and educational outreach. 
The UNC CFAR provides a variety of epidemiological, statistical, and clinical support 
services to researchers pursing these goals in the field of HIV/AIDS.133  
A major endeavor of the UNC CFAR has been the creation and maintenance of the 
Clinical and Research Database and the Clinical and Socio-Demographic Survey 
(CSDS).The UNC CFAR Database includes over 1,700 HIV-infected individuals receiving 
primary HIV care at the UNC Infectious Diseases Clinic. Data is collected on received 
clinical care, including laboratory data, medications and illnesses. The CSDS is an in-person 
interview conducted with HIV-infected patients in the UNC Infectious Diseases Clinic that is 
designed to collect data not routinely available in medical records, including social, 
behavioral, and lifestyle characteristics. To date, just over 300 patients have completed the 
CSDS interview. 
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FIGURE 3.1. Algorithm of the Procedures of the North Carolina Department of Health and 
Human Services for HIV Testing, Notification, and Surveillance. Reproduced with permission 
from the Massachusetts Medical Society.103 Copyright © 2005 Massachusetts Medical 
Society. All rights reserved.  
 
 
 
 CHAPTER FOUR: METHODS 
 
 
 
 
SPECIFIC AIM 1 
a. Describe the prevalence and types of sexually transmitted infections (STI) among 
individuals acutely infected with HIV at the time of testing in North Carolina. 
 
b. Evaluate variation in the time from HIV acquisition to testing among individuals with acute 
HIV infection by the presence of STIs at the time of HIV testing and testing site type. 
 
c. Determine differences in median serum viral load (copies/ml) by the presence of STIs at 
the time of HIV testing and testing site type. 
 
Study Design Overview 
To understand the overlapping epidemiology of acute HIV and STIs, we conducted a 
secondary data analysis of data collected as part of the Screening and Tracing Active 
Transmission Program (STAT) in North Carolina. The STAT study population is an optimal 
population with which to study acute HIV infection because of its defined geographic area, 
intensive and thorough interview process, and its rigorous laboratory algorithms to detect 
acute infection. Our goal was to describe the prevalence and types of STI co-infections and 
describe the potential effect of co-infection on testing behavior. This study was ruled as 
exempt by the UNC Institutional Review Board as it is a secondary analysis of existing de-
identified data. 
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Study Population 
Identification of Acute HIV-1 Patients. The study population consists of persons who 
presented for HIV counseling and testing at all publicly funded sites in North Carolina 
(n~135) between November 1, 2002 and October 31, 2006. All testing was confidential and 
was linked to patient information with the use of a system of unique identifiers, according to 
state public health statutes. The routine HIV testing algorithm in North Carolina includes a 
pooling strategy to detect HIV-1 RNA positive, antibody negative individuals in the acute 
phase of infection. Serum samples submitted for HIV testing are first tested for HIV-1 
antibody, and then all antibody negative samples are screened for HIV-1 RNA by pooling.130 
Antibody indeterminate samples are tested for HIV RNA individually. Standard Vironostika 
HIV-1 enzyme immunoassay (EIA) and Western Blot analysis kits (Bio-Rad Laboratories) 
are used for antibody screening. Pools were screened by nucleic acid amplification (NAAT) 
for HIV-1 RNA with the Procleix HIV-1 assay (GenProbe) and then in July 2005 with the 
EasyQ HIV-1 quantitative assay (bioMerieux).103 Individuals for whom HIV-1 RNA is 
detected but have not yet seroconverted were considered to be acutely infected. 
 Upon notification of a possible case of acute HIV infection, the NC Department of Health 
and Human Services (NC DHHS) assigns the case to a team of specially trained disease-
intervention specialists (DIS). DIS are located throughout the state and perform the initial 
interviews, confirmatory testing, and referrals to care within 72 hours of notification. All 
partners within six months of testing are ascertained at the initial interview; partner 
notification is then prioritized according to the time of potential exposure. Immediate 
intervention is required for partners with exposures less than 48 hours from the test date – 
post-exposure prophylaxis is considered in this situation. Sexual or needle sharing partners 
with contact less than eight weeks from the initial interview with the index case are notified 
by DIS and offered testing within 72 hours of the index interview. Partners outside of the 8-
week window period are notified after confirmatory testing by the index. 103 
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Selection Criteria 
Inclusion criteria: All consenting persons who presented for HIV counseling and testing at all 
publicly funded sites in North Carolina between November 1, 2002, and October 31, 2006 
and diagnosed with acute HIV infection were included in the study.  
Exclusion criteria: Individuals with acute HIV infection identified as part of the STAT program 
who were unable to be located by DIS for notification and referral (lost to follow-up) or those 
who refused DIS field services were excluded from the analysis.  
 
Data Collection 
Interviews by DIS and completion of STAT forms. After interviews with the index patient and 
partners in the exposure window, DIS officers complete a series of forms about acute 
retroviral symptoms, sexually transmitted diseases, testing history, and sexual behavior with 
recent partners. Individuals must consent to disclose health information as part of the DIS 
interview; individuals who do not sign the authorization will not have STAT forms completed. 
Individuals can consent to the DIS interview but refuse to identify partners for DIS-
conducted partner counseling and referral services or choose to conduct partner notification 
on their own. Completed forms are mailed to the STAT data manager (S. McCoy) for data 
entry. Forms are routinely audited for complete and valid information. None of the 
information was identifiable by any of the study investigators; all databases were de-
identified and cannot be linked back to individuals.  
 
Conference calls to discuss each STAT case. In addition to the information collected on the 
required STAT data collection forms, DIS, acute HIV specialists, and other study personnel 
participate in a weekly conference call to discuss all new cases of acute HIV. Although 
information from this call is not formally entered into any database, detailed notes are kept 
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on each case and stored in a secure location available to study investigators. All cases are 
discussed using a numeric code that cannot be linked back to individuals.  
 
Counseling and Testing Data from the NC DHHS. The NC DHHS routinely shares the 
counseling and testing data for all HIV tests conducted in public testing sites with STAT 
personnel at UNC. Clients who presented for HIV testing at publicly funded sites in North 
Carolina before 2007 were required to sign an informed consent form authorizing the 
collection of personal information. Information collected as part of counseling and testing 
included demographics, reason for testing, risk factor information, and testing site. This 
dataset was merged with the STAT database to match the pre-test counseling information 
with the information collected by the DIS during notification and referral.  
Together, these three sources of information will provide the data to address Aim #1. In 
the next section, “Measurements and Analysis Plan,” we describe the methods for 
ascertaining the exposure, outcome, and covariates and the analysis plan for each of the 
sub-aims of Specific Aim #1. The “Data Management” and “Limitations” sections which 
follow apply to all of the sub-aims. 
 
Measurements and Analysis Plan – Specific Aim 1a 
Specific Aim 1a. Describe the prevalence and types of sexually transmitted infections (STI) 
among individuals acutely infected with HIV at the time of testing in North Carolina. 
 
Measurements 
Outcome: Co-infection with an STI. STI history is captured on the STAT data collection form 
with the question “Has the patient ever been diagnosed with an STD?” and if yes, the 
diagnosis and the date (month/year). Dates of diagnosis were compared to the initial test 
date when acute HIV was diagnosed to determine if the STD diagnosis was made at or near 
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the same time as HIV testing. If the date of diagnosis of the STD and acute HIV infection 
were in the same month and year, the potential co-infection was confirmed by chart review 
by the appropriate regional DIS.  
 
Additional covariates. Additional patient data includes demographic characteristics (e.g., 
age, sex, race), acute retroviral symptoms, and risk factor information.  
– Age was collected as a continuous variable but was categorized in this analysis for 
presentation of prevalence by age group (≤25 years, 26-35 years, and ≥36 years). Age 
was entered as a three level categorical variable in all models (Specific Aims #1b-1c).  
– Sex was coded as a dichotomous variable (1=Male, 0=Female).  
– Race is self-identified on the HIV counseling and testing report form which 
accompanies all HIV tests sent to the state laboratory. Race was first categorized into 
“Black,” “White, non-Hispanic,” “White, Hispanic,”  “Native American/Alaskan Native,” 
and “Unknown.” In addition to this classification, race was also be dichotomized into 
“White, Non-Hispanic” and “Non-White” due to small numbers of people with STI co-
infections.  
– Acute retroviral symptom information is collected by DIS during the initial interview with 
the patient and entered onto STAT forms with the onset date. We considered 
appropriate symptoms (e.g. fever, headache, night sweats, weight loss, body aches) 
reported during a window period of eight weeks of testing (± four weeks of the test 
date, inclusive) to be acute retroviral syndrome. The onset of symptoms was 
considered the earliest date of any symptom onset. Symptoms consistent with acute 
retroviral syndrome were constructed as two dichotomous variables, one for symptoms 
at or before testing (present/not present) and one variable for symptoms that 
developed at any time (present/not present). We also considered a 3-level variable for 
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symptoms at or before testing, symptoms that developed after testing, and no 
symptoms.  
– We created a three-level gender and risk category of women, heterosexual men, and 
men who have sex with men (MSM). A man who reports any male partners was 
classified as MSM, whereas a man with all female partners was classified as 
heterosexual. We utilized two data sources for this information – the counseling and 
testing data from pre-test counseling as well as the STAT forms completed by DIS that 
include the gender of partners. 
– Any report of injecting drug use was included as a dichotomous variable (1=Yes, 
0=No). This information was abstracted from the STAT forms as well as from the 
counseling and testing data.  
 
Data Analysis 
Frequencies of STI co-infection. We present frequencies of the number of individuals with 
STI co-infection and the types of infections. We also present the number and percent of 
individual STIs and determine the prevalence, pˆ , by computing A / N, where A refers to the 
number of individuals with the outcome (co-infection) and N represents the total number of 
acute infections. The 95% exact confidence intervals were computed and presented.  
 
Bivariable associations. We also present the prevalence of STI co-infection by age group, 
race, testing site, gender and risk behavior, and symptoms. To determine factors associated 
with STI co-infection, we computed the prevalence of co-infection in each stratum and 
present prevalence ratios (PR) and 95% exact confidence intervals to test associations 
between co-infection and selected covariates. Statistically significant differences in 
proportions were determined with Fisher’s exact test. 
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Measurements and Analysis Plan – Specific Aim 1b 
Specific Aim 1b. Evaluate variation in the time from HIV acquisition to testing among 
individuals with acute HIV infection by the presence of STI at the time of HIV testing and 
testing site type. 
 
Measurements 
Outcome: Time from HIV acquisition to HIV testing. The date of HIV acquisition was 
estimated using the dates of symptom onset and seroconversion reported by DIS. The date 
of seroconversion was calculated as the midpoint between the last antibody negative or 
indeterminate test and the first positive western blot. For individuals with symptoms 
consistent with acute retroviral syndrome, the date of HIV infection was calculated as 14 
days prior to the date of symptom onset.134-136 For individuals without symptoms, the time 
from HIV infection to seroconversion reported in the literature ranged from a median of 46 
days on  2nd generation EIA tests among health care workers to over 88 days in plasma 
donors.137-139 Because of this inconsistency, we utilized an average plausible seroconversion 
interval of 35.5 days with a 2 week window on either side (21.5 to 49.5 days). The rationale 
for this interval is presented in Table 4.1. As the NC DHHS used a 2nd generation EIA at the 
time of the study, we computed an average interval between infection and seroconversion of 
35.5 days. This interval was consistent with reports from the CDC of median time to 
seroconversion of 46 days, respectively, but less that that reported by Horsburgh of 72 
days.137, 138 
 
Exposure: Testing site type. Testing site type is collected on the pre-test counseling and 
testing report form. Testing sites are collected as: 
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– HIV Counseling and Testing Site (CTS) – STD Testing Site 
– Drug Treatment    – Family Planning 
– Prenatal/Obstetrics    – Tuberculosis 
– Prison/Jail     – Hospital/PMD 
– Field Visit     – Other 
 
Preliminary analyses from the first three years of the STAT program (11/1/2002 – 
10/31/2005) indicated that 47% of individuals diagnosed with acute HIV infection were 
tested at STD testing sites, followed by 21% at dedicated HIV CTS sites and 19% at “Other” 
testing sites. Because few acutely infected individuals tested during prenatal care/obstetric 
visits, at family planning clinics or were people with tuberculosis, we grouped any testing site 
other than CTS and STD into an “Other” category. 
 
Additional covariates. Covariates for consideration for this sub-aim include demographic 
characteristics (e.g., age, sex, race), symptoms, and risk factor information (e.g., MSM, 
IDU). The coding of these variables was described for Specific Aim 1A. 
 
Data Analysis 
Variation in the time from the estimated date of HIV acquisition to testing was evaluated with 
two proportional hazards models with 1) the presence of an STI co-infection as the exposure 
and 2) with the testing site type as the exposure.  
Proportional hazards regression models the hazard rate, which is based on the 
number of events per interval of time. Hazard rates are comparable to incidence rates, but 
conditional on survival in the immediately preceding time interval. The proportional hazards 
model takes the form of  
hx(t)=ho(t) • eβX , 
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where X is a vector of explanatory variables (x1, x2, …, xk), ho(t) is the baseline hazard (e.g. 
when all explanatory variables equal 0, X=0), and hx(t)  is the hazard at X=x. The 
interpretation of eβX in a multivariable model is the hazard ratio comparing those with x=1 to 
those with x=0 (the referent category) at all times t adjusted for other variables in the model. 
A key assumption of the proportional hazards model is that the hazard ratio (eβX) in the 
model is assumed to be constant across time. This means that the ratio of the hazard 
function in the exposed to the hazard function in the unexposed is a fixed constant over time 
(“hazards are proportional”).140  
The proportional hazards model was used to examine variation in the time from HIV 
acquisition to HIV testing by STI co-infection and testing site type. In the bivariate models, 
the only explanatory variable were the binary exposure of co-infection (1=Yes, 0=No) or site 
type (‘STD’, ‘non-STD’, or ‘CTS’). The proportional hazards assumption was evaluated for 
each exposure and covariate graphically with the use of a log(-log(S(t))) curve and was 
tested by adding an interaction with time to the model (Cox Test). If necessary, the 
proportional hazards assumption was relaxed using a stratified model or by adding 
categorical or continuous time interactions. We assessed goodness of fit of the model by 
examining deviance residuals and influence statistics. Equality of the survival functions 
between those with and without the exposure was assessed with a Log-Rank Test or 
Wilcoxon Test, depending on the shape of the survival curves (Wilcoxon gives more weight 
to early times than late times).  
We evaluated effect measure modification (EMM) and confounding for both STI co-
infection and testing site type. We then constructed a single, fully adjusted model with both 
main exposures and all relevant interaction terms and confounders.  
 
Assessment of Effect Measure Modification. To assess EMM, we examined the exposure-
outcome relationship while adjusting for one covariate at a time in the model. The covariate 
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was entered into the model individually as a main effect and as an interaction with the main 
exposure. The significance of the interaction term was assessed by comparing the likelihood 
ratio of the “full” model with the interaction term to the model without the selected interaction 
term by the likelihood ratio test (LR). Important interaction terms were included in the 
multivariable model along with their corresponding main effect terms. 
 
Assessment of Confounding. Potential confounders were considered those covariates that 
were not found to be effect measure modifiers and that changed the unadjusted HR by more 
than 10% according to the formula ln|(HRunadjusted/HRadjusted)|. Potential confounders were 
included in the final multivariable model. 
 
Multivariable associations. We examined the joint effect of STI co-infection and testing site 
type in a multivariable proportional hazards model. Due to the small sample, we were limited 
to examining approximately seven explanatory variables in the model.141 We utilized a 
backward, manual elimination modeling strategy to assess the joint effects of covariates. 
The main exposure, potential confounders, and effect measure modifiers along with the 
appropriate interaction terms were added to the model, constituting the fully adjusted model. 
EMM was assessed first by examining the LR test result for the model with and without 
selected interaction terms. Confounding was examined next – covariates were removed 
from the model in order of p-value magnitude if the estimated HR for STI co-infection 
changed by more than 10% from the unadjusted association.  
The results from Specific Aim 1b are presented in Appendix A.  
 
Measurements and Analysis Plan – Specific Aim 1c 
Specific Aim 1c. Determine differences in median serum viral load (copies/ml) by the 
presence of STIs at the time of HIV testing and testing site type. 
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Measurements  
Outcome: Baseline viral load. Quantification of HIV-1 RNA is routinely conducted on the 
venous blood sample provided at the time of the initial HIV test and on confirmatory samples 
drawn in the field by DIS. An HIV-1 reverse transcriptase polymerase chain reaction assay 
(Amplicor HIV-1 Monitor Test, version 1.5, Roche Diagnostic) was used to measure viral 
load. It is based on reverse transcription (RT) of the target HIV-1 RNA, and polymerase 
chain reaction (PCR) amplification of the resulting cDNA.142 The limits of detection of the 
Amplicor assay are 50 (lower limit) and 750,000 (upper limit) copies per ml.  
 
Additional covariates. Covariates considered in this sub-aim included demographic 
characteristics, symptoms, and risk factor information. The coding of these variables was 
described for Specific Aim 1A. 
 
Data Analysis  
Differences in the baseline mean log10(HIV-1 RNA) between those with an STI co-infection 
and those without an STI infection was examined with a one-way analysis of variance 
(ANOVA). Similarly, we compared the mean log viral load by testing site type using the 
same method. In addition, we were interested in the relationship between study covariates 
and viral dynamics in order to understand more about the timing of testing. Towards this 
end, we examined the viral dynamics among the subset of participants with both initial and 
confirmatory HIV RNA values using two common epidemiologic models: 
 
1. Logistic regression. We classified patients as having an increasing or decreasing HIV 
RNA slope. We then used exact logistic regression to assess the relationships between this 
dichotomous indicator of HIV RNA slope (1=increasing slope, 0=declining slope) and study 
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covariates. We assumed that a positive HIV RNA slope was indicative of testing before the 
peak viremia. Logistic regression takes the form 
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Yi is a binary response variable, Xi is a known constant from the ith participant, and β0 and 
β1 are parameters.143 The results from this approach are presented in Chapter Five.  
 
2. Linear regression. We constructed linear regression models with the change in log10(HIV 
RNA) as the outcome. Linear regression takes the form E(Yi)=β0+ β1Xi, where E(Yi) is the 
expected response at level i of predictor variable X, β0 is the intercept parameter, or mean 
when X=0.  β1 is the slope of the regression line.143 A key assumption of the model is that 
the outcome is normally distributed (Yi~N(β0+ β1Xi, σ2)) so the skewed distribution of serum 
viral load was log transformed. The results from this analysis are presented in Appendix B.  
 
Data Management 
The data used for this secondary data analysis project were collected as part of the 
Screening and Tracing Active Transmission Database housed at the UNC Center for AIDS 
Research. The database was located on a server in a secured access area. Access to the 
server was restricted to key personnel such as computer support staff and the data 
manager. All information in the database was de-identified, with linking files kept separately 
at the NC Department of Health and Human Services. When data analysis files were 
created these were linked by a nonsense unique record identifier. All analyses were 
conducted in SAS version 9.1.2 (Cary, NC).  
 
Sample Size. Our study represents the first four years of the STAT program; a statewide 
collaboration to detect acute HIV at all publicly funded HIV testing sites in North Carolina. To 
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date, no other state in the U.S. has implemented such a program. Information on 75 acute 
HIV patients identified through the STAT program was available for analysis, a sample size 
that is unrivaled for acute HIV research in the United States.  
Because our sample size was fixed, we solved for the power available for the two 
sample t-test of the log10(HV RNA) comparing those with and without STI co-infection and 
those from STD and non-STD testing sites. The results are presented in Figure 4.1. Graph A 
in the figure describes the expected power for a two-sample t-test to detect a difference by 
STI co-infection. Various hypothesized standard deviations of the outcome and effect sizes 
(differences between the means) are presented for a 0.05 two-sided significance level. We 
assumed that approximately 30% of our sample will have an STI co-infection, translating to 
a fixed sample size of 23 and 53. For example, with a pooled standard deviation of 2.0, we 
had 84% power to detect a difference in mean log10 (HIV RNA) of 1.5. 
Graph B in the figure describes the expected power for detecting a difference in 
mean log10(HIV RNA) by testing site type. We knew that 34 people tested at STD clinics and 
42 people tested at other types of clinics. Similarly, we found that with a pooled standard 
deviation of 2.0, we had 89% power to detect a difference in mean log10 (HIV RNA) of 1.5. 
 
Approach to Missing Data. Individuals who could not be located by DIS for interview were 
excluded from the analysis. The presence of an STI co-infection is indicated on the 
conference call and on STAT forms when present, however, we do not have data on four 
individuals who did not consent to take part in the study and receive counseling (5.1%). 
Likewise, the absence of STAT forms resulted in missing dates of symptom onset and 
seroconversion for the same four individuals, the endpoint of the main outcome. These 
individuals will therefore be excluded from the analysis, leaving 75 cases with which to 
examine STI co-infection. Testing site type is currently available on all STAT cases in the 
study period. Viral load values are available for 74 of 75 consenting participants (99%) of the 
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STAT cases in years 1-4. This small amount of missing data is not expected to bias the 
results, but will result in a loss of precision. 
In proportional hazards regression, we will utilize a complete case analysis 
approach. This is expected not to bias the data because of the small number of missing data 
for the main exposure and outcome; however, we can expect a loss in precision of our 
estimates. Any covariate for which more than 5% of values are missing will be excluded 
from the analysis.  
 
Strengths and Limitations 
The primary strength of this study is the reliance on the STAT program, a unique 
collaboration to routinely detect acute HIV in public health settings. We had access to four 
years of data from the STAT program, translating to 75 cases of acute HIV for examination. 
Few studies have access to such a large and rich database about acute HIV infection. 
However, several factors limit the validity or generalizability of our findings: 
 
Potential for selection bias. There are two potential sources of selection bias in this study. 
First, this analysis only includes cases of acute HIV identified through publicly funded HIV 
testing sites. While the type and number of public testing sites are diverse, more than half of 
the HIV tests in the state are conducted in private facilities and not eligible to be included in 
the STAT program public testing arm. It is possible that individuals who test for HIV at 
private sites are systematically different that those who test in public sites (e.g., race). This 
could limit the transferability of our findings beyond the public HIV testing system. Second, 
the recent revised testing guidelines underscore the recommendation for routine HIV testing 
of all STD clinic attendees and those seeking treatment for STDs in other clinical settings.49 
This testing practice may bias our findings toward overestimating the prevalence of STI co-
infection with acute HIV (e.g., diagnostic bias).144  
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Algorithm to determine the date of infection. We used an algorithm to estimate the time of 
HIV acquisition for the acutely infected study participants. This algorithm is subject to 
several design flaws. 1) Symptomatic patients: Although most studies of acute or primary 
infection note the onset of symptoms approximately 2 weeks after infection, it is possible 
that the estimated date of exposure to the virus in these small samples was incorrect. 
Further, the three studies on which this calculation was based were conducted in only 12, 
12, and 10 patients, respectively.134-136  In addition, seroconversion times may differ based 
on route of exposure. 2) Asymptomatic patients: There is mixed information about the times 
from infection to seroconversion among asymptomatic patients, and most available 
information is from health care exposures. To approach this problem, we utilized multiple 
sources of information and considered a plausible range of intervals from infection to 
seroconversion. 
 
Serum viral load as outcome. We examined the differences in serum viral load among those 
with and without STI co-infection and those from different testing site types. Optimally, we 
would have seminal viral load or viral load from genital secretions to make inferences about 
transmissibility. Although plasma viral load is correlated with HIV transmission probability, 
Cohen et al. demonstrated that men co-infected with urethritis had seminal plasma HIV 
concentrations eight times higher than those without urethritis with no difference in blood 
plasma RNA. 61, 107 This finding suggests that even if we find no difference between plasma 
viral load concentrations in our study population, important differences may remain in the 
genital tract, which has implications for sexual transmission.  
 
Possible influence of STI co-infection on seroconversion. Co-infection with an STI could 
influence the time to seroconversion, and it is impossible to know this in our study. Since we 
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are replying on a range of plausible outcomes to determine the date of infection for 
asymptomatic patients, our results will be biased if co-infection is found to affect the time to 
seroconversion. If co-infection shortens the pre-seroconversion interval, we will overestimate 
the date of infection for all asymptomatic individuals who are co-infected. In contrast, we will 
not rely on the date of seroconversion for symptomatic patients (date of symptom onset is 
used). Plasma viral load has been shown to be stable with urethritis co-infection although 
seminal plasma increased, suggesting that STIs might not have any effect on 
seroconversion.107 
 
SPECIFIC AIM 2 
Describe the effect of perceived social support on late presentation to medical care among 
HIV positive persons receiving care at the UNC Infectious Disease (ID) Clinic. 
 
Study Design Overview 
To determine the effect of perceived social support on HIV care-seeking behavior, we 
conducted a secondary data analysis of the UNC-CFAR HIV/AIDS Clinical Socio-
Demographic Survey (CSDS) and the UNC Center for AIDS Research (CFAR) HIV Clinical 
and Research Database. The CSDS is a comprehensive in-person interview completed by 
UNC CFAR HIV Cohort participants. The Clinical and Research Database includes medical 
record information on patients receiving HIV care at UNC. Detailed data are collected on 
demographic, social, behavioral, clinical and lifestyle characteristics. This secondary 
analysis was ruled as exempt by the UNC Institutional Review Board.  
 To enhance the accuracy of our findings, we conducted a validation sub-study to 
determine the reliability of the self-reported date of diagnosis contained in the CSDS. We 
compared the self-reported value to the value reported to the NC Department of Health and 
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Human Services through routine infectious disease reporting. We also compared these 
values to the date recorded in the UNC medical record. 
 
Study Setting 
The parent study for this analysis was conducted in the University of North Carolina at 
Chapel Hill Infectious Disease Clinic. As a large, university-based medical center, the Clinic 
follows approximately 1,300 HIV infected patients per year and provides comprehensive HIV 
primary services including antiretroviral therapy, chemoprophylaxis, health maintenance 
services, and referrals to specialty care. Patients in the clinic are predominantly from central 
and eastern North Carolina, although patients from all 100 counties and surrounding states 
are accepted for care.145 Overall, approximately one-third of all HIV-infected patients seen at 
UNC-ID are women, 62% African Americans, 2% Native Americans, and 4% 
Hispanics/Latinos.146 Patients are referred to the Clinic from public testing venues, private 
offices, and inpatient services.145  
 
Study Population 
For this secondary data analysis project we merged the clinical data available in the UNC 
CFAR Database with the social and behavioral data available in the CSDS. All patients 
participating in the UNC CFAR Database and the CSDS interview provided written informed 
consent to participate in these respective studies. The merge of the databases was done 
among patients who provided written informed consent to participate in both studies. A 
description of the UNC CFAR CSDS and the UNC CFAR Database is available in Chapter 
Three of this dissertation.  
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Selection Criteria 
Inclusion criteria: All HIV infected patients participating in the UNC CFAR Clinical and 
Research Database project and the CSDS who received care at the UNC Infectious 
Diseases clinic and who met the inclusion criteria were eligible. The inclusion criteria were: 
(1) At least 18 years of age 
(2) Provided written informed consent to participate in the UNC CFAR Research and 
Clinical Database  
(3) Provided written informed consent to participate in the Clinical Socio-Demographic 
Survey 
(4) Date of HIV diagnosis known (either self-reported, in NC DHHS records, or in the 
UNC medical record, please see description of measurements below) 
(5) Date of initial entry to HIV care at UNC is known 
(6) At least 80% of the social support questions were complete in the CSDS interview. 
 
Sampling  
To be eligible to participate in the CSDS Interview, patients must have been in care at the 
UNC Infectious Diseases Clinic, provided written informed consent to participate in the UNC 
CFAR Research and Clinical Database, were at least 18 years of age, able to speak 
English, and able to provide written informed consent.  
 
Recruitment 
Potential participants were identified and approached for participation by their primary care 
provider in the UNC Infectious Diseases Clinic on the day of their HIV clinic visit. Primary 
care providers informed their patients of the study and asked the patient if they were willing 
and able to speak with study personnel. If the patient agreed then study personnel met with 
the patient in a private and quiet office in the UNC Infectious Diseases Clinic or the UNC 
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General Clinical Research Center. Patient information was only collected once the patient 
agreed to participate and provided written informed consent and HIPPA authorization. 
 
Data Collection 
Study personnel explained the study and went through the informed consent form and the 
HIPPA authorization form with the patient. If the patient agreed to participate they were 
asked to sign the informed consent form and the HIPPA authorization form. A copy of the 
informed consent form and HIPPA authorization form was given to the participant.  
 Trained research assistants or study investigators conducted all CSDS in-person 
interviews. Interviews were conducted in a private and quiet office in the UNC Infectious 
Diseases Clinic or the UNC General Clinical Research Center. Participants were told that 
they could decline to respond to any question and could refuse to continue the interview at 
any time. During the interview all participant responses were entered on paper forms. 
Patients were given $15 at the completion of the interview for their time. Data from the 
interviews were entered into a Microsoft ACCESS database which is housed on a secured 
server.  
 
Measurements 
Main Outcome: Time from diagnosis until presentation for care. The main outcome variable 
is the time (months) from HIV diagnosis until entry to HIV care. The date of HIV diagnosis 
was obtained from the NC Department of Health and Human Services HIV/AIDS Reporting 
System. In cases where a match was not obtained with state records or the NC reporting 
system date was after the diagnosis date in the medical record, the date of diagnosis from 
the medical record was used. Five patients only had the self-reported date of diagnosis 
available. To correctly capture the date of entry to HIV primary care, as opposed to general 
health care visits, we defined entry to care as the first outpatient visit to the UNC ID clinic for 
 52 
 
  
patients only receiving care at UNC. For patients who received care at other institutions, we 
defined entry to care as the earliest non-hospitalized date of CD4 T-lymphocyte cell count, 
HIV RNA, antiretroviral therapy initiation, AIDS-defining clinical condition, or outpatient visit. 
In cases where a hospitalization was the first HIV–related care, we accepted the date of the 
first CD4 T-lymphocyte cell count as the entry to care date. Patients with only self-reported 
dates of entry to care were excluded from the analysis.  
 
Main Exposure: Perceived Social Support. The exposure of interest, perceived social 
support, was quantified with the Medical Outcomes Study (MOS) Social Support Scale 
(SSS). The MOS-SSS is a brief, multidimensional, 20-item survey. Two items measure 
structural support and the remaining 18 items measure four functional dimensions of social 
support: emotional/informational, tangible, affectionate, and positive social interaction.27 The 
modified version used in our study contained items to measure structural support and 13 of 
the 18 items to measure functional support (four of four tangible indicators, three of three 
affectionate indicators, four of eight emotional/informational indicators, and one of four 
positive social interaction indicators plus an additional positive social interaction indicator 
evaluated but not included in the MOS-SSS). The scale was developed for patients in the 
MOS, a two year study of patients with chronic illnesses (n=2,987). Thirty-nine percent of 
the sample was male, 20% were non-White, and 68% were married, and there was an 
average of 13.3 years of education. The structural measures of support were found to be 
distinct from the functional types, and the scale showed high convergent and discriminate 
validity of scale items.27 The modified MOS-SSS used in this study is presented in Table 4.2.  
 Structural social support was quantified with the following two measures of network size 
and connectedness from the MOS-SSS: 
(1) “About how many close friends do you have (people you feel at ease with and can 
talk to about what is on your mind)?” 
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(2)  “About how many close relatives?” 
 Overall network size was considered the summation of the number of close friends and 
relatives and considered as a continuous variable as well as categorized into 0-3, 4-7, 8-12, 
and 13 or more close friends and relatives. 
 Functional social support was quantified with a score for each dimension of functional 
social support. Reponses to items on the 5-point Likert scale of responses were assigned a 
numeric value (1: Support type is never present – 5: Support type is always present) and a 
composite average number was generated for the functional social support dimension. This 
average was transformed so that the lowest possible score was 20 and the highest possible 
score was 100. We also computed a composite functional social support score for each 
participant.  
 Internal consistency of the scale was measured with Cronbach’s alpha, a value that 
ranges between 0 and 1 and indicates the level of internal consistency of the scale (whether 
a single underlying construct is being measured). A widely accepted rule of the thumb is that 
values of at least 0.7 are required to indicate good internal consistency.147 The coefficient 
alpha was calculated as: 
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where k indicates the number of items, 2Ts  is the total variance of the sum of the items, and 
2
Is  is the variance of an individual item.147  
 As our scale was modified from the original 19 item MOS-SSS scale, we used 
confirmatory factor analysis (CFA) to determine the validity of the model in our study 
population. The purpose of CFA is to identify a set of latent factors that account for the 
variation and covariation of a set of indicators (indicators are the actual questions asked). A 
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latent factor is unobservable and accounts for the correlations of observed indicators. The 
researcher determines the latent factors and pattern of indicator and factor loadings in 
advance and then uses concepts of structural equation modeling to solve the multiple 
resulting models.148 The goal is obtain estimates for each parameter that produces a 
predicted variance-covariance matrix that resembles the sample variance-covariance matrix 
as closely as possible.148  
 The CFA common factor model for this analysis is presented in Figure 4.2. We had four 
first-order latent factors corresponding to the four dimensions of functional social support. 
These latent factors were related to individual indicators (factor loadings). We also had one 
second order latent factor corresponding to a single, composite measure of functional social 
support. A fundamental equation of the common factor model is: 
 
 jjjY δηλ += 11 , where 
 
Yj represents the jth indicator (in our example, A-M) obtained from a sample of independent 
subjects, λj1 represents the factor loading relating indicator j to the mth factor η, and δj 
represents the unique variance (measurement error) for indicator Yj.148  
 We first evaluated the first order solution to see if the four dimensions of functional social 
support were valid in our sample. We allowed for the errors of two similarly worded 
questions to be correlated (“Someone to give you good advice about a crisis” and “Someone 
who’s advice you want”). We determined model fit based on a CFA model with 332 patient 
records, 13 indicators, four latent variables (emotional/informational, affectionate, tangible, 
and positive interaction types of functional social support), and a robust weighted least 
squares fitting function. We then examined the suitability of the higher-order model with the 
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single measure of functional social support. CFA analyses were done with Mplus 
software.149 The results of the CFA are presented in Chapter Six. 
 We present medians, means and standard deviations for each level of functional 
support. The distributions of functional support were skewed so we investigated several 
methods to model each dimension of functional social support.  
(1) We created 4-level variables which corresponded to quartiles of each functional 
social support dimension. Using these variables in proportional hazard models, we 
found no evidence to suggest that any of the functional social support terms were 
linear in the hazard. Use of continuous terms for social support was therefore not 
indicated. 
(2) To determine if the fit of a linear term could be improved with linear splines, we 
entered each of the dimensions of functional social support into a proportional 
hazards model and created three linear spline terms corresponding to knots at the 
specified percentiles depending on the distribution of each functional support 
variable. We tested the statistical contribution of the spline terms with the LR test. 
None of the models with the linear spline terms improved the fit of the model. The 
creation of spline variables is described in more detail in Table 4.3  
(3) We examined scatter plots of the survival function estimate and the linear functional 
support dimension. Based on this graphical display of data, a 3-level or 2-level 
categorization of each functional social support variable seemed reasonable. The 
scatter plots for each functional support dimension is presented in Figure 4.3.  
 
Based on these preliminary analyses, the functional support scores were categorized for 
entry into a proportional hazards model based on levels corresponding to social support 
being available <70 (“Less than most to all of the time”), and ≥70 (“Most to all of the time”). 
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Additional Covariates. Additional patient data included demographic characteristics (e.g., 
age, sex, race); clinical factors (e.g., CD4 cell counts, AIDS defining illnesses), and risk 
factor information (e.g., ever spent time in prison, ever homeless). Age was calculated as 
the difference between the date of birth and the date of the interview, and classified into ≤30, 
31-40, and ≥41 years. Sex was a dichotomous variable. Race was categorized into “Black,” 
“White,” and “Other.”  
 Potential confounders of the relationship between social support and HIV care included 
substance abuse (alcohol and llegal drugs, dichotomized into “ever had a drinking problem,” 
or “ever used illegal drugs on a regular basis”) and ever having been homeless or in prison 
(Yes/No). Substance abuse treatment and mental health history were not available for the 
analysis. Other variables of interest that were investigated included income, availability of 
transportation for medical visits, education, transactional sex, and self-identified sexual 
identity. We also examined the number of biological children as a 3-level variable of no 
children, one child, and two or more children. The hypothesized causal model is presented 
in Figure 4.4 
 
Validation Sub-study. We conducted a validation sub-study to examine the reliability of the 
self-reported first positive HIV test by comparing to state HIV/AIDS morbidity records and 
UNC medical records. In the first phase of the sub-study, we matched all the patients that 
consented to participate in the CSDS to the NC DHHS HIV/AIDS Reporting System (HARS) 
using a 4-step algorithm. First, patients were matched deterministically using the first four 
letters of the last name, first three letters of the first name, month and year of birth, and sex. 
In the second stage, single matches are removed and the remaining non-matched subjects 
were matched deterministically by social security number, if available. The remaining non-
matched subjects were then manually matched by record lookup using an inexact matching 
algorithm and rotating the first name, last name, date of birth, and sex though the lookup 
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system to identify changed names, gender errors, etc. Finally, multiple matches for a single 
patient were investigated and resolved and all matches were manually reviewed for potential 
errors. This phase of the analysis was approved by the NC DHHS under statute 10A NCAC 
41A.0101, “Reportable Diseases and Conditions.” In the second phase of the analysis, we 
examined the diagnosis date available in the UNC medical record. The results of the 
validation sub-study are presented in Appendix C. 
For the main analysis, the date of HIV diagnosis was determined with an algorithm to 
select the earliest of: self-reported diagnosis date, provider report in the UNC medical 
record, or date of diagnosis recorded in North Carolina HIV/AIDS Reporting System. 
 
Data Management and Data Analysis 
To ensure data integrity, the UNC CFAR Clinical and Research Database and the CSDS 
rely on rigorous data management and quality control procedures that we utilized for this 
study. In addition to data entry systems that include range checks and assessment of 
completeness and consistency across items, the UNC CFAR staff engaged in several levels 
of error detection and correction. Questionable values were flagged for verification against 
paper records. The UNC CFAR Database and the CSDS are located on a dedicated server 
in a secured access area where most administrative University servers are housed. Access 
to the server is restricted to key personnel such as computer support staff. All information in 
the databases are de-identified, with linking files kept separately under additional security 
and password protections. Access to any of the data requires passwords that change each 
90 days, and again only key personnel have access to these files, including the database 
manager and SAS programmer. When data analysis files are created these are linked by a 
unique patient identifier.  
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Validation sub-study. Self-reported dates of diagnosis that were within the same year as the 
HARS reported date or the date in the UNC medical record were considered concordant, 
likewise, dates more one year discrepant were considered discordant. We report the percent 
agreement between the self-reported date of diagnosis and the validated date of diagnosis. 
For individuals who were missing a self-reported date of diagnosis, a date of diagnosis in 
the HARS system, or a date of diagnosis in the UNC medical record, we took the earliest of 
the available dates as the date of diagnosis.  
 
Descriptive Statistics. We first performed basic descriptive analyses, including calculating 
means, standard deviations, and frequencies of the exposure and covariates. A summed 
measure of structural support was generated, along with summary scores of the four types 
of functional social support. The mean structural and functional support score is presented 
and compared to the MOS population for which the scale was validated. 
 
Bivariable Associations. Each functional dimension of functional social support was 
quantified with the modified MOS-SSS Scale and entered into a Cox proportional hazard 
model as a 3-level variable to determine differences in the time to seeking HIV care. The 
proportional hazards model is described in the methods for Specific Aim 1.  
We began our analysis by modeling each of the four functional social support terms 
as the main exposure. For all variables, the proportional hazards assumption was evaluated 
graphically with the use of a log(-log(S(t))) curve and was tested by adding an interaction 
with time to the model (Cox Test). If necessary, the proportional hazards assumption was 
relaxed using a stratified model or by adding categorical time interactions or continuous time 
interactions. We assessed goodness of fit of the models by examining deviance residuals 
and influence statistics. Equality of the survival functions between the exposure levels was 
tested with a Log-Rank or Wilcoxon test, depending on the shape of the survival curve. We 
 59 
 
  
present the Kaplan-Meier curves, unadjusted hazard ratios for all four models, and 95% 
confidence intervals.  
 
Assessment of Effect Measure Modification. To assess effect measure modification (EMM), 
we examined the exposure-outcome relationship for each of the four dimensions of 
functional social support while adjusting for one covariate at a time in the model. The 
covariate was entered into the model individually as a main effect and as an interaction with 
the main exposure. The significance of the interaction term was assessed by comparing the 
likelihood ratio of the “full” model with the interaction term to the model without the selected 
interaction term by the likelihood ratio test (LR). Important interaction terms were included in 
the multivariable models along with their corresponding main effect term. 
 
Assessment of Confounding. Each covariate in the analysis was examined for confounding 
of the functional social support measures. Potential confounders were considered those 
covariates not found to be effect measure modifiers in the bivariate models and that 
changed any level of the unadjusted HR by more than 10% ln|(HRunadjusted/HRadjusted)|. 
Confounders were included for further assessment in the multivariable models. 
 
Multivariable Associations. We constructed four fully adjusted models and then reduced 
each model to only the most essential EMMs and confounders with a backwards elimination 
modeling strategy. In the first step of the analysis, the main exposure, covariates, and 
interaction terms (based on the assessment of EMM in the bivariable analyses) were added 
to the model, constituting the fully adjusted model. EMM was assessed first with the LR test. 
Confounding was examined next – covariates were removed from the model if the estimated 
social support coefficients changed by more than 10% from the unadjusted association. 
After a final model was generated for each dimension of functional social support, we 
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combined the models into a single model with all four measure of functional social support. 
The model was then reduced to eliminate unnecessary interaction terms and confounders. 
 
Approach to Missing Data. Of 336 unique people in the CSDS, four had not completed the 
MOS-SSS up to the 80% criterion (n=4, three non-completers, one with 11 items missing). 
These people were excluded from the analysis. After these exclusions, 13 people had 
missing data in the social support scale. Because each value was required to compute the 
summary scores, we used several methods to determine the optimal method for handling 
the missing data: 
(1) Complete case analysis 
(2) Single imputation with the mean of other values given by the same person 
(3) Single imputation with the mean of the values given the study sample 
(4) Single imputation with the low value (1) 
(5) Single imputation with the high value (5) 
(6) Conditional mean imputation with a linear model. Predictive multiple linear regression 
models were constructed using the subset of the sample with complete data. The 
outcome was the variable of interest and the predictor variables were all the other 
variables in the MOS-SSS scale and age, race, and risk factor information.  
The results of the missing data analysis are presented in Table 4.4. As the results were 
consistent across methods of handling missing data, we proceed by singly imputing missing 
questions with the mean of available values across all participants (option #3).  
 
Sample Size 
The sample size in this study is fixed so we calculated the power available for the non-
parametric log-rank test for equality of the survival curves. We assumed that the hazard ratio 
was constant over time and that there was no accrual or dropouts (a reasonable assumption 
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since all participants in the cohort eventually experience the outcome of entering medical 
care and we will treat time 0, the date of diagnosis, as the same for all patients). We 
included the proportion of patients not in care at three months as a parameter for our 
calculations. From preliminary analyses on a subset of the full dataset, we found that we 
have 78 patients with low functional social support and 261 patients with high functional 
social support (fixed). The results are presented in Table 4.5. The hazard ratio can be 
interpreted as the hazard of not being in care in the group with low social support compared 
to the group with high social support. 
For example, when the sample size in group one is 78 and the sample size in group 
two is 261, the log-rank test for equality of survival curves with a 0.05 two-sided significance 
level will have approximately 79% power to detect the difference between the survival 
curves assuming a constant hazard ratio of 2.29. This estimate of power was based on the 
assumption that 60% of those with low social support will be in care at three months and 
that 80% of those with high social support will be in care at three months.  
 
Strengths and Limitations 
Strength: Timeliness and geographical focus of topic. Much of the discussion about HIV 
prevention has shifted to focus on prevention for positives.9 In line with the goal to target 
prevention messages to HIV-positive individuals, this dissertation examines factors 
associated with care-seeking behavior which could translate to reduced transmission either 
directly via reduced viral load by ARV therapy, or indirectly, by behavior change. Further, 
40% of all persons living with AIDS in the U.S. resided in the southern U.S., and from 2001 
to 2005, the number of deaths from AIDS increased in the region, while other regions of the 
U.S. experienced declines.33 To help to understand these disturbing trends, our study 
focuses on the care-seeking behavior of individuals in the South, which may be different 
from the behavior of HIV-positive individuals in other areas of the U.S. 
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Limitation: Selection bias. Participation in the CSDS is likely biased toward individuals with 
fewer obligations and who need financial support. The effect of this bias is unknown – 
persons who decline to participate in the study may have different levels of social support 
than those who do participate and may also have different care-seeking behaviors.  
 
Limitation: Unmeasured Confounders. Some important confounders are unmeasured in this 
study such as mental health diagnoses, substance abuse treatment, life stress and coping 
style and therefore cannot be included in the analysis.  
 
Limitation: Temporality of exposure and outcome. We do not know if the reported levels of 
social support were present at the time of diagnosis. It is feasible that being diagnosed with 
HIV impacts the level of social support by increasing access to support providing services 
(e.g. support groups, case management). The inability to establish temporality restricts our 
ability to make causal inferences. 
 
SPECIFIC AIM 3 
Describe attitudes and beliefs about HIV testing and care among HIV infected persons 
attending the UNC ID clinic who present with clinically advanced illness. 
 
Study Design Overview 
I conducted a qualitative, semi-structured interview study in the UNC outpatient clinic with 
patients who presented to care late in the course of illness to increase our understanding of 
the process of testing HIV positive and seeking medical care. I interviewed 24 clinic patients 
and discussed their experience testing positive, their decision-making process about 
seeking medical care, and their experience in the clinic once they sought care. Using the 
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Health Belief and Information-Motivation-Behavioral Skills Model as our conceptual 
framework, we present barriers and facilitators to testing and seeking care in North Carolina. 
 
Study Setting 
This study was conducted in the UNC Infectious Disease Clinic. 
 
Study Population 
I conducted semi-structured, individual qualitative interviews of HIV-infected persons who 
presented to care at the UNC Infectious Disease Clinic in the previous year with moderate to 
advanced immunosuppression, defined as an indication for HAART therapy (CD4+ T-
lymphocyte cell count <350 cells/mm3).150  
Patients of the clinic are typically followed every three months for therapeutic, 
virologic, and immunologic monitoring.28 Although the initial clinic visit representing the point 
of initiation of care would theoretically be ideal for our interview, this visit is time-consuming 
for the patient and would have resulted in poor response rates. The first clinic visit typically 
includes a complete medical history, physical examination, laboratory testing, and meetings 
with social workers and case management services. More appropriately, a follow-up visit 
offers the opportunity to recruit patients who have had at least one contact with HIV care 
providers and have returned for continuing care. It is common for patients to have a follow-
up visit shortly after their initial visit, usually 2-4 weeks afterward. Returning patients may 
differ from patients on their first visit in that they may be more reflective of their attitudes and 
beliefs about medical care and they may have formed new opinions since their first visit. 
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Selection Criteria 
Inclusion criteria: The study population was all HIV positive persons who received care at 
the UNC Infectious Diseases clinic and who met the inclusion criteria. The inclusion criteria 
were: 
(1) At least 18 years of age 
(2) Provided written informed consent to participate in the study 
(3) Willing to complete the interview on the same day as the clinic appointment or willing 
to be contacted by phone to schedule another time to return to the clinic 
(4) Mentally and physically able to be interviewed, in a conversational style, for up to 1.5 
hours (determined by study screener) 
(5) New to the UNC ID clinic since April 2006 
(6) Had not received any HIV-related medical care at any other institution 
(7) CD4+ T-lymphocyte cell count <350 cells/mm3 at the first visit (eligible for HAART). 
In this study, we were interested in ‘late testers’ as well as individuals who delayed care 
after a more distal diagnosis. We expected that individuals who tested late in the course of 
illness, often prompted by the onset of symptoms, would represent the majority of the study 
population.  
 
Recruitment 
UNC Infectious Disease Outpatient Clinic employes a research screener who meets with all 
new patients to determine eligibility for the various research protocols. Patients are typically 
screened on their second or third study visits, when laboratory results are available and the 
patient has time to discuss participation in research projects. Patients interested in learning 
more about research studies, including those who consent to participate in the UNC CFAR 
Clinical and Research Database, will be eligible for the study.  
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We utilized a two-pronged approach to recruit patients for the study. Eligible patients 
were approached by the clinic-based research screener to determine interest in study 
participation. Patients interested in learning more about the study met with the study 
interviewer (S. McCoy) before or immediately after their regular clinic visit, at their next 
regularly scheduled clinic visit, or at a separate appointment time selected by the patient. 
The study interviewer explained the study and obtained written, informed consent at the 
start of the interview. 
 
Data Collection 
We conducted in-depth, face-to-face, semi-structured interviews with study participants. All 
interviews were audio recorded and took place in private interview rooms in the UNC 
Infectious Disease Outpatient Clinic. Interviews took approximately 45 minutes.  
An interview guide approach was used to conduct the interviews. Qualitative 
interviews using an interview guide use pre-determined issues to be covered in the interview 
beforehand, however the interviewer is free to change the sequence and the wording in the 
course of the interview.151 Interviews are conversational in style but the interview guide 
format ensures that data collection is somewhat systematic thorough the study. A weakness 
of this technique is that important topics may be missed due to interviewer inflexibility and 
that differences in wording from interview to interview may change the meaning and 
interpretation of the questions.151 In-person, qualitative interviews were the most appropriate 
method for our research question because we sought to understand the process, meaning, 
and context within which HIV positive persons make decisions about health care.152 In-
person interviews, as opposed to focus groups, were best suited to this study due to the 
sensitive and highly personal nature of the subject area. Interview questions were 
comprised of three main types of questions. Main questions addressed the themes of the 
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research questions and were intended to be broad in nature. Follow-up questions sought 
additional details, and probes encouraged even deeper, more detailed information.151  
Participants were compensated for their time at the end of the interview with a $40 
gift card to a local grocery retailer (Food Lion). At the completion of the interview, interview 
summaries were created to record the non-verbal attributes of the interview, first 
impressions of the data, and successes or suggested improvements for future interviews. 
 
Data Management and Data Analysis 
All interviews were digitally taped with consent from the study participants and transcribed 
verbatim within a week of the interview. Interviews were securely stored on the CFAR server 
which was backed-up nightly. Interviews did not contain personal identifiers but were 
identified with a unique study ID in the file name. Consent forms, containing patient 
identifiers, were be stored in a locked, separate file cabinet accessible only to study staff. 
Analysis was ongoing and first involved single-case analysis, including the 
generation of memos and interview summaries, followed by cross-case analyses to identify 
emergent themes, barriers, and patterns.152 Atlas/ti qualitative analysis software was used 
for analysis.153 
 
Memo writing. Memos are brief, unstructured narratives which can assist in the development 
of new ideas and the identification of themes and patterns which emerge from the data.152 
Memos record, reflect, demonstrate, describe and interpret ideas.154 Memos were utilized to 
record field notes after every interview, after reviewing transcripts, and to record surfacing 
themes. 
 
Coding of interviews. Reviewing transcripts and coding began once data collection 
commenced. A start list of organizational and deductive, descriptive codes developed from 
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the Health Belief and Information-Motivation-Behavioral skills (IMB) models was used to 
begin coding, however, coding was continuous and evolving.151, 152, 155 Interpretive, inductive 
codes were added to the code list as themes and patterns emerged from the data. Data 
displays and memo writing facilitated the development of new codes. Codebook evolution 
was documented by noting the dates and interviews from which new codes emerged.151 The 
final codebook for analysis is presented in Table 4.6.  
 
Description of the Study Population. We first present a description of our study population, 
including sample size and demographic breakdown (gender, race, and age). We also 
present information on baseline clinical characteristics of the participants when they first 
sought medical care (year of diagnosis, CD4 T-cell count and time since diagnosis).  
 
Single Case Analysis. The formal qualitative analysis of the data began with data immersion 
into individual interviews. Interviews were broadly coded for themes, examined for narrative 
structure, and compared to the conceptual framework. Segments of text were read for 
multiple dimensions, including the primary message content, attitudes, individual or group-
level ideas, and the degree to which the ideas represented factual or hypothetical 
experience.151 
 
Cross-Case Analysis. Once we completed analysis on 15 interviews, we performed coding 
sorts to examine each theme in more detail. Coding sorts are collections of similarly coded 
passages from multiple interviews.151 Detailed memos with emerging themes and concepts 
were written for each coding sort. The codes used for this analysis included “Facilitators,” 
“Barriers,” “Susceptibility,” “Cues to Action,” “Starting Care,” “Prior HIV Knowledge,” 
“Personal Experience,” and “Stigma.” 
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Data Reduction and Interpretation. Data reduction is the process of reducing the data to its 
most essential concepts, ideas, and relationships.151 We developed a conceptual diagram to 
graphically illustrate the most important concepts that emerged from the data (presented in 
Chapter Seven). We also present the main barriers and facilitators to HIV testing and prompt 
linkage to primary care. 
 
Sample Size 
For this study, we employed a small, purposeful sample to understand the reasons that 
many people do not seek testing and medical care early in the course of illness. Data 
collection was guided by the achievement of theme saturation – when little new information 
was being heard from study participants we had likely interviewed enough participants.151, 156 
Our study consisted of 24 interviews. 
 
Validity Issues, Strengths and Limitations 
The goal of this study was to understand the process of seeking HIV testing and medical 
care with an emphasis on understanding potential barriers and facilitators that may be 
structural (e.g., insurance status, transportation), psychosocial (e.g. lack of social support, 
depression), or behavioral (e.g. risk awareness, fear). Towards this end, ensuring valid, 
credible interpretations of the data was paramount. Common threats to validity in qualitative 
research are researcher bias, the “lens” through which the researcher views the world, and 
reflexivity, the concept that the researcher is part of the world that he/she studies.152 To 
ensure the trustworthiness of the data, we utilized several techniques to validate the 
credibility of our findings. 
One such technique was the maintenance of a comprehensive audit trail. An audit 
trail is a record that allows the researchers and outsiders to track the process that lead to 
the study’s conclusions.151 In this study, the audit trail includes unedited transcripts, tape 
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recordings, and field notes of interviews, coding lists and codebook evolution memos, data 
reduction and analysis notes, diagrams, hypotheses, study protocol documents, and 
instrument development notes.151 These documents ensure that the findings from the study 
could be confirmed by other researchers. 
As we developed explanations for the actions of the study participants, we actively 
looked for ‘rival hypotheses’ or negative cases to invalidate our hypotheses. The bias that is 
introduced by the researcher’s influence over the interpretation of the results was addressed 
by discussions with study team members, the collection of in-depth data, and by the 
generation of an accurate representation of the concepts offered by the study participants. 
Despite the commitment to ensuring the validity of our findings, one limitation of our 
study is the ability to apply our findings to other populations. Our study focuses on HIV 
positive patients who come to the UNC outpatient clinic for primary care, therefore we have 
limited generalizability of outside of the UNC catchment area. Although UNC patients come 
from all 100 counties in North Carolina, our findings may not be transferable to clinics with a 
high proportion of rural residents, or clinics where injecting drug use is more prevalent. We 
can, however, expect that our findings will be transferable to other HIV/AIDS clinics in the 
southeastern U.S. 
 
LIMITATIONS 
The limitations of the proposed methods for the study aims were presented at the 
conclusion of each research design section. Here we repeat certain limitations that apply to 
several or all of the aims. 
 
Limitation: Limited generalizability outside of the Southern U.S.  
This dissertation focuses exclusively on patients with HIV in North Carolina. Our findings 
may not be directly applicable to the national epidemic; however, they are likely relevant for 
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other areas in the southern U.S. which may have similar rates of poverty, STDs, and 
proportion of residents living in rural areas. 
 
Limitation: Causal inference.  
Because of the retrospective nature of all of the data utilized in this proposal, we have 
limited ability to infer causality to our findings. Both the CSDS questionnaire and the 
qualitative interviews ask patients to recall their behavior after testing positive. 
Misclassification of exposures and outcomes may have occurred. Similarly, patients may 
have reported factors that hindered or helped their successful linkage to care, but it is 
possible that the importance of reported factors changed over time and the reported factors 
and actual factors differed.  
 
Limitation: Limited power to detect differences.  
For Aim 1 and 2, we had low statistical power to detect small differences. This resulted in 
imprecise estimates. However, although our number of acute HIV cases was small, it is a 
large number with respect to previous studies of acute HIV patients. Further, our study of 
social support and entry to care is one of the few studies on the topic and is a valuable 
contribution to the literature despite any imprecision. 
 
SUMMARY 
The new testing recommendations issued by the Centers for Disease Control in 2006 aim to 
incorporate HIV testing into routine medical care. A comprehensive understanding of how, 
when, and why newly diagnosed individuals enter care is therefore necessary to ensure that 
the new screening guidelines yield their maximum benefit. Towards this end, we sought to 
understand the HIV testing and care-seeking behavior of individuals in North Carolina. We 
undertook a multidimensional approach, relying on data from diverse sources and utilizing 
 71 
 
  
different methods of data collection. This dissertation is innovative in that it relied on 
intensive interviews with the DIS in the field, psychosocial factors from interviews in the 
clinic, as well as qualitative interviews with patients. This multifaceted approach expanded 
our current knowledge about HIV testing and medical care in the region.  
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TABLE 4.1. Estimates of time periods between HIV infection and detectable HIV antibody 
on 2nd and 3rd generation EIAs. 
 
Window1 Description Reported Estimates Average Interval 
 
1 
 
HIV infection to infectivity 
 
10 days137, 157 
2.5 days158 
 
6.3 days 
2 Detectable HIV RNA 11 days157 
9 days159 
10 days 
3 Detectable p24 antigen 3 days 137 
5 days157 
6 days (Genprobe assay) 159 
4.2d (Roche assay)159 
7 days (50 copies/ml)139 
5 days (100 copies/ml)139   
5.0 days 
 
4 
 
Antibody detection via 3rd generation EIA 
 
5 days137  
6 days157 
5.3 days139, 159 
 
5.4 days 
5 Antibody detection by 2nd generation EIA 8.8 days139 8.8 days 
 
 
1.  Window periods are the time between the previous interval and the next event. For example, 
window period two represents the time between HIV infectivity to detectable HIV RNA.  
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FIGURE 4.1. Power estimates for the two sample t-test test of log(HIV RNA). Graph A (top) 
illustrates the power for detecting a difference between individuals co-infected with an STI 
and those without co-infection; Graph B (bottom) illustrates the power for detecting a 
difference between testing site type.  
 
A. 
 
B. 
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TABLE 4.2. Modified Medical Outcomes Study Social Support Survey  
 
  
1.    About how many close friends do you have (people you feel                                __________(No. close friends) 
at ease with and can  talk to about what is on your mind)?        
  
2.    About how many close relatives.....?                                                                         _________(No. close relatives) 
  
3.    People sometimes look to others for companionship, assistance, or other types of support.  How often is each 
of the following kinds of support available to you if you need it? 
  
  None of 
the time 
A little of 
the time 
 Some of 
the time 
Most of 
the time 
All of the 
time 
Skip=7 
Dk=8 
RF=9 
a.  Someone to have a good time 
     or hang with 
  
1 
  
2 
  
3 
  
4 
  
5 
  
7  8  9 
              
b. Someone to do things with and 
    help you get your mind off things 
  
1 
 
2 
  
3 
  
4 
  
5 
  
7  8  9 
              
c. Someone to help you if you were 
confined to bed. 
  
1 
  
2 
  
3 
  
4 
  
5 
  
7  8  9 
              
d. Someone to give you good advice about 
a crisis. 
  
1 
  
2 
  
3 
  
4 
  
5 
  
7  8  9 
              
e.  Someone who's advice you want.   
1 
  
2 
  
3 
  
4 
  
5 
  
7  8  9 
              
f.  Someone to take you to the doctor if you 
needed it. 
  
1 
  
2 
  
3 
  
4 
  
5 
  
7  8  9 
              
g.  Someone who shows you love and 
affection. 
  
1 
  
2 
  
3 
  
4 
  
5 
  
7  8  9 
              
h.  Someone you can count on to listen 
when you need to talk. 
  
1 
  
2 
  
3 
  
4 
  
5 
  
7  8  9 
              
 i.  Someone who hugs you. 1 2 3 4 5 7  8  9 
              
j.  Someone to prepare your meals if you 
were unable to do it. 
  
1 
  
2 
  
3 
  
4 
  
5 
  
7  8  9 
              
k.  Someone to share your most private 
worries and fears with 
  
1 
  
2 
  
3 
  
4 
  
5 
  
7  8  9 
              
l.  Someone to help with daily chores if you 
were sick. 
  
1 
  
2 
  
3 
  
4 
  
5 
  
7  8  9 
              
m. Someone to love and make you feel 
wanted. 
  
1 
  
2 
  
3 
  
4 
  
5 
  
7  8  9 
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FIGURE 4.2. Common factor model used for confirmatory factor analysis of the modified 
MOS Social Support Scale. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: 
 
A-M: Observed indicators 
δ = Unique variance (measurement error) for each indicator 
λ = Factor loadings or regression slopes for predicting the indicator values from the latent factor 
η = First-order latent factors (unobserved) 
ξ = Second-order latent factor (unobserved) 
ζ = Factor errors 
φ = Factor covariances 
γ = Association of exogenous and endogenous latent factors 
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TABLE 4.3. Creation of linear spline terms for each dimension of functional social support. 
Knots were created at appropriate cutpoints, entered into a proportional hazards model, and 
tested for statistical contribution to the model with the likelihood ratio test.  
 
 
Affectionate 
Support 
Emotional 
Informational 
Support 
Tangible Support Positive Social Interaction 
 
Knot 1 (score) 
 
10th percentile 
(53.3) 
 
 
10th percentile 
(50.0) 
 
10th percentile 
(40.0) 
 
10th percentile 
(40.0) 
 
Knot 2 (score) 
 
25th percentile 
(73.3) 
 
50th percentile 
(80.0) 
 
50th percentile 
(85.0) 
 
50th percentile 
(80.0) 
 
Knot 3 (score) 
 
50th percentile 
(93.3) 
 
75th percentile 
(95.0) 
 
70th percentile 
(95.0) 
 
75th percentile 
(90.0) 
 
LR test of spline 
terms (p-value) 
 
0.83 
 
0.73 
 
0.89 
 
0.86 
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FIGURE 4.3. Scatter plots of survival function estimates and functional social support. A: Emotional/informational support; B: 
Affectionate support; C: Tangible support; D: Positive social interaction support.   
A.          B.  
A.  
 
 
 
 
 
 
C.          D.   
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FIGURE 4.4. Hypothesized causal diagram of the relationship between social support and 
delayed HIV care. Dashed lines indicate potential associations that are unmeasured or 
unknown in the data. The relationship between race and sex and perceived social support 
has not been described. 
 
 
 
Low Perceived 
Social Support 
Delayed HIV Care  
After Diagnosis 
Ever  
Homeless 
Substance 
Abuse 
Ever 
Jail/Prison 
Race
Sex 
Mental Health 
? 
Unmeasured 
Confounders 
Stress 
Coping Style 
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TABLE 4.4. Results of analysis strategies for handling missing data in the modified MOS-
Social Support Scale. Thirteen of 332 (3.9%) participants completing the CSDS had any 
missing data in the 13-item functional support scale (9 had one missing value, three had two 
missing values, and one person had three missing). The mean and standard deviation for 
each of the functional social support types is presented for each missing data strategy. 
 
 
1. Missing values were imputed with the mean of the available data within each respondent. 
2. Missing values were imputed with the mean of the same question for the study sample. 
3. Missing values were imputed with the lowest value (1). 
4. Missing values were imputed with the highest value (5). 
5. Predictive multiple linear regression models were constructed for each question on the MOS-
SSS using the subset of the sample with complete data. The outcome was the indicator of 
interest and the predictor variables were all the other variables in the MOS-SSS scale and 
demographic factors. If a record was missing more than one value in the scale, the model 
was constructed using only the available indicators. The predicted value for each person was 
then used in place of the missing value. 
 
Complete Case 
Analysis (n=319)  Single Imputation
1  Single Imputation2 
Functional Support Type 
Mean SD  Mean SD  Mean SD 
 
Positive Interaction 
Tangible  
Emotional/information  
Affection 
 
Total 
 
71.8 
79.7 
78.9 
83.8 
 
79.2 
 
22.8 
21.5 
19.3 
21.7 
 
18.0 
 
 
71.9 
79.5 
78.8 
83.5 
 
79.1 
 
22.6 
21.4 
19.3 
21.9 
 
18.0 
 
 
71.8 
79.6 
78.8 
83.5 
 
79.1 
 
22.6 
21.3 
19.3 
21.9 
 
18.0 
Single Imputation 
(1)3  
Single Imputation 
(5)4  
Conditional mean 
imputation5 Functional Support Type 
Mean SD  Mean SD  Mean SD 
 
Positive Interaction 
Tangible  
Emotional/information  
Affection 
 
Total 
 
71.7 
79.0 
78.7 
83.5 
 
78.8 
 
22.7 
21.7 
19.3 
21.9 
 
18.0 
 
 
71.9 
79.8 
78.9 
83.6 
 
79.2 
 
22.6 
21.2 
19.3 
22.0 
 
18.0 
 
 
71.9 
79.5 
78.9 
83.5 
 
79.0 
 
22.6 
21.4 
19.3 
21.9 
 
18.0 
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TABLE 4.5. Power estimates for the log-rank test for equality of the survival curves comparing the time to entry to medical care by 
levels of social support.1 
 
Expected Constant Hazard Ratio, HR 
 HR=4.10 HR=3.10 HR=2.29 HR=1.60 HR=5.63 HR=4.26 HR=3.14 HR=2.19 
Test significance level, α 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
2-sided test Yes Yes Yes Yes Yes Yes Yes Yes 
N1  (Low Social Support) 78 78 78 78 78 78 78 78 
N2  (High Social Support) 261 261 261 261 261 261 261 261 
% Not in care at 3 mo, Group 1  80 80 80 80 85 85 85 85 
% Not in care at 3 mo, Group 2 40 50 60 70 40 50 60 70 
Power 99 97 79 30 99 99 92 62 
 
1. Accrual is expected to be 100% at 3 months with no dropouts – all participants eventually experience the outcome. 
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TABLE 4.6. Codebook for coding qualitative interviews. 
No. Code Name Created / Modified Brief Definition Full Definition When to Use When Not to Use 
Level 1 Codes – Organizational 
 
 
 
L1 Decision to Test Start List How individual was tested for HIV 
Answers to question: “Tell me 
about your decision to get tested 
for HIV.” 
N/A N/A 
 L1 Testing process Start List What testing was like 
Answers to question: “Tell me 
about the actual testing process 
for HIV.” 
N/A N/A 
 L1 Impact of Result Start List Finding out you are HIV positive 
Answer to question: “How were 
you affected by learning that you 
were positive?” 
N/A N/A 
 L1 Knowledge of HIV Start List 
How much known 
about HIV before 
diagnosis 
Answer to question: “did you know 
about HIV when you were first 
diagnosed?” 
N/A N/A 
 L1 Seeing a Doctor Start List Thoughts about seeing a doctor 
Answer to question: “Did you think 
about seeing a doctor after your 
diagnosis?” 
N/A N/A 
 L1 Medical Care Start List Thoughts about seeking care 
Answer to question: “What was it 
like seeking medical care for the 
first time for HIV?” 
N/A N/A 
 L1 Come Back Start List Thoughts about staying in care 
Answer to question: “Why did you 
come back this time?” 
Also use this code for 
references to staying in 
care after the initial 
contact with the clinic.  
N/A 
 Great quotes Start List Great quotes 
Vivid, insightful, and/or unusual 
descriptions of feelings and 
thoughts 
N/A N/A 
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No. Code Name Created / Modified Brief Definition Full Definition When to Use When Not to Use 
Level 2 Codes – a priori Themes and Concepts 
1. Trauma of discovery Start List Reactions to diagnosis 
Feelings and thoughts about 
learning one is HIV positive 
If talking about immediate 
reactions to the diagnosis, 
use this code; often 
occurs as shock, sadness, 
depression, fatalism 
Not appropriate for 
current thoughts and 
feelings about diagnosis 
2. Suicide 11/28/07, Interview 1 
Subcode of Trauma 
of Discovery 
Suicidal thoughts and feelings 
about learning one is HIV positive 
Use for “pre-existing” 
suicide as well as suicide 
thoughts or attempts after 
diagnosis 
 
3. Denial 12/11/07, Interview 2 
Subcode of Trauma 
of Discovery 
Refusal to recognize or 
acknowledge the gravity of the 
HIV diagnosis 
Use this code for patients 
who seem indifferent 
about their diagnosis or 
who refuse to accept the 
seriousness of the 
disease 
 
4. Fatalism 12/11/07, Interview 2 
Subcode of Trauma 
of Discovery 
The acceptance of the HIV 
diagnosis as inevitable   
5. Depression 12/11/07, Interview 3 
Subcode of Trauma 
of Discovery 
References to depression before 
or after the diagnosis   
6. Being overwhelmed 12/11/07, Interview 3 
Subcode of Trauma 
of Discovery 
To be presented with an 
excessive amount of something, 
usually information 
  
7. Personal experience Start List Contact with PLWHA 
Narratives about participants’ past 
experience with HIV positive 
persons 
Use this code when 
patients refer to knowing 
PLWHA prior to diagnosis 
Not applicable to 
experiences with 
PLWHA after diagnosis  
8. Prior HIV knowledge Start List Prior HIV/AIDS knowledge 
Knowledge about HIV/AIDS 
before seeking medical care, 
including transmission, clinical 
course, and treatment. 
Use to describe all 
knowledge about 
HIV/AIDS biology, 
treatment, or outcomes 
prior to diagnosis 
This code is not 
appropriate for 
knowledge obtained 
about HIV/AIDS after 
diagnosis 
  
83 
No. Code Name Created / Modified Brief Definition Full Definition When to Use When Not to Use 
9. Barriers Start List Obstacles to testing and medical care 
Self-identified reasons for not 
seeking testing or medical care 
after diagnosis  
Use for instances when 
the patient describes 
obstacles to seeking 
testing or care, whether 
self-imposed (perception 
of risk) or structural (did 
not know where to seek 
testing or care). 
 
10. Drugs/Alcohol 12/11/07, Interview 2 
Subcode of 
Barriers 
References to way that drugs or 
alcohol abuse may impede testing 
or seeking care 
  
11. Facilitators Start List 
Factors which 
provoked testing 
and medical care 
Self-identified reasons for seeking 
testing or medical care after 
diagnosis 
Appropriate for all reasons 
why the individual sought 
testing and medical care, 
including personal 
(wanted to know) and 
structural (provider-
initiated testing) 
This code should not be 
used to code references 
to the potential benefits 
of seeking testing or care 
– in this case the code 
‘Benefits’ is more 
appropriate. 
12. Susceptibility Start List Vulnerability to HIV/AIDS 
Beliefs about perceived 
susceptibility to HIV disease, 
whether before testing positive or 
after testing positive 
Use this code for all 
references to individual 
perceived risk of 
acquisition; also for 
references to severity of 
disease after acquisition. 
 
13. Benefits Start List 
Advantages to 
seeking testing and 
care 
Beliefs about the advantages of 
seeking testing and medical care 
after diagnosis 
Use this code when the 
participant refers to 
thoughts about the 
positive aspects of testing 
and medical care. These 
thoughts do not 
necessarily have to be the 
ones that incited testing or 
seeking care. 
References to actual 
reasons for seeking 
testing or medical care 
should be coded as 
‘Facilitators.’ 
14. Cues to action Start List Prompts to take action 
Stimuli which ultimately resulted in 
seeking testing or medical care 
Appropriate for references 
about the pivotal event 
that incited testing or 
seeking medical care, 
such as an illness, 
provider-initiated testing, 
or an incident STI.  
Not appropriate for 
references to benefits or 
facilitators of testing, this 
code is reserved for the 
actual prompt which 
incited testing or seeking 
care. 
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No. Code Name Created / Modified Brief Definition Full Definition When to Use When Not to Use 
15. Provider-initiated testing 
11/28/07, 
Interview 
1, 
3/19/07 
modified 
Subcode of Cue to 
Action. When a 
patient did not seek 
testing  
Testing events where the patient 
did not request or seek testing, 
rather, testing was recommended 
by a provider 
Use this code for testing 
experiences that did not 
include client-initiated 
testing 
 
Level 3 Codes – Inductive codes – Emergent Themes and Concepts 
16. Missed opportunities 12/11/07, Interview 3 
Subcode of 
provider-initiated 
testing 
Missed opportunities for provider-
initiated testing   
17. Near death  11/28/07, Interview 1 
Near-death 
experiences 
Experiences of the patient that 
were perceived to be near death 
Use for perceived near 
death experiences as well 
as major medical 
episodes experienced by 
the patient 
Not for references to 
death-related thoughts 
and planning 
18. Spirituality 11/28/07, Interview 1 
The role of God or 
religion 
References to God, religion, or 
spirituality 
Use this code for all 
references to God, 
religion, or spirituality, 
named or implicit 
 
19. Punishment 11/28/07, Interview 1 
Subcode of 
Spirituality 
Thoughts that God is punishing 
the patient by giving them HIV   
20. Confusion 11/28/07, Interview 1 
Uncertainty about 
the HIV diagnosis or 
meaning 
References to confusion about the 
testing process, results, or 
meaning 
  
21. Changes after diagnosis 
11/28/07, 
Interview 1 
How an individual’s 
life was altered  
References to changes after an 
HIV diagnosis 
References to changes in 
material possessions, job 
status, or behavior after 
diagnosis 
 
22. Social support 11/28/07, Interview 1 
Resources from 
other people 
References to the existence or 
quantity of social relationships 
and the resources provided by 
other persons. 
Can be used for 
references to structural or 
functional social support.  
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No. Code Name Created / Modified Brief Definition Full Definition When to Use When Not to Use 
23. Starting care 11/28/07, Interview 1 
Thoughts and 
feelings about 
starting HIV care 
References to the patient’s 
thoughts or feelings about starting 
HIV care 
Use for references to fear, 
stigma, being 
overwhelmed, or 
anticipation 
 
24. Medical care challenges 
11/28/07, 
Interview 1 
Subcode of starting 
care. 
Difficult aspects of 
medical care 
References to challenges staying 
in care, taking ARVs, being 
overwhelmed, etc. 
  
25. Staying in care 12/11/07, Interview 2 
Subcode of starting 
care. 
References to the challenges of 
staying in care, or how the person 
successfully stays in care 
  
26. Stigma 11/28/07, Interview 1 
References to 
stigma, experienced 
or perceived  
(Unfavorable) attitudes, beliefs, 
and policies directed toward 
people perceived to have 
HIV/AIDS 
Use for references to 
experienced or perceived 
stigma, including fear of 
stigma and decisions 
made with stigma in mind, 
also for fear of people 
finding out or talking about 
someone with HIV 
 
27. Disclosure 12/11/07, Interview 2 
The act of revealing 
one’s HIV status to 
another person 
The process of telling someone 
else, outside of the healthcare 
system, that you are HIV positive  
Use for all references to 
the process of disclosure, 
the good and bad 
outcomes of disclosure, 
and thoughts about 
disclosing 
 
28. Double-whammy disclosure 
12/12/07, 
Interview 5 
Subcode of 
disclosure 
The process of disclosing HIV 
status and another secret (e.g., 
being gay, having an affair) 
  
29. 
Planning for death 
 
Modified to just 
“Planning” 
12/11/07, 
Interview 2 
 
12/12/07, 
Interview 5 
Thoughts about 
planning after 
diagnosis 
References to planning after 
diagnosis, including planning for 
death, preparing estates, 
finances, or family members 
  
30. Hope 12/11/07, Interview 2 
To have confidence 
in the future 
The feeling that what is wanted 
can be had or that events will turn 
out for the best 
  
 CHAPTER FIVE: Sexually Transmitted Infections among Patients with  
Acute HIV in North Carolina 
 
 
 
 
ABSTRACT 
Objective: Our objective was to describe the frequency and types of STI co-infections 
among patients with acute HIV infection (AHI). Methods: We examined surveillance data 
from publicly-funded HIV testing sites in North Carolina. Antibody negative specimens are 
retested for HIV RNA using specimen pooling. Demographics, symptoms, and STI infections 
are collected. We calculated the prevalence of co-infection and determined risk factors for 
co-infection with prevalence ratios (PR). Results: Between 11/1/2002 and 10/31/2006, 75 
clients with AHI were identified. Of these, 23 (31%) had STI co-infections at the time of 
diagnosis — nine (39%) had gonorrhea and five had trichomoniasis (22%). The prevalence 
was highest in women (53%) compared to 35% in heterosexual men (PR=0.67, 95% CI 
0.31, 1.45) and 18% in men who have sex with men (PR=0.34, 95% CI 0.15, 0.76). The type 
of co-infection differed by gender with women more likely to be diagnosed with 
trichomoniasis (p<.01). Non-Whites were 3.9 times as likely to report a co-infection as 
Whites (95% CI 1.00, 15.10). Conclusions: STI co-infection is common among patients with 
AHI. Differences in the prevalence of co-infection by gender, risk and race suggest that STIs 
may have a role in the heterosexual HIV epidemic in North Carolina.  
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INTRODUCTION 
Acute HIV-1 infection (AHI) is the 4-6 week interval in the HIV disease course when 
the virus can be detected in the blood prior to seroconversion.83 During this time, the virus is 
distributed to cellular reservoirs throughout the body and infected persons experience a 
dramatic increase in plasma viral load and viral shedding from the genital tract.83-85, 160 
Roughly half to two-thirds of people with AHI will develop symptoms of acute retroviral 
syndrome about two weeks after infection.103-105, 134, 135 The acute phase of infection has 
been identified as a key intervention period to interrupt HIV transmission because the peak 
viremia characteristic of AHI may dramatically increase the likelihood of sexual transmission 
during this time. 61, 84, 87, 89 
Sexually transmitted infections (STIs) have a well-established synergistic relationship 
with HIV infection. Co-infection with HIV and an STI can increase the probability of HIV 
transmission to an uninfected partner by increasing HIV concentrations in genital lesions, 
genital secretions, or both.90, 107 STI infection can also increase the likelihood of HIV 
acquisition by interrupting mucosal barriers, increasing the access to and concentration of 
HIV receptor cells, and, in women, changing the vaginal microflora to favor HIV infection.17, 
108-110 Among patients with AHI, co-infection with an STI may be common. More than 70% of 
AHI patients had an STI co-infection in a Malawian sexually transmitted disease (STD) clinic 
in two separate studies.104, 160 However, little is known about the frequency of STI and acute 
HIV infection co-infection outside of the STD clinic setting. 
In addition to facilitating HIV transmission, STIs may also influence HIV testing 
behavior. Symptomatic STIs in recently HIV-infected individuals may provide motivation to 
seek medical care and to consequently receive HIV counseling and testing services earlier 
than persons without co-infections, either by provider- or client-initiated testing. However, 
recently revised testing recommendations only recommend RNA testing in patients with 
compatible clinical syndromes and recent high-risk behavior.49 Under these guidelines, 
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patients who co-acquire HIV and an STI infection may be missed by standard HIV antibody 
tests when STI symptoms appear, given the short incubation periods of some bacterial STIs. 
Since individuals with AHI represent the earliest possible time point for entry into the 
medical system and public health intervention, a thorough understanding of factors relating 
to testing behavior during AHI is warranted. 
To further examine these issues, we conducted a secondary data analysis of 75 AHI 
patients identified from the statewide Screening and Tracing Active Transmission Program 
(STAT) in North Carolina (NC) from 2002-2006. Our goals were to describe the prevalence 
and predictors of acute HIV and STI co-infection in a systematically collected, statewide 
sample of AHI patients and to examine whether STI co-infection might influence the 
likelihood of presenting early during AHI.   
 
 
METHODS 
Study Design and Population 
Persons with AHI are routinely identified through the STAT Program of the North Carolina 
Department of Health and Human Services (NC DHHS) and the University of North Carolina 
at Chapel Hill (UNC). The screening methodology has been previously described.103, 130 In 
brief, all clients presenting for confidential HIV counseling and testing at approximately 135 
publicly funded sites in NC are included in a testing algorithm to detect HIV-1 RNA positive, 
antibody negative individuals. Serum samples submitted for HIV testing are first tested for 
HIV-1 antibody, and then all antibody negative samples are screened for HIV-1 RNA by 
pooling.130 Antibody indeterminate samples are tested for HIV RNA individually. Vironostika 
HIV-1 enzyme immunoassay (EIA) and Western Blot analysis kits (Bio-Rad Laboratories) 
are used for antibody screening. Pools were screened by nucleic acid amplification (NAAT) 
for HIV-1 RNA with the Procleix HIV-1 assay (GenProbe) and then in July 2005 with the 
EasyQ HIV-1 quantitative assay (bioMerieux). Samples in which HIV-1 RNA is detected and 
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are either EIA negative or EIA positive and Western Blot negative or indeterminate are 
considered to represent acute infections, and are confirmed by follow-up antibody testing. 
We included clients with AHI during the first four years of the STAT program, November 1, 
2002 through October 31, 2006.  
 
Follow-up and Confirmatory Testing 
The NC DHHS assigns potential AHI cases to a team of disease intervention specialists 
(DIS). DIS are located throughout the state and perform initial interviews, confirmatory 
testing, and referrals to care within 72 hours of notification.103 After interview with the patient 
and medical record review, DIS complete standardized case report forms. This information 
is merged with pretest counseling and testing data from the NC DHHS, including risk factor 
information and testing site. All data are de-identified.  
 
HIV-1 RNA Quantification 
Quantification of HIV-1 RNA is routinely conducted for all AHI patients on the initial and 
confirmatory venous blood samples. An HIV-1 reverse transcriptase polymerase chain 
reaction assay is used to quantify serum HIV-1 RNA (Amplicor HIV-1 Monitor Test, version 
1.5, Roche Diagnostic, limits of detection 50–750,000 copies/milliliter). HIV RNA was not 
detected in one patient despite having RNA detected initially; this was likely due to 
specimen degradation secondary to shipping delays. This patient was excluded from viral 
load analyses. 
 
Statistical Analysis 
We assigned sexual risk groups according to the gender of partners reported in the previous 
eight weeks. Men with any male partners were classified as men who have sex with men 
(MSM) and men with only female partners were classified as heterosexual. All of the women 
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in the study reported only male partners (classified as heterosexual). We defined STI co-
infection as the diagnosis of gonorrhea, chlamydia, trichomoniasis, Human Papillomavirus 
(HPV), genital herpes, bacterial vaginosis (BV), or syphilis during the same month and year 
of the initial AHI diagnosis, as the data collection forms only require the month and year of 
STI diagnoses. STI infections were confirmed by medical record review. For two AHI 
patients, the date of STI diagnosis was in the month preceding the HIV diagnosis by 13 and 
18 days, respectively. We considered these situations to represent STI co-infections. 
Information on self-reported STI-compatible symptoms was assessed if present at or within 
four weeks prior to AHI diagnosis. Similarly, we considered appropriate symptoms reported 
during a window period of eight weeks of testing (± four weeks of the test date, inclusive) to 
be acute retroviral syndrome. 
We describe the characteristics of the study population and the proportion of AHI 
patients with an STI at the time of AHI diagnosis. To determine factors associated with STI 
co-infection, we computed the prevalence of co-infection, prevalence ratios (PR), and 95% 
exact confidence intervals to test associations between co-infection and selected covariates. 
Because viral load is associated with the likelihood of sexual transmission of HIV, we 
examined variations in mean log10(HIV-1 RNA) from initial testing samples with one-way 
analysis of variances to determine predictors of HIV-1 RNA variation.61 Similarly, we were 
interested in the relationship between study covariates and viral dynamics in order to 
understand more about the timing of testing. Towards this end, among the subset of 
participants with both initial and confirmatory HIV RNA values, we classified patients as 
having an increasing or decreasing HIV RNA slope. We then used exact logistic regression 
to assess the relationships between this dichotomous indicator of HIV RNA slope (outcome) 
and study covariates. We assumed that a positive HIV RNA slope was indicative of testing 
before the peak viremia. The statistical significance of covariates entered individually in 
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models was assessed with an exact probability test of the β parameter(s). All analyses were 
performed with SAS Software (version 9.1.2, SAS Institute, Cary, NC).  
 
Human Subjects Protection 
Clients who presented for confidential HIV testing in NC were required to sign an informed 
consent form authorizing the collection of personal information. Patients with AHI signed an 
additional consent to release information and blood to the STAT program. This analysis was 
approved by the UNC Institutional Review Board. 
 
RESULTS 
From November 1, 2002 to October 31, 2006, 79 persons with AHI were detected 
through the STAT program. Of these, three could not be located for interview and one 
refused post-test counseling and partner notification services, leaving a sample of 75 
patients with AHI for analysis. Seventy-five percent of the study population were male (Table 
5.1), and 52% were MSM. The median age was 28 years (range: 16-56). The majority of the 
population were Black, followed by a quarter White, non-Hispanic. Half of the cases were 
identified at STD clinics. A majority of persons (n=45, 60%) reported at least one acute 
retroviral symptom at or before the initial testing date. The most common symptoms were 
fever (37%), night sweats (24%), fatigue (24%), body aches (21%), and nausea (21%). Of 
those persons with symptoms, 87% reported two or more symptoms and 58% reported three 
or more symptoms at or before the initial test. A small number of persons (9) reported 
symptom onset after the test date.  
  Nearly one third of patients (n=23, 31%) had an STI at or near the time of the AHI 
diagnosis, consistent with co-infection. Five (22%) of the 23 participants with STI co-
infections had more than one concurrent STI diagnosis at the time of AHI recognition. One 
person reported three STI co-infections: HPV, genital herpes, and syphilis. Medical record 
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review confirmed 26 of 29 (90%) individual STI diagnoses from the DIS, which 
corresponded to 21 (91%) of the 23 patients with co-infections. The most common co-
infections were gonorrhea (39%), trichomoniasis (22%), and syphilis (17.4%) (Table 5.2). 
Co-infections differed substantially by gender – the majority of male co-infections were 
gonorrhea (54%) whereas among women the most common co-infection was trichomoniasis 
(50%, Fisher’s exact test, p<.01). An additional five patients (7%) self-reported STI 
compatible symptoms (e.g. genital discharge or sores, scrotum pain, or burning upon 
urination) within four weeks before the test date that did not result in an STI diagnosis. 
These patients were all non-White, predominantly men (80%), and diagnosed with AHI at 
STD clinics (80%). 
 We identified a strong interrelationship between gender, race, risk category, and STI 
co-infection. The prevalence of co-infections was lower in MSM (18%, PR=0.34, 95% CI 
0.15, 0.76) and heterosexual men (35%, PR=0.67, 95% CI 0.31, 1.45) than women (53%, 
Table 5.3). Non-Whites were 3.9 times as likely to report a co-infection as Whites (95% CI 
1.00, 15.10). Among MSM, all seven STI co-infections occurred in non-Whites (p=.03); this 
finding was consistent for heterosexual men as all six co-infections were in non-Whites, 
although only one White heterosexual man was in the study population. All four syphilis 
infections were detected in non-White men (3 MSM, one heterosexual). Among women, two 
of the three White women were co-infected and half (8 of 16) of the non-White women 
reported an STI co-infection.  
 The prevalence of STI co-infection was roughly equal among AHI patients detected 
at HIV counseling and testing (CTS) locations (35%, 95% CI 14.2, 61.7) and STD testing 
locations (36%, 95% CI 20.8, 53.8). However, AHI patients detected at other types of clinics 
(e.g., prison/jail, obstetrics/gynecology, outreach testing events) were less likely to have a 
co-infection identified (18.2%, 95% CI 5.2, 40.3). AHI patients with acute retroviral 
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symptoms at or before testing were also somewhat less likely to report STI co-infections 
(PR: 0.61 95% CI 0.31, 1.20), although the estimate is imprecise. 
 We found little variation in serum viral load at the time of testing (Table 5.4). The 
overall mean viral load at the time of testing was 5.2 log10 copies/ml.  MSM had slightly 
higher mean log10(HIV RNA) at testing compared to both heterosexual men and women 
(p=.36). Individuals at least 36 years of age had the highest mean HIV RNA (5.48 log10 
copies/ml) compared to both those ≤25 years (5.0 log10 copies/ml) and those 26-35 years 
(5.1 log10 copies/ml). Non-Hispanic Whites had higher mean HIV RNA than non-Whites 
(p=.22). Individuals with STI co-infections had slightly lower mean HIV RNA at testing (4.9 
log10 copies/ml) compared to those without co-infections (5.3 log10 copies/ml, p=.13).  
 We used logistic regression to assess the role of demographic and behavioral factors 
on the slope of log10(HIV RNA) using a subset of 44 clients for which both the initial and 
confirmatory HIV RNA values were available (Table 5.4).  The samples were collected an 
average of 16 days apart. We hypothesized that some factors would be predictive of an 
increasing HIV RNA slope, suggesting that the initial HIV test was performed before the 
peak viremia, whereas other factors may be associated with declining slopes suggesting 
that the test was performed near or after the HIV RNA peak. Factors associated with 
increasing HIV RNA slopes were younger age, non-White race, and symptoms at or before 
testing. In particular, non-Whites were almost twice as likely to have an increasing HIV RNA 
slope than Whites (OR=1.70, 95% CI 0.31, 11.99), and individuals with symptoms were 
about three times as likely to have an increasing RNA slope than those without symptoms 
(OR=2.94, 95% CI 0.67, 15.67). The only factor that was associated with a declining HIV 
RNA slope was testing location; compared to HIV CTS sites, both STD clinics and other 
testing sites were associated with a declining HIV RNA slope. Gender, risk behavior and STI 
co-infection had little relationship with HIV RNA slope.  
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DISCUSSION 
In a large study evaluating STI co-infection during acute HIV infection, we 
demonstrated that STIs are commonly detected among people who very recently acquired 
HIV. As we have defined them, co-infections can represent three potential scenarios. First, 
co-infections may signify infections where HIV and an STI were acquired simultaneously in a 
co-transmission event. They can also represent prevalent infections present before HIV 
acquisition. Finally, co-infections can represent incident STI infections obtained after HIV 
acquisition. We believe that this latter possibility is unlikely, since most of the AHI patients 
were detected within several weeks of infection. Assuming that co-infection corresponds to 
the first two situations – co-acquisition events or prevalent STI infections –  a causal role for 
STI infection in facilitating HIV transmission is possible, either by increasing the likelihood of 
HIV transmission from the source partner or by increasing the susceptibility of the index 
patient.  
Although this study represents one of the largest examinations of persons with AHI, 
the sample size remains small and does not represent all HIV cases identified in NC. The 
STAT program routinely tests for HIV RNA in all samples from publicly funded clinics 
throughout the state but approximately 60% of NC HIV cases are detected outside of the 
public testing system. If people who test through the publicly-funded system are 
systematically different than those who test outside of the publicly-funded system, selection 
bias may be introduced. In addition, our modest sample size results in limited power to 
detect small differences and a decreased ability to control confounding in multivariable 
models. Despite these important shortcomings, our study is one of the largest to evaluate 
STI co-infection in the setting of acute HIV infection. 
The high proportion of AHI patients with STI co-infections is surprising as our study 
was not limited to the STD clinic setting. Although about half of the AHI cases were 
identified in STD clinics, the proportion with co-infections from STD clinics (35%) was 
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roughly the same as those cases identified from HIV counseling and testing sites (36%). 
While the coding of testing site type is variable from county to county and therefore subject 
to misclassification, our results underscore the importance of STI symptoms as an indicator 
of AHI risk, even in non-STD clinic settings. Further, since co-infection rates do seem to vary 
by population and geography, high rates of co-infection in NC may suggest the importance 
of STIs on HIV transmission in the U.S. South, a region that has been disproportionately 
impacted by HIV and STIs. 33, 34, 37, 38, 161  
Our most compelling finding was the variation in the prevalence of STI co-infection 
by gender, risk category, and race. MSM in our study were less likely to have a co-infection 
(18%) than heterosexual men (35%) or women (53%), and almost all (91%) co-infections 
occurred in non-Whites. These findings may help to explain the epidemiology of the NC HIV 
epidemic where racial disparities are dramatic – the HIV rate for non-Hispanic blacks is 
more than eight times greater than for non-Hispanic Whites – and heterosexual transmission 
is nearly as prominent as MSM transmission.33, 162 Heterosexual transmission of HIV in NC 
occurs largely among African-Americans; high rates of STIs in this group would facilitate HIV 
transmission and may be a necessary component of the HIV epidemic for this population.162 
Although STIs were present among MSM AHI patients, they may not be necessary to 
maintain transmission of HIV in the context of higher-risk activities such as unprotected anal 
sex. These findings imply that the magnitude of the STI cofactor effect may be greater 
among heterosexuals than MSM in the South.  
We hypothesized that STI co-infection may act as a biological cue to seek testing. In 
our study, 31% of AHI patients had an STI co-infection and 76% of AHI patients had either 
an STI co-infection or acute retroviral syndrome symptoms at or before testing (not shown), 
suggesting that these factors may motivate people to seek testing as does partner 
notification or provider referral. Although STI co-infection did not have an influence on the 
timing of testing during AHI, we did observe that the presence of acute retroviral symptoms 
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at or before testing was associated with testing before the peak viremia. We also identified 
testing location as a potential factor related to the timing of testing. AHI patients identified at 
CTS sites were more likely to have an increasing HIV RNA slope than those who tested at 
STD clinics or other types of sites. Individuals who seek testing at HIV CTS sites may differ 
in several important ways which could explain this result. CTS sites may attract a more risk-
aware clientele, which is a key factor associated with testing. 66, 67 In this case, anxiety over 
the risk of exposure may be a key factor that drives HIV testing shortly after infection. AHI 
clients who are detected at STD clinics may present later, once acute HIV or STI symptoms 
appear. Given the inconsistent usage of testing site type across the state, additional 
examination of reason for testing and presenting location would help to elucidate these 
issues.  
Despite data from our study and others that people with primary infection often 
present to medical care, the opportunity for diagnosis is frequently missed either by not 
recognizing acute retroviral syndrome or reliance on antibody testing alone.134, 163-165 In the 
case of STI co-infections, we would expect infected individuals to present to care at 
symptom onset. However, standard antibody EIAs will often not detect HIV during this time 
(Figure 5.1). Gonorrhea and trichomoniasis, the most common STIs in our study population, 
also have two of the shortest incubation periods.166 It is therefore not unexpected that, in 
these cases, HIV was only detected with NAAT testing. This is an important limitation of 
strategies to offer HIV testing services to all STI patients, as HIV will often be missed in 
settings where testing is limited to standard third-generation EIAs.   
 We found little variation in viral load at the time of HIV testing. In particular, viral load 
was not higher among those with STI co-infections. During established HIV infection, both 
ulcerative and non-ulcerative STIs increase viral shedding from the genital tract, but their 
impact on blood plasma viral load is less well-defined.17, 167 Among men-only or 
predominantly male studies, syphilis, genital ulcer disease, and herpes simplex virus (HSV) 
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shedding was significantly associated with increased plasma HIV RNA.168-171 Among 
women, plasma HIV RNA levels increased with gonorrhea infection and HSV lesions.172 In 
contrast, a study of men with urethritis found that while seminal plasma HIV levels were 
higher in the urethritis group than in among controls, plasma levels did not differ at baseline 
or after therapy.107 Given these previous reports, it is possible that systemic effects of STIs 
differ by gender and STI type and our sample size prohibited further stratification to explore 
these variations. It is also feasible that during AHI, STI-related plasma HIV RNA increases 
are overwhelmed in magnitude by the ramp-up viremia. The absence of a measurable effect 
of STIs on peak viremia could also suggest that STIs impact spread in acute transmission 
networks principally through susceptibility rather than infectiousness. However, we only had 
access to blood serum for HIV RNA quantification, whereas semen or genital secretions are 
preferable for inferences about transmissibility. In addition, our serum samples are often 
subject to testing and shipping delays, which may bias quantification of HIV RNA downward 
for both initial and confirmatory samples. Given our findings, further investigation of how STI 
infection during AHI impacts viral dynamics in the blood and genital tract is an area for future 
exploration.  
 The detection of AHI affords a tremendous public health opportunity to interrupt 
transmission and detect networks at high risk, but recognition requires a unique synergy of 
clinical suspicion, risk awareness, and appropriate diagnostic tests. We have shown that co-
infection with STIs is common in a large sample of AHI patients in NC; antibody testing 
alone in many of these patients would have missed their HIV infection precisely when they 
present an increased transmission hazard to sexual partners. The frequency of STI co-
infection among women and heterosexual men hints that STIs help to fuel the heterosexual 
HIV epidemic in the South. 
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TABLE 5.1. Demographic characteristics of 75 patients with acute HIV infection in North 
Carolina, November 1, 2002 through October 31, 2006. 
 
Characteristic N (%)1 
 
Year of identification 
Year 1 (11/2002 – 10/2003) 
Year 2 (11/2003 – 10/2004) 
Year 3 (11/2004 – 10/2005) 
Year 4(11/2005 – 10/2006) 
 
 
21 
19 
19 
16
 
 
(28.0) 
(25.3) 
(25.3) 
(21.3) 
 
Gender and risk behavior 
Man who has sex with men 
Heterosexual man 
Female 
 
 
39 
17 
19
 
 
(52.0) 
(22.7) 
(25.3) 
 
Age (years) 
≤ 25 
26-35  
36-45  
≥46  
 
 
33 
20 
12 
10
 
 
(44.0) 
(26.7) 
(16.0) 
(13.3) 
 
Race or ethnic background 
White, non-Hispanic 
White, Hispanic 
Black 
Native American/Alaskan Native 
Unknown 
 
 
20 
4 
49 
1 
1
 
 
(26.7) 
(5.3) 
(65.3) 
(1.3) 
(1.3) 
 
Testing Location 
HIV Counseling and testing site 
STI Clinic 
Other type of clinic 
 
 
17 
36 
22
 
 
(22.7) 
(48.0) 
(29.3) 
 
History of injection drug use 
Yes 
No 
 
2 
73
 
(2.7) 
(97.3) 
 
STI co-infection at diagnosis 
Yes  
No 
 
 
23 
52
 
 
(30.7) 
(69.3) 
 
Symptoms at or before testing 
Yes  
No 
 
 
45 
30
 
 
(60.0) 
(40.0) 
 
1.  Percentages may not add to 100% due to rounding. 
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TABLE 5.2. Types of STI co-infections among 23 patients diagnosed with acute HIV and 
another STI in North Carolina, November 1, 2002 through October 31, 2006.  
 
STI Type1 N (%) Men  (n=13) 
Women  
(n=10) 
Gonorrhea 9 (39.1) 7 (53.8) 2 (20.0) 
Trichomoniasis 5 (21.7) 0 (0) 5 (50.0) 
Syphilis 4 (17.4) 4 (30.8) 0 (0) 
Herpes  3 (13.0) 2 (15.4) 1 (10.0) 
Chlamydia 3 (13.0) 1 (7.7) 2 (20.0) 
Bacterial vaginosis 3 (13.0) --- 3 (30.0) 
Genital ulcer disease, unspecified 1 (4.3) 1 (7.7) 0 (0) 
 
1.  Five (21.7%) of 23 participants with an STI co-infection had more than one concurrent STI 
diagnosis. 
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TABLE 5.3. Frequency and prevalence of STI co-infections by demographic factors among 
75 patients with acute HIV in North Carolina.  
STI co-infection 
at diagnosis1 
Characteristic 
Yes 
(n=23 )
No  
(n=52)
Prevalence  
(95% CI) 
Prevalence Ratio 
(95% CI) 
 
Gender and risk behavior 
Man who has sex with men 
Heterosexual man 
Female 
 
 
7 
6 
10 
 
 
32 
11 
9 
 
 
18.0% (7.5, 33.5) 
35.3% (14.2, 61.7) 
52.6% (28.9, 75.6) 
 
 
0.34 (0.15, 0.76) 
0.67 (0.31, 1.45) 
Referent 
 
Age (years) 
≤ 25 
26-35  
≥36 
 
 
13 
4 
6 
 
 
20 
16 
16 
 
 
39.4% (22.9, 57.9) 
20.0% (5.7, 43.7) 
27.3% (10.7, 50.3) 
 
 
1.97 (0.74, 5.21) 
Referent 
1.36 (0.45, 4.14) 
 
Race or ethnic background 
White, non-Hispanic 
Non-White 
 
 
2 
21 
 
 
18 
33 
 
 
10.0% (1.2, 31.7) 
38.9% (25.9, 53.1) 
 
 
Referent 
3.89 (1.00, 15.10) 
 
Testing Location 
HIV Counseling and Testing 
STI Clinic 
Other type of clinic 
 
 
6 
13 
4 
 
 
11 
23 
18 
 
 
35.3% (14.2, 61.7) 
36.1% (20.8, 53.8) 
18.2% (5.2, 40.3) 
 
 
Referent 
1.01 (0.66, 1.55) 
0.52 (0.17, 1.54) 
 
History of injection drug use 
Yes 
No 
 
 
1 
22 
 
 
1 
51 
 
 
50.0% (1.3, 98.7) 
30.1% (19.9, 42.0) 
 
 
1.66 (0.40, 6.93) 
Referent 
 
Symptoms at or before testing 
Yes  
No 
 
 
11 
12 
 
 
34 
18 
 
 
24.4% (12.9, 39.5) 
40.0% (22.7, 59.4) 
 
 
0.61 (0.31, 1.20) 
Referent 
 
 
1.  Numbers may not add to 75 due to missing data. 
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TABLE 5.4. Mean serum viral load (log10copies/ml) at the time of testing and logistic 
regression models of HIV RNA slope among patients with acute HIV in North Carolina. 
Logistic Models of HIV RNA slope2 
Characteristic 
Mean HIV RNA 
(log10 copies/ml, 
n=74) 
p-value1
Mean 
change3 OR (95% CI) p-value 
 
Gender and risk behavior 
Man who has sex with men 
Heterosexual man 
Female 
 
 
5.4 (5.0, 5.7) 
4.9 (4.3, 5.6) 
5.1 (4.6, 5.6) 
 
 
0.36 
 
 
-0.46 
-0.24 
-0.47 
 
 
1.20 (0.29, 4.93) 
1.20 (0.23, 6.39) 
Referent 
 
 
0.96 
 
Age (years) 
≤ 25 
26-35  
≥36  
 
 
5.0 (4.7, 5.4) 
5.1 (4.6, 5.7) 
5.5 (5.0, 5.9) 
 
 
0.29 
 
 
-0.05 
-0.68 
-0.71 
 
 
3.33 (0.53, 20.91) 
1.25 (0.19, 8.44) 
Referent 
 
 
0.26 
 
Race or ethnic background 
White, non-Hispanic 
Non-White 
 
 
5.4 (5.0, 5.9) 
5.1 (4.8, 5.4) 
 
 
0.22 
 
 
-0.87 
-0.22 
 
 
Referent 
1.72 (0.38, 7.85) 
 
 
0.48 
 
Testing Location 
HIV Counseling and Testing  
STI Clinic 
Other type of clinic 
 
 
5.0 (4.5, 5.5) 
5.3 (4.9, 5.7) 
5.1 (4.7, 5.6) 
 
 
0.57 
 
 
0.61 
-0.72 
-0.81 
 
 
Referent 
0.19 (0.04, 0.94) 
0.36 (0.07, 1.88) 
 
 
0.12 
 
STI co-infection at diagnosis 
Yes  
No 
 
 
4.9 (4.4, 5.4) 
5.3 (5.0, 5.6) 
 
 
0.13 
 
 
-0.33 
-0.45 
 
 
1.30 (0.36, 4.72) 
Referent 
 
 
0.69 
 
Symptoms at or before testing 
Yes  
No 
 
 
5.3 (5.0, 5.6) 
5.1 (4.6, 5.5) 
 
 
0.41 
 
 
-0.18 
-0.78 
 
 
3.02 (0.78, 11.66) 
Referent 
 
 
0.11 
 
1.  P-values from one way analysis of variance (ANOVA)  
2.  44 patients with AHI had both initial and confirmatory values available for analysis. Seventeen 
patients (38.6%) had increasing viral loads between the initial and confirmatory samples. Bivariate 
models were constructed with the difference between the log-transformed initial and confirmatory viral 
load values as the response variable (1=increasing slope, 0=decreasing slope). 
3.  Mean change in HIV RNA (log10 copies/ml) from the initial and confirmatory specimens  
 102 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 5.1. Potential impact of STI co-infection on the detection of HIV infection. At the 
time of symptom onset of several common STIs, HIV would be missed by standard 2nd and 
3rd generation EIAs. The horizontal timeline represents the time elapsed after co-acquisition 
of HIV and a concurrent STI. Vertical boxes represent the approximate times when HIV 
could be detected by RNA, 4th generation antigen/antibody enzyme immunoassays (EIA), 
and 3rd generation EIA tests. Horizontal bars below the timeline illustrate the approximate 
incubation periods for common STIs.134-136, 139, 166, 173 
 CHAPTER SIX: Social Support and Delays Seeking Care after HIV Diagnosis,  
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ABSTRACT 
Background: Many adults enter primary care late in the course of HIV infection, countering 
the clinical benefits of timely HIV services and missing opportunities for risk reduction. Our 
objective was to determine if perceived social support was associated with delay entering 
care after an HIV diagnosis. Methods: Two hundred sixteen patients receiving primary care 
at a large, university-based HIV outpatient clinic in North Carolina were included in the 
study. Dimensions of functional social support (emotional/informational, tangible, 
affectionate and positive social interaction) were quantified with a modified Medical 
Outcomes Study Social Support Scale and included in proportional hazard models to 
determine their effect on delays seeking care. Results: The median delay between diagnosis 
and entry to primary care was 5.9 months. Levels of social support were high but only 
positive social interaction was associated with delayed presentation in adjusted models. The 
effect of low perceived positive social interaction on the time to initiation of primary care 
differed by history of alcoholism (no history of alcoholism, hazard ratio (HR): 1.43, 95% 
confidence interval (CI): 0.88, 2.34; history of alcoholism, HR: 0.71, 95% CI: 0.40, 1.28). 
Conclusions: Ensuring timely access to HIV care remains a challenge in the southeastern 
United States. Affectionate, tangible, and emotional/informational social support were not 
associated with the time from diagnosis to care. The presence of positive social interaction 
may be an important factor influencing care seeking behavior after diagnosis. 
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INTRODUCTION 
Early presentation for medical care among HIV infected persons can improve the 
length and quality of life by providing access to antiretroviral drugs and prophylactic 
treatment for opportunistic infections.1, 57 Further, HIV testing and counseling and knowledge 
of one’s serostatus has been shown to reduce high-risk behavior, thereby reducing 
transmission to others.2, 3 Despite these benefits, many adults enter care late in the course 
of HIV infection, countering the benefits of timely access to HIV services and missing 
opportunities for risk reduction.6-8 Consequently, linking HIV positive persons to high-quality 
care and prevention services has been identified as a priority of the U.S. Centers for 
Disease Control and Prevention (CDC).9 
The process of an HIV-infected individual presenting to primary care can be divided 
into two meaningful time periods: 1) the time between acquisition of infection and testing; 
and 2) the time between testing and presentation to care.19 Delayed testing is common in 
the United States -  40% of those tested in 2004 were diagnosed with AIDS less than one 
year after the initial HIV diagnosis, a figure that has remained relatively stable since 1994.6, 
33 In contrast, delayed initiation of medical care after diagnosis is less well-characterized. 
Median reported delays from HIV diagnosis to presentation for care range from 30 days to 
over a year.14, 19, 20, 63 Demographics, health insurance status, injection drug use, and the 
testing and counseling history are associated with delayed presentation, but the role of 
psychosocial factors, such as perceived social support, on care-seeking behavior have not 
been thoroughly evaluated.11, 14, 19, 20  
Social support can be subdivided into structural and functional aspects of support. 
Structural support includes the size, type, contact, and density of social networks and ties.112 
Functional support represents the capacity of relationships to fulfill particular functions, such 
as providing affection, a sense of belonging, or material aid.111 Together, structural and 
functional support describes the types of resources we receive from other people. Social 
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support can influence health directly by influencing the adoption of healthy (or unhealthy) 
behaviors and adherence to social norms.111 It can also influence health indirectly by 
buffering the pathogenic effects of stressful events through the processes of stress 
perception and coping.117 Social support may improve coping with HIV and quality of life, 
improve adherence among patients on highly active antiretroviral therapy (HAART), and 
improve patient retention in care.22-26, 126 Therefore, HIV positive individuals with higher 
levels of perceived social support may seek medical care earlier than those with less 
perceived social support. Towards this end, our objective was to describe levels of support 
available to patients in a Southeastern HIV clinic and determine if social support was 
associated with delays between HIV diagnosis and presentation for care.  
 
METHODS 
Study Population 
The source population for the study was the University of North Carolina at Chapel Hill 
Infectious Disease (UNC ID) Clinic. As a large, university-based medical center, the Clinic 
follows approximately 1,300 HIV infected patients per year and provides comprehensive HIV 
primary care services. Patients in the clinic are predominantly from central and eastern 
North Carolina, although patients from all 100 counties and surrounding states are accepted 
for care.145 For this study, we conducted a secondary data analysis of the UNC Clinical and 
Socio-Demographic Survey, originally designed to collect sociodemographic and behavioral 
data not available in medical records. The primary goal of the analysis was to describe the 
effect of social support on the time between HIV diagnosis and presentation for HIV care. 
 
Recruitment and Data Collection 
Patients receiving care at the UNC Infectious Diseases Clinic who are at least 18 years of 
age, English speaking, and able to provide written informed consent were eligible to 
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complete the survey. Potential participants were identified and approached for participation 
by trained research assistants in the clinic. Consenting patients were interviewed in a quiet 
and private room, typically after their clinic visit. Data from the interviews were entered into a 
Microsoft Access database housed on a secured server. 
 
Measurements 
The main outcome variable is the time (months) from HIV diagnosis until entry to HIV care. 
The date of HIV diagnosis was obtained from the NC Department of Health and Human 
Services HIV/AIDS Reporting System. In cases where a match was not obtained with state 
records (n=36) or the NC reporting system date was after the diagnosis date in the medical 
record (n=115), the date of diagnosis from the medical record was used. In five cases, only 
the self-reported date of diagnosis was available. To correctly capture the date of entry to 
HIV primary care, as opposed to general health care visits, we defined entry to care as the 
first outpatient visit to the UNC ID clinic for patients who only received care at UNC. For 
patients who received care at other institutions, we defined entry to care as the earliest non-
hospitalized date of CD4 T-lymphocyte cell count, HIV RNA, antiretroviral therapy initiation, 
AIDS-defining clinical condition, or outpatient visit. In cases where a hospitalization was the 
first HIV–related care, we accepted the date of the first CD4 T-lymphocyte cell count as the 
entry to care date. Patients with only self-reported dates of entry to care were excluded from 
the analysis.  
 As the aim of our study was to determine factors associated with the time between 
diagnosis and care, we excluded patients whose clinical presentation prompted testing and 
entry to care. These people represent those who significantly delayed testing and the onset 
of symptoms instigated rapid linkage to primary care. Methodologically, considering delayed 
testing and delayed presentation to care as distinct outcomes, with overlapping etiologies, is 
necessary to prevent mixing the effects of late testing with delayed care. We assumed that 
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patients with less than three weeks between diagnosis and entry to care with an AIDS 
defining illness before, at, or 45 days after diagnosis represented people who were 
diagnosed due to AIDS related illnesses, and they were excluded from Cox proportional 
hazards models (n=18). We reviewed medical records of patients with less than three weeks 
between diagnosis and entry to care and CD4 cell counts ≤200 cells/mm3 without AIDS 
defining illnesses; those diagnosed as inpatients or diagnosed because of illness were 
excluded (n=6). We evaluated the time from diagnosis to entry to care for 10 years after 
diagnosis; patients not in care at this time were censored. 
 The exposure of interest, perceived social support, was quantified with a modified 
version of the Medical Outcomes Study Social Support Scale (MOS-SSS). The MOS-SSS is 
a brief, multidimensional, 20-item survey. Two items measure structural support and the 
remaining 18 items measure four functional dimensions of social support: 
emotional/informational, tangible, affectionate, and positive social interaction.27 The modified 
version used in our study contained items to measure structural support and 13 of the 18 
items to measure functional support (four of four tangible indicators, three of three 
affectionate indicators, four of eight emotional/informational indicators, and one of four 
positive social interaction indicators plus an additional positive social interaction indicator 
evaluated but not included in the MOS-SSS). We included participants who completed at 
least 80% of the MOS-SSS.  
 Consistent with the methods for the original MOS-SSS, structural social support is 
measured by overall network size, or the summation of the number of close friends and 
relatives. Reponses to each functional support indicator on the 5-point Likert scale of 
responses are assigned numeric values (1: Support type is never present – 5: Support type 
is always present) and a composite average number is generated for each participant 
representing the four dimensions of functional social support. This average is transformed 
so that the scores range from 20 to 100.  
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Confirmatory Factor Analysis 
As our scale was modified from the original 19 item MOS-SSS scale, we used confirmatory 
factor analysis (CFA) to determine the validity of the model in our overall study population, 
before exclusions. We evaluated model fit based on a CFA model with 332 patient records, 
13 indicators, four latent variables (emotional/informational, affectionate, tangible, and 
positive interaction domains of functional social support), and a robust weighted least 
squares fitting function. CFA analyses were done with Mplus software.149 
 
Statistical Analysis 
Eight participants had missing data in the social support scale. We compared the results of 
complete case analysis, mean imputation, imputing the high and low values, and conditional 
mean imputation and found little difference in the resulting scores. For the analyses 
presented here, we imputed missing values with the mean of known values for the variable.  
We first performed basic descriptive analyses, including calculating means, standard 
deviations, medians, and frequencies of the exposure and covariates. In bivariable 
analyses, we examined the effect of social support on the time to seeking HIV care using 
Cox proportional hazards regression. We excluded factors from Cox models that violated the 
assumption of temporality, for example, events or measurements that took place after HIV 
diagnosis (e.g. number of times moved since diagnosis, CD4 cell count at entry). We 
assumed that other factors could be assumed to be valid at the time of diagnosis despite 
being measured after care was initiated, such as income, ever being homeless, or ever 
spending time in prison. The proportional hazards assumption was evaluated for all 
exposures and covariates graphically with the use of a log(-log(S(t))) curve and was tested 
by adding an interaction with time to the model (Cox test). If necessary, the proportional 
hazards assumption was relaxed with a stratified mode or with categorical or continuous 
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interactions with time. Equality of survival functions was tested with the log-rank test. We 
present hazard ratios (HR) and 95% confidence intervals (CI).  
In multivariable analysis, we used a manual, backward, change-in-estimate model 
building strategy. Measurements or events that took place after HIV diagnosis were 
excluded from Cox models. Potential effect measure modification was assessed by fitting 
appropriate product interaction terms and comparing models with and without the interaction 
terms with the likelihood ratio test. Potential confounding variables were assessed by 
examination of the change in social support estimate; we set a cutpoint of a 10% change in 
the parameter estimate or more to classify confounding. We first constructed multivariable 
models for each of our four functional support domains, and then created a single 
multivariable model with all four levels of social support and relevant confounding and 
modifying covariates. 
 
Human Subjects Protection 
All participants in the study provided written informed consent to participate in the interview 
and HIPAA authorization to access medical information. This study was approved by the 
UNC Institutional Review Board.  
 
 
RESULTS 
From July 2000 to June 2006, 216 patients completed the interview and met the 
criteria for inclusion in the analysis. Women comprised 40% of the population, heterosexual 
men represented about 26% of the population, and men who have sex with men (MSM) 
were 33% of the population (Table 6.1). Seventy percent of the population was Black; the 
median age was 36 years at diagnosis and 43 years at the time of interview. At entry to 
care, the median CD4 T-lymphocyte cell count was 346 cells/mm3 (range: 4-1,428). Ever 
having spent time in prison was common (30.2%), as was ever having been homeless or 
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living on the streets (28.7%), ever having a drinking problem (34.7%), ever having used 
illegal drugs on a regular basis (70.1%), and ever having sex for drugs or money (27.4%). 
Most (67.4%) patients reported having a main partner or spouse and less than two sexual 
partners in the previous year (72.7%). 
 
Confirmatory Factor Analysis 
The validity of the four factor functional social support model in our sample was evaluated 
with confirmatory factor analysis. The overall goodness-of-fit indices suggested that the four 
factor CFA model fit the data reasonably well: χ2(30)=108.1, p<.01, root mean square error 
of approximation (RMSEA) 0.089, comparative fit index (CFI) 0.969, and Tucker-Lewis Index 
(TLI) 0.992.148 All freely estimated parameters were statistically significant; standardized 
factor loadings ranged from (0.56-0.97), and indicator reliability ranged from 0.32 to 0.92 
with eight indicators having reliabilities greater than 0.7.  All indicator reliability estimates 
were significant (p<.01). We allowed for correlated errors between two similarly worded 
emotional/informational indicators. The reliability of the four latent variables was 0.72 for 
emotional/informational support, 0.83 for positive social interaction, 0.86 for tangible support 
and 0.90 for affectionate support174. Cronbach’s alpha indicated that the scale was internally 
consistent (0.93). Higher order factor analysis did not support the creation of a single 
construct for functional social support. 
 
Social Support 
The clinic population had high levels of social support. The median network size of close 
friends and relatives (structural social support) was six people (range: 0-1,030). Functional 
support scores were skewed and clustered near levels corresponding to the level of support 
being present “most to all of the time.” Levels of affectionate support were the highest 
(median score=93.3, mean=83.7), followed by tangible support (median=85.0, mean=79.8), 
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emotional/information support (median=80.0, mean=78.8) and positive social interaction 
(median=80.0, mean=71.5, Table 6.2). Although the median network size was the same for 
patients with and without a spouse or main partner, those with a spouse or main partner 
reported higher median levels of affectionate support (p<.01), positive social interaction 
(p=.08), and emotional/information support (p=.02). 
 
Delays between Diagnosis and HIV Care 
The median delay between diagnosis and entry to care was 5.9 months (inter-quartile range: 
1.8 to 38.3 months). Although 57% of patients initiated care within the year after diagnosis, 
only 12.5% of patients initiated care in the second year. Overall, 69% were in care by two 
years post diagnosis, 74% were in care by three years, and 79% by four years (Figure 6.1). 
Thirty-eight patients (17.6%) delayed entering HIV care for five or more years.  
Twenty-eight patients (13%) had an AIDS defining illness at or before entering HIV 
care. Of these patients, Pneumocystis carinii pneumonia was the most common diagnosis 
(39%) followed by candidiasis (18%). Half of patients entered care within a month following 
an AIDS defining illness diagnosis; however, seven of the 28 patients (25%) with an AIDS 
defining illness  at or before HIV diagnosis delayed HIV care longer than one year.  
In unadjusted analyses, the time to presentation varied little by functional social 
support (Figure 6.2). Across all four domains of functional social support, those with levels of 
support available “less than most of the time” had shorter median times to care than those 
with the level of support available “most to all of the time,” although these results were not 
statistically significant. In multivariable analyses, tangible, emotional/informational, and 
affectionate support remained unassociated with the time between diagnosis and entry to 
care (Table 6.3). The effect of positive social interaction on the outcome differed by a history 
of alcoholism. In those who had ever had a drinking problem, those with lower levels of 
positive social interaction had about 0.7 times the hazard of entering care over time 
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compared to those with the highest levels of positive social interaction. However, those 
without a history of a drinking problem and who had positive social interactions present less 
than “most of the time” had about 1.4 times the hazard of entering care over time than those 
with positive social interactions present “most to all of the time” (HR: 1.43, 95% CI: 0.88, 
2.34). 
 
DISCUSSION 
Successful efforts to reduce HIV-related morbidity and mortality and improve quality 
of life are contingent on the timely receipt of primary care services. Although highly active 
antiretroviral therapy has been the cornerstone of HIV care in the United States since its 
widespread adoption in the late 1990’s, the survival benefit of HAART is strongly related to 
baseline immunosuppression.1 In addition to clinical services, patients in care benefit from a 
host of social services which can improve the maintenance of care and adherence to 
therapy, as well as prevention programs to reduce the frequency of transmission to partners. 
Despite these benefits, prompt linkage to primary care is not always possible. Recently 
diagnosed individuals must cope with discovering their status, notify at-risk partners, 
contemplate disclosure to friends and family members, confront fears about morbidity and 
mortality, and initiate, establish, and adhere to medical care.175 It is therefore not surprising 
that some patients enter care quickly whereas others remain unconnected with the health 
care system for months or years after diagnosis. 
 The median delay of six months between diagnosis and primary care we report is 
slightly longer than other reports. Studies in New England, Arkansas, and Alabama each 
reported median delays of three months or less.14, 19, 63 This inconsistency may be due to 
efforts we took to enhance the validity of our data or because our clinic serves a different 
patient population. For example, we obtained dates of diagnosis from state surveillance 
records instead of self-reported estimates alone. We also excluded patients from the 
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analysis with both very short times to care and who were likely tested due to AIDS-related 
illness to prevent biasing our results by including a population that entered care due to 
symptoms and not due to testing results. Considering the proportion of people who had 
spent time in prison, been homeless, or ever had transactional sex, the delay in presentation 
for care we observe may reflect a patient population that is particularly disenfranchised from 
the health care system. 
 Levels of social support were very high in our study. Compared to both the 
ambulatory patient sample in which the scale was developed and a separate study at an 
urban hospital-based HIV clinic, patients in our study had higher median levels of tangible, 
affectionate, and emotional/informational support, despite having similar median network 
sizes.27, 74 Levels of positive interaction were similar across studies, suggesting that health 
care systems may have little impact on creating a sense of social belonging. In our study, 
each subscale of functional support was available most to all of the time for the majority of 
patients (60.6%-81.5%). Tangible and emotional/informational support needs, the types of 
functional support most directly modifiable by HIV primary care and social services, were not 
being met for only 12% and 7% of the study sample, respectively. Consistent with previous 
reports, we found that those with a spouse or main partner reported higher median levels of 
affectionate support, emotional/informational support, and positive social interaction, 
highlighting that quality, not quantity, of support is most meaningful.74  
 Tangible, affectionate, and emotional/informational support did not have an effect on 
delays between HIV diagnosis and primary care in this study. This observation is somewhat 
unexpected, given that the presence of some types of social support has been associated 
with shorter delays, such as having a living mother or having a spouse or partner.19 In 
addition, social support has been found to improve adherence in most studies.25, 26, 81, 122, 123 
However, many of these studies did not use a validated scale – it is recommended that 
social support should be quantified with at least two of the three main aspects of social 
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support: 1) existence and quantity; 2) aspects of network structure; and 3) functional content 
and quality of relationships.176 Further, the high levels of support we observe may mask any 
true effect on the time to care. The one study that assessed social support using the MOS-
SSS found no relationship between functional social support and the time from diagnosis to 
care.74  
In contrast to the null findings for tangible, affectionate, and emotional/informational 
support, we found a moderate association between positive social interaction and care 
initiation. Among those with a history of alcoholism, those with lower levels of positive social 
interaction were slightly less likely to enter care than persons with high levels of positive 
social interaction. However, persons who had never had a drinking problem, but had very 
little positive social interaction entered care about 40% more rapidly than those with the 
most positive social interaction. This small group (n=22) of persons was less likely to have 
ever been homeless (18 vs. 30%), spent time in prison (23 vs. 31%), had transactional sex 
(9 vs. 30%), or have a main partner or spouse (50 vs. 69%) than the rest of the study 
sample. This finding may suggest that some socially isolated individuals who do not abuse 
alcohol access care rapidly after diagnosis, perhaps to meet their support needs. They may 
have fewer outlets for distraction from their diagnosis than others, such as social interaction 
and substance abuse.  
Our study, and other similar clinic based studies of delays between diagnosis and 
care, must be cautious against over interpretation of data with methodological limitations. As 
patients must be in care to participate in the study, we do not observe the person-time of 
patients who delay entering care past the study period. This truncation represents an 
important selection bias which is most apparent by examining the effect of year on delays 
after diagnosis. Later diagnoses (in calendar time) will always appear to be associated with 
shorter delays. Some investigators have accounted for this bias with carefully selected risk 
periods, and in our analysis we included year of diagnosis in the multivariable analysis.20 In 
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addition, our analysis did not support the creation of linear social support terms, so we may 
have measurement error in our broad categories of perceived social support. Finally, as 
patients were interviewed once they were in care, we do not know if the levels of social 
support we observed were present at the time of diagnosis. An optimally designed study to 
answer questions about delayed presentation to care would follow a cohort of newly 
diagnosed individuals over time, but as Samet et al. points out, this study design may be 
biased by the Hawthorne effect and would require a lengthy follow-up period.19 However, as 
CDC recommendations for the adoption of routine HIV screening in all health care settings 
are implemented, effective linkage to HIV care will likely be a marker of program success, 
highlighting the need to understand and improve the process of care initiation.49  
 We have found that ensuring timely access to HIV care remains a challenge in the 
southeastern U.S. Although much remains to be learned about care-seeking behavior after 
HIV diagnosis, our findings suggest that social belonging and social interaction are 
important elements of the decision to initiate care. It is unknown if tangible, affectionate, and 
emotional/informational support are important after the initiation of primary care, such as on 
the maintenance of care and adherence to therapy. Additional research on how to translate 
this information to practice could have beneficial outcomes for both the patient and the 
community. 
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TABLE 6.1. Sociodemographic, behavioral, and clinical characteristics of 216 patients with 
HIV infection in North Carolina, July 2000-June 2006. (Table continues on next page) 
 
Characteristic N (%)1 
SOCIODEMOGRAPHIC CHARACTERISTICS 
 
Gender and risk behavior 
Women 
Man who has sex with men / bisexual 
Heterosexual man 
87 
72 
57
(40.3) 
(33.3) 
(26.4) 
 
Race 
Black 
White 
Other 
152 
46 
18
(70.4) 
(21.3) 
(8.3) 
 
Age at diagnosis 
≤30 
31-40 
41 or greater 
23 
145 
43
(10.9) 
(68.7) 
(20.4) 
 
Year of Diagnosis 
1981-1989 
1990-1994 
1995-1999 
2000-2005 
24 
71 
77 
44
(11.1) 
(32.9) 
(35.6) 
(20.4) 
 
Education (highest completed) 
Less than high school 
High school graduate or GED 
Some college 
College graduate or higher 
Vocational/technical school 
66 
74 
47 
23 
6
(30.6) 
(34.3) 
(21.8) 
(10.7) 
(2.8) 
 
Annual income 
<$5,000 
$5,000 to <$10,000 
$10,000 to <$30,000 
≥$30,000 
54 
88 
48 
23
(25.4) 
(41.3) 
(22.5) 
(10.8) 
CLINICAL CHARACTERISTICS 
 
CD4 T-cell count at entry to care2 
≤200 cells/mm3 
201-350 cells/mm3 
>350 cells/mm3 
71 
36 
105
(33.5) 
(17.0) 
(49.5) 
 
AIDS defining illness at or before entry to care2 
Yes 
No 
 
28 
188 
(13.0) 
(87.0) 
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Characteristic N (%)1 
 
Goes to other clinics or doctors for general health 
care 
Yes  
No 
79 
135
(36.9) 
(63.1) 
SOCIAL SUPPORT 
 
Structural Social Support (network size) 
0-3 
4-7 
8-12 
13 or more 
66 
58 
40 
50
(30.8) 
(27.1) 
(18.7) 
(23.4) 
 
Positive Social Interaction 
Most to all of the time 
Sometimes 
None to little of the time 
 
131 
49 
36
 
(60.6) 
(22.7) 
(16.7) 
 
Tangible Support 
Most to all of the time 
Sometimes  
None to little of the time 
 
167 
23 
26
 
(77.3) 
(10.6) 
(12.0) 
 
Emotional / Informational Support 
Most to all of the time 
Sometimes 
None to little of the time 
 
163 
37 
16
 
(75.5) 
(17.1) 
(7.4) 
 
Affectionate Support 
Most to all of the time 
Sometimes 
None to little of the time 
 
176 
17 
23 
(81.5) 
(7.9) 
(10.6) 
 
 
1.  Percentages may not add to 100 due to rounding. Numbers may not add to 216 due to missing 
data.  
 
2.  These factors were not included in Cox proportionate hazards models as they could not 
reasonably be assumed to be valid at the time of HIV diagnosis.
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TABLE 6.2. Functional social support definition and scores from the modified MOS Social Support Survey among HIV clinic patients, 
North Carolina 
 
Functional  
Support Type Definition
1 Scale Items  (“How often is this kind of support available when you need it?”) Mean Score (SD)
2 
 
Positive Social 
Interaction 
 
Shared social activities, a 
sense of social belonging 
 
Someone to have a good time or hang with 
Someone to do things with and help you get your mind off things 
 
71.5 (23.3) 
 
Tangible Support 
 
Provision of material aid 
 
Someone to help you if you were confined to bed 
Someone to take you to the doctor if you needed it 
Someone to prepare your meals if you were unable to 
Someone to help with daily chores if you were sick 
 
79.8 (21.9) 
 
Emotional / 
Information Support 
 
Expressions of comfort and 
caring, provision of advice and 
guidance 
 
Someone to give you good advice about a crisis 
Someone’s whose advice you want 
Someone you can count on to listen when you need to talk 
Someone to share your most private worries and fear with 
 
78.8 (19.4) 
 
Affectionate Support 
 
Expressions of love and 
affection 
 
Someone who shows you love and affection 
Someone who hugs you 
Someone to love and make you feel wanted 
 
83.7 (22.2) 
Overall Functional Support  79.1 (18.5) 
 
 
1.  See references 27, 112 
 
2.  Functional social support scores range from 20 (low) to 100 (high). 
  119 
FIGURE 6.1. Distribution of time from HIV diagnosis to the initiation of HIV care among 216 
patients in North Carolina. 
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FIGURE 6.2. Kaplan-Meier curves of the percent of newly diagnosed patients in care over time by functional social support type. A) 
Affectionate support, log-rank p=.57; B) Positive social interaction, log-rank p=.84; C) Emotional / Informational support, log-rank 
p=.31; D) Tangible support, log-rank p=.83. 
 
   
  
121 
 
 
 
 
 
  
122 
TABLE 6.3. Multivariable proportional hazards models of functional social support and time to presentation for medical care after HIV 
diagnosis. 
 
Characteristic Median time from diagnosis to care, months (95% CI)1 
Unadjusted Hazard 
Ratio (95% CI) 
Adjusted Hazard Ratio2 
(95% CI) p-value
3 
 
Tangible Support 
Most to all of the time 
None of the time or sometimes 
 
 
6.35 (4.28, 12.40) 
4.01 (2.14, 20.23) 
Referent 
0.97 (0.69, 1.35) 
Referent 
0.93 (0.53, 1.63) 
 
0.80 
 
 
Emotional / Informational Support 
Most to all of the time 
None of the time or sometimes 
7.14 (4.90, 13.98) 
3.55 (2.30, 9.84) 
Referent 
1.18 (0.86, 1.62) 
Referent 
1.23 (0.73, 2.09) 
0.44 
 
 
Affectionate Support 
Most to all of the time 
None of the time or sometimes 
 
 
6.20 (4.28, 11.55) 
4.87 (2.30, 20.49) 
Referent 
0.90 (0.63, 1.29) 
Referent 
1.06 (0.56, 1.98) 
0.87 
 
 
Positive Social Interaction 
 
Had a drinking problem (ever) 
Most to all of the time 
None of the time or sometimes 
 
Never had a drinking problem 
Most to all of the time 
None of the time or sometimes 
 
 
 
 
 
6.97 (4.15, 17.50) 
21.27 (17.14, 60.76) 
 
 
5.94 (3.03, 13.98) 
3.22 (2.14, 5.20) 
 
Referent 
0.67 (0.42, 1.08) 
 
 
Referent 
1.54 (1.08, 2.19) 
 
Referent 
0.71 (0.40, 1.28) 
 
 
Referent 
1.43 (0.88, 2.34) 
 
 
 
 
0.10 
 
 
 
 
 
1.  Confidence interval 
 
2.  Adjusted for gender and risk behavior, year of diagnosis, income, ever used drugs on a regular basis, ever had a drinking problem (main effect) 
and number of household members.  
3.  Represents the likelihood ratio test for the β coefficient(s) equaling 0 in the adjusted model.
 CHAPTER SEVEN: Barriers and Facilitators to HIV Testing and Primary Care:  
Narratives of People with Advanced HIV in the Southeast 
 
 
 
ABSTRACT 
 
Persons with unrecognized HIV infection forgo timely clinical intervention and may 
unknowingly transmit HIV to partners. However, in the United States, unrecognized infection 
and late diagnosis are common. To understand barriers and facilitators to HIV testing and 
care, we conducted a qualitative study of 24 HIV infected persons attending a Southeastern 
HIV clinic who presented with clinically advanced illness. The primary barrier to HIV testing 
prior to diagnosis was perception of risk; consequently, most participants were diagnosed 
after the onset of clinical symptoms. While most patients were anxious to initiate care rapidly 
after diagnosis, some felt frustrated by the passive process of connecting to specialty care. 
The first visit with an HIV care provider was identified as critical in the coping process for 
many patients. Implications for the implementation of recent CDC HIV routine screening 
guidelines are discussed. 
 
 
 
INTRODUCTION 
Unrecognized HIV infection has important public health consequences. In addition to limiting 
the benefits of early medical care including antiretroviral therapy and prophylaxis for 
opportunistic infections, persons with unrecognized infection may unknowingly transmit HIV 
to partners.41, 42 Despite these benefits, unrecognized infection and consequently, late 
diagnosis, are common among HIV infected adults. In the United States, 40% of those 
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tested in 2004 were diagnosed with AIDS less than one year after the initial HIV diagnosis.33, 
62 Further, approximately 25% of all adults living with HIV/AIDS in the U.S. do not know their 
status, and as many as one-third may not be receiving care.167 Even more concerning is that 
the severity of immune suppression at first presentation may be worsening among some 
groups.177 Promoting earlier detection of HIV was the focus of recent Centers for Disease 
Control (CDC) guidelines for the adoption of routine, voluntary HIV screening for patients in 
all health care settings.49  
Most of the research on late presentation to care has focused on descriptive 
characteristics of individuals who present late in the disease course, information often 
derived from medical records or clinical cohorts.12, 63, 177 While these data are informative 
about the population at risk, without context they limit causal inference and the subsequent 
design of public health interventions. Among people with late diagnosis, few have 
investigated the availability of voluntary counseling and testing services (VCT), the ease 
with which persons utilized the services, the barriers and facilitators to utilizing services, and 
the personal belief systems which influenced the decision-making process. Similar issues 
are relevant after diagnosis when the patient initiates HIV care. Although VCT services are 
widely available in most U.S. settings and safe and effective therapy has extended the life 
expectancy of those diagnosed with HIV to greater than 20 years, many obstacles to timely 
HIV diagnosis remain in the current U.S. system.75 
 In the present study, our objective was to understand barriers and facilitators to HIV 
testing and care among HIV infected persons attending a Southeastern HIV clinic who 
presented with clinically advanced illness. HIV positive patients in this region of the U.S. 
may face different challenges than the rest of the country, given the rural nature of the 
region and the degree to which heterosexual involvement is evident in the epidemic.64 We 
developed a conceptual framework for VCT utilization based on constructs described in the 
Information-Motivation-Behavioral Skills (IMB) model and the Health Belief Model (HBM) to 
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inform the development of our interview guide (Figure 7.1). The IMB model postulates three 
determinants of risk reduction: 1) basic information about HIV transmission and prevention, 
2) motivation to act on one’s knowledge about HIV transmission and prevention, and 3) 
behavioral skills for performing specific HIV preventative acts.30 The HBM consists of five 
dimensions which explain preventative health behavior: perceived susceptibility, perceived 
severity, perceived benefits and barriers, and cues to action.29 We felt that cues to action, 
factors that stimulate a person to action, were particularly relevant to understanding access 
and use of VCT services. Through detailed patient narratives, we describe the process of 
diagnosis and entering care among a unique group of HIV positive patients. 
 
 
METHODS 
Study Setting and Population 
The source population for the study was a large, university-based medical center that 
follows approximately 1,300 HIV infected patients per year and provides comprehensive HIV 
primary care services. Patients of the clinic are typically followed every three months for 
therapeutic, virologic, and immunologic monitoring. Patients were eligible for the study if 
they (1) were at least 18 years of age, (2) entered care between April 2006 and April 2008 
and had not received HIV care elsewhere, (3) had a CD4+ T-lymphocyte cell count <350 
cells/mm3 at entry, and (4) were cognitively competent to participate in the study.  
 
Recruitment 
 Eligible patients were approached by a clinic-based research assistant on their second or 
third clinic visits, after laboratory results were available and the patient was given the 
opportunity to discuss participation in various research projects. Patients interested in 
learning more about the study met with the study interviewer before or immediately after 
their regular clinic visit, at their next regularly scheduled clinic visit, or at a separate 
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appointment time selected by the patient. We employed a small purposeful study sample to 
collect in-depth narratives about barriers and facilitators to testing and care. The completion 
of data collection was guided by the achievement of theme saturation.151, 156  
 
Data Collection 
A single female study interviewer explained the study and obtained written, informed 
consent at the start of the interview. In-depth, face-to-face, semi-structured qualitative one-
on-one interviews were then conducted with study participants. All interviews were audio 
recorded and took place in a private and quiet interview room in the clinic. The average 
interview length was 43 minutes. Patients were compensated with a gift card to a local 
grocery retailer.  
An interview guide approach was used to conduct the interviews. With this approach, 
the interviewer uses the guide to address specific pre-determined issues, but is free to 
change the sequence and the wording in the course of the interview.151 Interviews are 
conversational in style but the interview guide format ensures that data collection is 
systematic and consistent throughout the study. We identified in-person, qualitative 
interviews as the most appropriate method for our research question because we sought to 
understand the process, meaning, and context within which HIV positive persons make 
decisions about health care.152  
Interview questions were comprised of three main types of questions based on the 
HBM and IMB model.29, 30 Main questions addressed the research themes and were broad in 
nature (e.g., “Tell me about your decision to get tested for HIV”). Follow-up questions and 
probes encouraged deeper, more detailed information (e.g., “Why did you decide to test?” 
“Did you think that you were at risk?” “Were there reasons you might have been 
reluctant?”).151 We assumed that most people would perceive HIV to be a severe disease so 
our interview instrument did not include questions about perceived severity. At the 
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completion of each interview, interview summaries were created by the interviewer to record 
the non-verbal attributes of the interview, first impressions of the data, and successes or 
suggested improvements for future interviews. 
 
Analysis 
All interviews were digitally recorded and transcribed verbatim. Analysis was ongoing and 
first involved single-case analysis, including the generation of memos and interview 
summaries, followed by cross-case analyses to identify emergent themes and patterns.152 A 
start list of deductive, descriptive codes were used to begin coding, however, coding was 
continuous and evolving.151, 152, 155 Interpretive, inductive codes were added to the code list 
as themes and patterns emerged from the data. Interviews were broadly coded for themes, 
examined for narrative structure, and compared to the conceptual framework. Segments of 
text were read for multiple dimensions, including the primary message content, attitudes, 
individual or group-level ideas, and the degree to which the ideas represent factual or 
hypothetical experience.151 Coding sorts were used to examine themes in more detail. Sub-
themes of each code were evaluated with particular emphasis on differences in the variation 
and context of narratives within the same code. Atlas/ti qualitative analysis software was 
used for analysis.153 
 
Human Subjects Protection 
All participants in the study provided written informed consent to participate in the interview 
and HIPAA authorization to provide access to medical information. This study was approved 
by the UNC Institutional Review Board.  
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RESULTS 
The study was conducted from April 2007 through April 2008. During this time, 89 
eligible patients had visits in the clinic, of which 41 of 46 (89%) approached about the study 
were interested in participation. Of these 41, 24 (59%) interviews were completed, one 
person refused, and the remaining 16 people could not be re-located or wanted to be 
interviewed at another time. Most (67%) patients presented to care with less than 200 CD4 
T-lymphocyte cells/mm3, and most initiated primary care quickly after diagnosis (Table 7.1). 
 
HIV-related information and experience 
Prior to diagnosis, HIV-related knowledge varied. Most participants reported understanding 
fundamental HIV concepts, including mode of transmission and clinical impact. The media 
was often cited as a source of information as well as experience with friends or family 
members living with HIV. However, there was a clear dichotomy of people who believed that 
an HIV diagnosis meant imminent illness and death and those who believed that HIV was a 
manageable illness. For example, one 43-year old female participant described her thoughts 
about HIV prior to diagnosis: 
“I thought if you catch HIV it was death, you know. You were gonna just deteriorate, lose 
weight, and die because there was like no cure and I never knew about a lot of medications 
and stuff that are helping people like me now. I just thought, like I said, you gonna 
deteriorate and die.” 
 
Similarly, a 41-year old male described his prior perceptions of HIV: 
 
“I thought if you’re HIV positive you walk around and you’re really skinny, your bones are 
showing, you’ve got sores all over you, your hair is falling out.” 
 
One participant stated that being infected with HIV meant that he was going to suffer. 
However, these views were not held by all participants. Several participants knew about 
advances in antiretroviral therapy, and knew that HIV was not generally a death sentence. 
Earvin “Magic” Johnson was cited several times as an example of how people living with 
HIV/AIDS could live long, productive lives. 
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More than half (71%) of participants knew someone with HIV prior to diagnosis. 
Despite having experience with people with HIV, many held stereotypes about the types of 
people affected by HIV. Often these stereotypes were supported by what they knew about 
their friends or relatives with HIV. For example, a 26-year old male explained why he did not 
perceive himself to be at risk for HIV: 
“I had been in a monogamous relationship and I honestly felt that the people that got it, the 
people that I knew who got it were into drugs. And I was like they’re doing things that are 
extremely risky, the needles, I mean the anonymous sex, and things like that. And it was 
one of those things, OK, so maybe they should have had an idea that that sort of thing 
would have existed for them. I definitely perceived it as oh gosh, kind of scary, you know, 
and definitely dangerous. I mean their lifestyle that they were leading.”  
 
Similarly, a 44-year old woman describes her perception of the people with HIV in her 
life: 
 
“I had a cousin who lived in California and he was gay. But he was pretty much a drag 
queen, but he was doing drugs, he was on the streets, but I don’t know how long he had it. 
… One particular time he came home and he said he was going to stay. And he said that he 
had AIDS. … And he still carried on like normal, I mean, he was very attractive, very well 
spoken but his lifestyle was just wild. … And then I had another friend, two friends that 
passed from it. They were very sexually active, had numerous partners, you know. I don’t 
know, I just never thought I would because I wasn’t, I was totally opposite of that.” 
 
Others held stereotypes about people with HIV that weren’t related to any personal 
experience with people living with the disease. These stereotypes tended to reflect 
perceptions of HIV being limited to the homosexual community. 
 
Perceived susceptibility 
The majority of participants did not perceive themselves as having been susceptible to HIV 
infection. The lack of perceived vulnerability could be broadly divided into three themes: 
people who did not recognize their behavior as risky, people who viewed their behavior as 
very low risk, and people who felt like exposure to HIV was unlikely, regardless of behavior. 
Among those who did not recognize any HIV risk, most felt as if HIV was not something that 
could happen to them. A 26-year old male described his shock at the diagnosis: 
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“It wasn’t something that had entered in my mind and I always knew that I could get in a car 
accident or things like that but I didn’t think that [HIV] was one of the possibilities, you 
know? That you could wind up with a disease. I just never really put any thought into that.” 
 
Another man described why he was shocked at being offered an HIV test:  
“I didn’t fit any of the, you know, I know I wasn’t using drugs, I didn’t sleep with men, and 
uh, I wasn’t sleeping around, you know.” 
 
For some people, even those who had begun to experience clinical symptoms, the 
possibility of HIV infection was not considered. A 35-year old male described his rationale 
about the onset of symptoms: “It never occurred to me. Actually at one point when I was so 
sick I thought maybe I have cancer. Never occurred to me the HIV, I was that in denial.” 
However, he went on to describe that despite not feeling at risk prior to diagnosis, he now 
acknowledges his risk behavior and recognizes that he should have been tested earlier:  
“I had tested once … and I was negative but soon there after I was having a lot of unsafe 
sex practices … It was one of those … Ignorance is bliss a little bit … In retrospect it was 
ridiculous that I didn’t go get tested. I could keep myself from a lot of, you know, illness 
there, the treatment. But, yeah, I think it was just easy to not think about it.” 
 
This description highlights the simultaneous and often contradictory accounts of how 
participants thought about testing prior to diagnosis.  
Several participants understood that they may have been engaging in risky behavior, 
but they felt as if their behavior wasn’t risky enough to expose them to HIV. When asked 
about how he’d thought about getting an HIV test before his diagnosis, one 33-year old male 
explained: 
“I knew that maybe along my life maybe I did a few slip-ups here and there but nothing that 
would lead me to HIV. I never had any STDs or venereal diseases so I was like there’s no 
way I have HIV or AIDS or anything like that.” 
 
Another 33-year old male felt his risk perception was clouded by substance abuse: 
 
“I knew that I knew I was taking some chances when I went out. Um, I experimented with 
the same sex but I didn’t consider myself to be in that same category if that makes any 
sense. And, …  in my addiction I got careless you know. You really don’t have any control 
over that drug. … Drugs’ll tell you anything and make you believe anything. Couple times it 
told me that I couldn’t get no STD.” 
 
Others felt that regardless of their personal acknowledgement of risk, HIV acquisition 
was a very unlikely event. One participant noted, “If you look at the numbers, it’s still a small 
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percentage of all the people, so I just never thought about it.” Another man noted, “The 
likelihood is just pretty slim. And in most cases it would be. It’s just that I fell on the side of 
uh, the bad statistic. It’s like the girl that has sex once and gets pregnant.” Another man, 
despite knowledge of HIV epidemiology in the Southeast, was still able to deny his 
susceptibility.  
“I pretty much knew to get tested and it affected African Americans a lot, especially in the 
male population. A lot of our women were suffering from it. Being in the homosexual 
community I knew that it was a big part. Get tested get tested. They promoted at clubs, they 
promoted at other venues. I knew that you needed to do it’s just I didn’t think it would come 
that close to home. I didn’t know anyone who had died from it within my circle.” 
 
These narratives indicate that most participants felt that their behavior did not place them at 
enough risk to warrant seeking testing, either because of beliefs about risk behavior or 
denial of the risks of their behaviors. 
 
Perceived benefits and barriers 
Perceived benefits and barriers comprise the decisional balance of taking action against a 
health threat. Participants were probed about their beliefs prior to diagnosis about the value 
of seeking VCT services (perceived benefits) and about the material or psychological costs 
(perceived barriers). We separated benefits from cues to action, which are antecedent 
events that motivated participants to take action. 
 
Benefits. Overall, few participants identified benefits of seeking an HIV test. Only three 
participants sought testing on their own, and all of them reported a cue to take action (the 
onset of symptoms or finding out a sexual partner was positive). In general, the facilitating 
factors to seek testing included being concerned about one’s health, wanting to take action 
in case one was positive, and being able to rule HIV out as a cause of illness.  
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Barriers. The lack of perceived susceptibility to HIV infection was the predominant barrier to 
testing. In addition to risk perception, participants listed numerous barriers to accessing VCT 
services. Fear and substance abuse were mentioned most frequently as reasons for not 
testing. One participant explained, “I think maybe I was scared. I think I was just scared to 
know or didn’t want to know or not that I thought I was but I just don’t know if I wanted to.” 
This sentiment was echoed by another who said, “In a way I felt like, you know, I ain’t got it 
so what’s the use of being tested? And then part of me was scared to find out, you know, if it 
was to come back positive.” Substance abuse was described as facilitating high-risk 
behavior as well as clouding one’s perception of risk. Both the presence and the absence of 
symptoms were described as barriers. Two participants reported feeling ill before their 
diagnosis, and not recognizing the symptoms as HIV-related. There were clearly missed 
opportunities for testing by both clients and their healthcare providers. While stigma was a 
predominant theme in the narratives about the trauma of discovering one’s HIV status, 
stigma was only mentioned explicitly by one person as a barrier to testing. However, 
patients expressed stigmatizing perceptions about the types of people affected by HIV, 
which was often related to an accurate personal perception of risk. 
 
Cues to take action 
All but one of the participants were eventually diagnosed because of an event that incited 
testing. The single participant that did not have a cue to action was diagnosed after donating 
blood in the mid-1980s. Overwhelmingly, participants were diagnosed after the onset of 
clinical symptoms, and the mechanism of diagnosis could be roughly grouped into three 
categories: contextual cues to action, cues to action that led to provider-initiated testing, and 
cues to action that led to client-initiated testing. 
 Several participants describe contextual situations where testing was directly offered. 
Their narratives do not suggest that testing was specifically recommended to the participant, 
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rather, they describe testing events or routine, structured testing. These situations included 
prison intake, a testing event at a residential substance abuse recovery program, and 
testing offered during clinical exams. Of the four patients with this mechanism of diagnosis, 
two were women. Participants reported being amenable to testing when it was readily 
available and free. One woman described being evaluated at the health department for a 
potential yeast infection: 
“There was a young lady that came in that also said they were doing free HIV testing. And 
as the years before then I know I’ve had friends and I’ve had family members that have 
passed from that disease. I kept saying over the years that I was going to get an HIV test. 
So they were doing free testing and that was the only reason why I took it.” 
 
This mechanism of diagnosis seemed particularly appropriate for individuals who did not 
perceive themselves to be at risk but wanted to be in control of their health. Although these 
participants indicated that they had thought about testing in the past, their narratives indicate 
that they did not have any immediate plans to seek testing before it was offered.  
 Most participants (58%) in the study were diagnosed because their provider initiated 
testing after the onset of symptoms. In some cases, HIV was a diagnosis of last resort, in 
others, HIV testing was recommended because of a clinically compatible presentation (e.g. 
Kaposi’s sarcoma) or the diagnosis of a sexually transmitted disease. Many patients relayed 
similar stories of constant illness or being hospitalized and undergoing an array of testing. 
This experience was typified by one participant: 
“I had been going through depression and things … I said well, I’m depressed. I’m going to 
the doctor and he ran test and ran test and said oh, there’s an issue, we need to look 
further. And then that’s where I got my HIV positive diagnosis was from one test led to 
another to another to another and it turned out that it was something that I personally never 
would have expected.” 
 
In addition to those tested because of symptoms, some were offered testing by a health 
care provider for reasons unrelated to the onset of symptoms. In these cases, the narratives 
suggest that participants believe that they were offered testing because the health care 
provider evaluated them to be at risk. One 51-year old gay man describes being offered 
testing after requiring stitches for a fall: 
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“I was getting all sewed up and I guess they were able to tell, I must had some outward 
appearance of something that it signaled to them you need to get tested because if they 
hadn’t said it I wouldn’t have acknowledged it for sure. And so they said “do you want to get 
tested?”” 
 
In these cases, the combination of an available and free test was sufficient to motivate 
acceptance of VCT. 
Few (n=3) participants sought testing on their own. Two participants suggested HIV 
testing to their provider after being admitted to the hospital for pneumonia-like symptoms. A 
48-year old woman recalled that during her hospital stay “It just came to my mind to be 
tested.” The third participant sought testing after finding out his ex-partner had recently died 
with HIV. 
 
Connecting to medical care 
Most patients were diagnosed due to symptomatic illness and consequently initiated medical 
care rapidly after diagnosis. However, some patients delayed medical care for 12 months or 
longer, and almost all participants reported having some fears or anxiety about initiating HIV 
care. Although the psychological impact of HIV was not the focus of this analysis, it was 
clear that the shock and devastation of diagnosis with advanced HIV had implications for 
connection to HIV specialty care with respect to deciding when and where to seek care. 
 Most patients were anxious to start care after diagnosis. The primary facilitator to 
enter care was avoidance of illness and death. In addition, many patients expressed wanting 
to take control of the situation and begin the journey toward health. When asked about any 
worries or fears about starting HIV care, a 26-year old man described his sense of urgency 
to schedule an appointment:  
“I felt like I was kind of on autopilot. Like it wasn’t one of those things where I think I’ll do 
this, no. It was, I have to do this. I have to make this phone call. I have to get this underway, 
I have to. You know, because I didn’t want to wind up sick.” 
 
Many patients learned at the time of diagnosis that they had an AIDS-defining condition, and 
this additional information added to their rush to take action. In addition to the avoidance of 
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illness, many participants experienced additional or continual symptoms after diagnosis 
which facilitated linkage to care. One patient entered care after a suicide attempt.  
 Patients listed several barriers to initiating medical care. While not a predominant 
barrier to VCT, stigma was often at the forefront of patient’s minds after diagnosis when 
considering attending an HIV clinic. Worries could be dichotomized into fears about being 
judged by healthcare professionals and fears about being recognized in the clinic. Patients 
reported not wanting to go through the ups and downs of care, and a handful expressed a 
willingness to die rather than deal with the medical system. One patient explained, “I wanted 
to die. I wanted to not go through this week you’re better, and next week you’re worse, and 
this week you’re better, and next week you’re worse. I didn’t want to go through that.” After 
diagnosis, five people reported feeling suicidal and of these, three made attempts. One man 
described the pain and depression of knowing that he may have infected someone else: 
“I was going through a lot of depression and sometimes I felt like I just wanted to blow my 
head off or I wanted to hang myself, you know, it made me feel like I hurt somebody … And 
I haven’t been with a woman since and this is 4 years. But, I don’t feel that I want to have a 
relationship with anybody else because I feel that if I do I’m taking somebody else’s life. I try 
to be, you know, calm and relaxed and I go through a lot of depression still now. And still to 
this day sometimes I just, I can’t handle it, you know. I feel so bad that I just, I want to take 
my life, and I wish there was some way easier to do this.” 
 
The desire to be remembered the way they were prior to getting sick was expressed by 
several patients. Transportation and financial concerns were rarely mentioned. Some 
patients reported challenges when being transferred from one doctor or institution to HIV 
specialty care. This phenomenon was described by one man as “passing the buck” and 
often patients felt isolated and frustrated about their healthcare provider’s lack of HIV 
knowledge. One patient described his experience being diagnosed by a rural doctor: 
“At that point he completely said ‘well, I have no idea what to do. I’m going to try and get 
you an appointment at the hospital, but you are very sick and you need help immediately.’ 
And that was absolutely terrifying to me.” 
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Another woman described her primary care physician, “He’s always like, ‘well, there ain’t 
nothing I can do for you…but give you a referral.’” However, in most cases the desire to 
avoid illness and death outweighed the barriers. 
 Three patients delayed care for more than one year after diagnosis. The first delayed 
13 months and his delay was related to being incarcerated at the time of diagnosis. He 
reported being assigned a case manager who would schedule his appointment but 
disappeared before the case management appointment happened. He subsequently did not 
enter care until he was hospitalized with pneumonia over a year later. Another patient 
delayed care 22 months after diagnosis. He reports being overwhelmed by his first visit and 
did not return for an additional eight months. He explains “They wanted to have more 
information about my body and how it works…and they were on top of me and it kind of 
made me scared. So when I went home I didn’t come back for a while.” The third patient 
was involved in a religious group after his diagnosis in the mid-1980s and did not enter care 
for over 20 years. Distrustful of western medicine, he reports avoiding any medical care that 
involved blood draws for fear of being “discovered” until he became ill in 2007. Together, 
these narratives suggest that the decision and process of engaging and maintaining care 
can be complex, and active referral may increase the chances of successful entry to care.  
The first clinical visit for HIV care was identified as a turning point in the coping 
process for some participants. Up until their first visit in the HIV outpatient clinic, many who 
were diagnosed by non-HIV specialty physicians felt abandoned, confused, and terrified 
about the impending medical care to come. Some attempted to research HIV, often online, 
and felt overwhelmed by the findings. It was not until they met with an HIV specialist that 
their fears were reduced. One 34-year old described his first meeting with his physician, “I 
was really scared, and I said, am I dying? …She looked at me and said, ‘Look. HIV is not a 
death sentence anymore if you take care of yourself.’ And that, I live by that now.” The 
importance of the first visit was echoed by a 26-year old man: 
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“I went in thinking that it was like a death sentence and I came out thinking, oh wow, my 
doctor rocks, you know? … To talk to someone who knew what they were talking about for 
a change. Someone that I understood and someone that knew all the treatments and knew 
exactly where I was and things like that. I mean I walked out ten times the person that I 
was, you know. I think I probably walked in looking at the floor and walked out looking at 
eye level.” 
 
For some, the first visit was the first time they felt in control since diagnosis. It was a time to 
allay some of the fears and haste they felt after learning how advanced their illness was. A 
43-year old woman describes her first HIV care visit: 
“When I first came up here, not knowing what a CD4 count or none of that is, when I come 
up here I find out my CD4 count, a normal person’s is supposed to be high. I found out mine 
is under 100, you know, and it’s like that’s a risk of AIDS right there already, and it was 
really scary. But then once I came in here and talked to her, [I] was a lot more relieved. It 
was a lot easier when I walked out the door.” 
 
According to participants, the important things learned at the first visit were 1) basics about 
HIV pathogenesis and immunologic monitoring, 2) that death wasn’t imminent and that they 
had time to carefully consider decisions about therapy, and 3) although antiretroviral therapy 
may have side effects for some people, HIV can be a manageable disease. During the 
period from diagnosis until entry to care, patients without this basic information may be 
paralyzed, suicidal, and isolated as they come to terms with HIV.  
 
DISCUSSION 
In the U.S. Southeast, a substantial proportion of people living with HIV are 
diagnosed or enter care late in the course of illness. In the hospital outpatient clinic where 
our study was conducted, 75% of all patients have an indication for antiretroviral therapy at 
their first clinic visit, and 50% have a CD4+ T-cell count less than 200 cells/mm3.12 Likewise, 
In Birmingham, Alabama, 41% of patients presenting to an HIV/AIDS outpatient clinic had 
progressed to CDC-defined AIDS.63 These findings and the knowledge of the unique HIV 
epidemic in the South raise special concerns about access to testing and medical services 
in the region.64  
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Our study examined barriers and facilitators to HIV testing and medical care among 
a group of HIV-positive patients in the southeastern U.S. who entered care with moderate to 
advanced immunosuppression. Our findings suggest that lack of perceived risk or lack of 
perceived susceptibility to HIV was the predominant barrier to early HIV testing. An accurate 
perception of HIV risk can act as a facilitator or barrier to HIV testing – either by increasing 
awareness and thus the likelihood of testing, or by increasing fear of testing positive.65-67 
Although our study was comprised of a small purposeful sample that cannot be used to 
make generalizations, the participants’ narratives suggest that among this group, risk 
perception is influenced less by personal behavior than perceptions about who is affected by 
HIV. Participants reported knowledge of HIV transmission and etiology, but inaccurate and 
often outdated stereotypes about people living with HIV interfered with accurate risk 
perception. Consequently, utilization of VCT services was not identified as a necessary 
component of comprehensive health care. Our findings suggest a role for health education 
and the media to portray a new, more accurate, representation of who is affected by HIV 
infection. 
The fact that public health messages to encourage HIV testing did not reach this 
group of individuals who were diagnosed recently, primarily in 2006 and 2007, is 
concerning. Southeastern residents live within a complex social and structural environment 
that may elevate their risk of HIV acquisition independent of personal behavior.39 Health and 
economic disparities are the underlying contextual framework for HIV transmission in the 
Southeast. High rates of sexually transmitted diseases increase the likelihood of HIV 
acquisition and transmission.37 The loss of African American men from their communities, 
either from excess mortality or incarceration, disrupts partnerships and promotes sexual 
concurrency.39, 178 Stigma, trust in providers, marriage rates, and injection and non-injection 
drug use are also associated with the epidemic.37, 38 These factors result in frequent 
heterosexual transmission and a non-urban epidemic.64 It is worrisome that public 
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awareness campaigns and routine contact with the healthcare system were ineffective in our 
study population, given the expanding HIV epidemic in the U.S. Southeast.  
 Predominantly, patients were tested and subsequently entered care due to the onset 
of clinical symptoms, consistent with other reports.7, 52, 62 This group of individuals missed 
the benefits of early medical care and some may have unknowingly transmitted to others. 
Our findings underscore the barrier that delayed diagnosis poses to HIV prevention efforts. 
Recent CDC testing guidelines for the adoption of routine testing in all healthcare settings 
may have an impact on reducing the numbers of individuals who first test positive late in the 
course of disease.49 From a public health perspective, even small changes in the proportion 
of persons living with HIV/AIDS who are aware of their serostatus can have large impacts in 
preventing new infections.179 In our study, most participants accepted testing when it was 
offered, suggesting that routine screening may increase the numbers of people tested and 
de-stigmatize the testing process. However, for the program to have impact, people living 
with unrecognized HIV infection must have contact with the healthcare system. Given that in 
the Southeast, HIV infection is often a disease of the rural and poor, new strategies to 
improve health care access will be a necessary precursor for any increased screening to 
reach the groups most at need. 
 Most patients felt an urgency to enter care after diagnosis, but also encountered 
multiple barriers and sources of frustration during this process. For some, the inability of 
their diagnosing health care provider to educate them about HIV or provide care for them left 
them feeling deserted. Participants were surprised that, after passive referral to an HIV care 
provider, no one contacted them to ensure that they successfully connected to care. As HIV 
screening becomes increasingly incorporated in non-traditional testing settings, specialized 
programs to rapidly and effectively link patients to care could bridge the gap between HIV 
diagnosis and primary care, and allay patient concerns during this unsettling time.128 For 
patients diagnosed late in illness, they must come to terms not only with the realization that 
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they are living with HIV, but also with the additional knowledge that they may have been 
infected for several years and are now facing an immediate health threat. At least 20% of 
participants in this study considered or attempted suicide after diagnosis. In this setting, 
active referral with follow-up should become the optimal standard of care. In addition, we 
have revealed an opportunity for physician education, as the approach to breaking bad 
news may have implications for coping with HIV after diagnosis.180, 181 
 Fortunately, the issue of late diagnosis and delayed presentation to care is receiving 
increased attention among public health and medical professionals. As evidenced by this 
study, a rote or passive approach to increasing HIV testing and the subsequent linkage to 
care may miss segments of the population, some of whom are at high risk. A reliance on 
personal awareness of risk to initiate testing did not work for this group of people who 
entered care with moderate to advanced immunosuppression. Many felt disillusioned after 
diagnosis as they encountered difficulties when trying to navigate the health care system. 
Focusing research efforts toward these issues may help to avert late diagnosis and delayed 
entry to care in the future.  
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FIGURE 7.1. Conceptual Framework of HIV Testing Utilization 
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TABLE 7.1. Descriptive characteristics of 24 HIV positive patients initiating HIV primary care 
between April 2006 and April 2008 at the University of North Carolina outpatient infectious 
disease clinic. 
 
Characteristic N (%) 
 
Year of Diagnosis 
1985 
2005 
2006 
2007 
 
 
1 
2 
15 
6
 
 
(4.2) 
(8.3) 
(62.5) 
(25.0) 
 
Gender 
Male 
Female 
 
 
19 
5
 
 
(79.2) 
(20.8) 
 
Race 
African American 
Hispanic 
White 
 
 
12 
1 
11
 
 
(50.0) 
(4.2) 
(45.8) 
Age1 42.5 years (26-62) 
CD4+ T-cell count at entry to care (cells/mm3)1 92 (17-332) 
Time between diagnosis and entry to care (days)1 40.5 (0- 22.7 years) 
 
HIV testing method 
Provider-initiated  
Client-initiated  
Contextual (e.g., blood donation, prison) 
 
 
16 
3 
5 
(66.7) 
(12.5) 
(20.8) 
 
 
1.  Median (range) 
 
 
 
 CHAPTER 8: DISCUSSION 
 
 
More than twenty-five years after the first reports of Pneumocystis carinii pneumonia 
among young men heralded the beginning of the HIV/AIDS pandemic, 33 million people live 
with HIV and two and a half million people were infected in 2007 alone.182 In North Carolina, 
home to two of the most prestigious HIV research institutions in the world, the story of HIV is 
one of poverty and disparity. Twenty-three percent of the state’s rural residents live in 
poverty, providing a backdrop of poor access to health care and competing health and 
economic priorities which facilitate HIV transmission.183, 184 The rate of HIV infection for non-
Hispanic blacks is more than eight times greater than for non-Hispanic whites, and North 
Carolina ranks second among states with the most AIDS cases from non-metropolitan 
areas.162 After a period of stability in the late 1990s and early 2000s, annual HIV disease 
reports have been rising since 2004.162 It is increasingly clear that routine HIV screening, in 
isolation, cannot slow HIV transmission. A comprehensive approach to VCT, risk-reduction, 
linkage to and retention in medical care, and adherence to antiretroviral therapy will be 
needed to have significant impact on the domestic epidemic.  
  
Summary of Findings 
 
In this dissertation, we described several findings which help to explain the HIV epidemic in 
the Southeast as well as highlight areas for additional public health intervention. In our first 
specific aim, we found that nearly one third of patients had another sexually transmitted 
infection at the time of the acute HIV diagnosis. This finding means that STIs are commonly
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involved in HIV transmission in NC, either by increasing the risk of HIV acquisition or 
transmission, and also underscores the importance of routine screening for HIV among 
people with STIs. The variation we observed in HIV/STI co-infection by gender, risk 
category, and race helps to explain the epidemiology of the HIV epidemic in the 
southeastern U.S. where racial disparities are remarkable and heterosexual transmission is 
nearly as prominent as homosexual transmission.33, 162 The high prevalence of STIs in 
women with incident HIV is troubling, and partially explains the increasing HIV rate in Black 
women since 2004.185 
In our second specific aim, we found that structural and functional social support was 
not strongly associated with delayed presentation to care, leaving us with several important 
questions. First, it is unclear if the surprisingly high levels of social support we observed 
were associated with HIV care. It is probable that once in care, newly diagnosed patients 
have access to support services and resources which change their levels of perceived social 
support. Our cross-sectional data were limited in that we could not examine changes in 
social support over time. Second, it is interesting that patients reported high levels of 
affectionate, emotional/informational, and tangible support, while levels of positive social 
interaction were lower. It is unclear what, if any, role positive social interaction plays in HIV-
related health services utilization. In addition, narratives from patients in the UNC ID clinic 
repeatedly cited social support as critical to the maintenance of care and adherence to 
medications (data not shown). While we found that there was little effect on the time to 
presentation to care, these data suggest that social support may be important for 
maintenance of care and adherence to therapy.  
Our third specific aim focused on barriers and facilitators to care among people who 
presented to care with moderate to advanced immunosuppression. We found that the 
primary barrier to early detection of HIV was that most patients perceived themselves to be 
at low risk for HIV infection – a perception enforced by stereotypes about who is affected by 
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HIV. In addition, the patient narratives indicate that the referral to care process was often 
frustrating, particularly while trying to cope with coming to terms with HIV. The first visit to an 
HIV care provider was identified as a critical time point in the coping process for HIV. While 
the analyses presented in this dissertation have described barriers to testing and care, 
future analyses on these data will focus on the trauma of discovering one’s HIV positive 
status as well as on stigma and disclosure in the Southeast.  
Together, these three studies have added to our understanding of the HIV epidemic 
in the Southeast. Our findings directly relate to the basic tenets of HIV transmission – 
biology and behavior. We found that STIs are an important biological factor in HIV 
transmission in the region. In contrast, inadequate health care access, utilization, and 
inaccurate perception of risk are important behavioral issues, shaped by underlying health 
and economic inequities. The biggest challenge for public health practitioners will be how to 
effectively influence biology and behavior within the complex social and economic context of 
the Southeast.  
 
 
Public Health Significance 
HIV testing is a critical point in the continuum of HIV care. It is the initial step toward 
accessing and maintaining HIV care, which has individual clinical benefit as well as public 
health benefit through risk-reduction counseling and the potential for reduced transmissibility 
via antiretroviral therapy.61 Persons who are aware of their serostatus tend to reduce their 
risk behavior and have lower onward transmission rates than persons unaware of their 
status.2, 41, 58, 59, 61, 186 Increasing testing and encouraging earlier detection of HIV without 
stigmatizing high-risk groups is one objective of the routine HIV screening recommendations 
issued by the CDC in 2006.49 
Our findings suggest that the adoption of routine HIV screening recommendations in 
healthcare settings may have an effect on earlier detection of HIV. The streamlined, opt-out 
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approach to testing without the requirements of a separate consent or prevention counseling 
may eliminate an important barrier to HIV testing – an accurate perception of HIV risk. Our 
qualitative data suggest that provider initiated testing was the predominant mechanism of 
diagnosis among patients who presented with moderate to advanced immunosuppression. 
When suggested by their healthcare provider, most of the patients in our study were 
amenable to testing, even those who perceived themselves to be at little to no HIV risk. The 
removal of risk-based testing criteria may de-stigmatize the risk perception and HIV testing 
process, resulting in fewer missed opportunities, increased screening, and more client 
acceptance.  
However, three important issues remain unaddressed by the CDC HIV testing 
guidelines. The first is access to medical care. The value of increased screening in all 
healthcare settings is based on the premise of contact with the health system, which will be 
limited for the uninsured and those living in medically underserved communities. The U.S. 
South has the highest proportion of people living in poverty (13.8%) and the highest 
proportion of people uninsured (19%).187 As a result, emergency departments (ED) serve as 
the healthcare safety net and provide care to many uninsured patients. EDs are a setting 
where time constraints may significantly oppose HIV screening efforts, although 
demonstration projects have indicated that ED-based screening is feasible, even using a 
voluntary opt-in approach.188 Further data are needed to describe successful routine testing 
programs at EDs and other non-traditional testing sites to reach those without regular health 
care providers. Similarly, the financial concerns of newly diagnosed patients need to be 
addressed as early as possible after diagnosis to allay economic concerns and encourage 
entry and retention in care. 
The second issue is prompt linkage to care after diagnosis. While the screening 
guidelines note that newly diagnosed patients “should receive or be referred for clinical care 
promptly,” recommendations on how best to execute this recommendation are scant. 
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Currently, in North Carolina, most newly-diagnosed patients are passively referred to HIV 
primary care by their diagnosing physician, post-test counselor, or DIS officer in the field. Is 
this system working? Our data suggest a need for improvement – 31% of patients 
participating in the CSDS survey in the UNC outpatient clinic were not in care two years 
after diagnosis and in 2005, approximately 7,000 North Carolina residents living with HIV 
who were aware of their status were not in care.189 Our qualitative data, with the significant 
limitation that all of the participants were in care at the time of the interview, provides 
evidence that passive referral to care can be ineffective and add to patient anxiety about 
wanting to take action. The patients we interviewed were motivated to enter care quickly and 
most did so, but one could speculate that the barriers they experienced may be significantly 
worse for other unobserved patients who remain unconnected with the healthcare system 
for years after diagnosis.  
With respect to onward transmission, a recent analysis of patients with AHI in North 
Carolina found that 28% of named partners with established HIV did not have a current care 
provider.190 Further, only three acute-acute transmission partnerships were identified, 
suggesting that HIV transmission in the southeastern U.S. may be driven by chronically-
infected persons, as opposed to the importance of acute to acute HIV transmission 
postulated in urban areas.94, 190 Ensuring that people with established HIV infection receive 
HIV care, periodic prevention counseling, and antiretroviral therapy, when indicated, needs 
further attention from policymakers. 
Finally, how much will routine screening cost? With the opt-out testing strategy 
without pretest counseling and an initial rapid test followed by a confirmatory Western blot, 
the cost per seropositive patient is US$97 and US$13 for seronegative patients.191 The cost 
for testing the approximate 166 million people not already being tested for HIV would be 
roughly 2.2 billion US dollars.191 In addition, once identified and in care, HIV positive patients 
on antiretroviral therapy incur approximately US$14,000 annually in prescription drug costs 
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alone.191 In 2007, although AIDS Drug Assistance Program state waiting lists have been 
nearly eliminated and client enrollment increased, state budget shortfalls and declining 
federal funding threaten future funding needs – for some of the most vulnerable individuals 
with HIV/AIDS.192 While HIV screening is cost-effective even in low prevalence settings, the 
financial impact of testing, diagnosis, and care of the nearly 250,000 people unaware of their 
HIV positive status is unknown.49, 193   
 
Future Directions 
An ideal study design to evaluate questions about HIV testing and care utilization would 
follow a defined population prospectively to identify causal factors associated with HIV 
testing. Newly diagnosed individuals would be followed to determine how and when they 
access HIV care. Of course, this idealized study design is infeasible because of the 
intensive resources required to follow a population over time and the rarity of the outcome. 
Further, it may produce biased results due to the Hawthorne effect. In the absence of this 
“optimal” design, we must make inferences to improve public health practice based on 
information at the point of care (e.g. VCT sites, HIV outpatient care). 
 An important surveillance project is already in the planning stages in North Carolina 
that will elucidate questions about when people test for HIV. Beginning in late 2008, people 
with a new HIV diagnosis in NC will be offered a free CD4 count on their initial testing 
specimen. These data will help to answer some important questions about the epidemiology 
of HIV in NC, such as the degree of immunosuppression at diagnosis overall and within 
strata of race, gender, and age. These data will also help to identify geographic areas and 
testing locations where people are diagnosed, on average, earlier or later than a specified 
referent group. A secondary goal of the study is to determine what proportion of newly 
diagnosed people have entered care within specified time intervals, using minimally 
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invasive, brief telephone questionnaires that will hopefully minimize any Hawthorne Effect 
biases.   
In this dissertation, an important finding was the challenges many newly diagnosed 
HIV positive persons face when initiating HIV primary care. As discussed in Chapter Seven, 
patients often felt isolated and deserted by their diagnosing healthcare provider when they 
received a passive referral to HIV specialty care. To further investigate this problem in a 
quantitative design, one could conduct a case-control study of patients initiating HIV primary 
care to compare people who rapidly initiated care to those who delayed care. It would be 
important to investigate factors such as where and how the diagnosis was made and how 
the patient eventually established care. Most research to date indicates that financial 
considerations and transportation only partially explain delays between diagnosis and care. 
 On a national level, the Medical Monitoring Project is an ongoing CDC-sponsored 
patient survey designed to answer questions about health service utilization among people 
living with HIV. Including data from 19 states and Puerto Rico, the survey is designed to 
describe how many people with HIV are receiving care, barriers to care and prevention 
services, and what needs of people living with HIV are not being met. North Carolina is one 
of the study sites, so we look forward to learning more about the findings of the Medical 
Monitoring Project to inform HIV care and policy in NC. 
 
Conclusions 
As routine HIV screening is adopted in all healthcare settings, accurate surveillance and 
monitoring of programmatic results will be paramount to evaluation of the program’s 
success. We envision several key outcomes. First, who is tested – and who is not tested – 
will quantify areas where additional implementation guidance, funds, or training are needed 
as well as groups who may be more inclined to opt-out of screening. Second, the numbers 
of newly diagnosed persons with HIV who are successfully linked to care will provide an 
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idea of how well routine screening can improve patient outcomes. Patients aware of their 
serostatus who do not enter HIV care may reduce onward transmission without individual 
clinical benefit. In addition, newly diagnosed patients identified as part of routine health 
screening may be particularly vulnerable to prolonged periods without care, especially if they 
did not perceive HIV risk at the time of testing. Finally, the implementation of routine 
screening requires a parallel effort of operations research to determine the combination of 
test type, staffing, and process which optimizes the logistical and financial feasibility of the 
program. Monitoring these outcomes will be essential to evaluating the long-term ability of 
routine screening to have impact on HIV transmission.  
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 APPENDIX A. Results for Specific Aim 1B  
 
 
INTRODUCTION  
In specific aim 1b, we sought to evaluate variation in the time from HIV acquisition to 
testing among individuals with acute HIV infection by the presence of a STI at the time of 
HIV testing and the testing site type. We hypothesized that persons diagnosed with acute 
HIV and a concurrent STI would be diagnosed earlier than those without a concurrent STI 
because of the short incubation periods of many bacterial STIs. We also hypothesized that 
persons diagnosed with acute HIV at STD testing sites are diagnosed earlier than those 
diagnosed at non-STD testing site types because of the routine HIV testing that is 
conducted among STD clinic clients. 
 
METHODS 
The study population, coding of covariates, and a detailed description of the methods 
for this specific aim is described in detail in Chapter Four. In brief, the outcome for this 
analysis was the time from HIV infection to HIV testing. The date of HIV acquisition was 
estimated using the dates of symptom onset and seroconversion reported by DIS. For 
individuals with symptoms consistent with acute retroviral syndrome, the date of HIV 
infection was calculated as 14 days prior to the date of symptom onset.134-136 For individuals 
without symptoms, we utilized an average plausible seroconversion interval of 35.5 days 
with a two week window on either side (21.5 to 49.5 days, see Table 4.1).  
 The main exposures for the analysis were testing site type and the presence of an 
STI co-infection at the time of acute HIV detection. A proportional hazards model was used 
to examine variation in the time from HIV acquisition to HIV testing by STI co-infection and 
testing site type. We evaluated all exposures and covariates for the assumption of 
proportional hazards and then evaluated all covariates for effect measure modification 
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and/or confounding of testing site type or co-infection in bivariable models. We then 
constructed a single, fully adjusted model with both main exposures and all relevant 
interaction terms and confounders. We did not evaluate the presence of acute retroviral 
symptoms in the model as this variable is in the causal pathway. Patients not tested after 35 
days were censored in all proportional hazards models.  
 
RESULTS 
Of the 75 patients with acute HIV infection from November 2002 through October 
2006, dates of seroconversion were available on 72 (96%). Fifty-four (75%) patients 
reported symptoms consistent with acute retroviral syndrome with a median time from 
infection to testing of 20.5 days. Of the 18 (25%) patients without symptoms, the median 
time to testing was 28.5 days (range: 14.5 to 42.5).  
The effect of testing site type on the time to testing differed by age, so all unadjusted 
testing site type results are presented stratified by age (Table A.1). People ≤30 years who 
were tested at CTS sites were tested the earliest after infection at 16.5 days. The longest 
times to testing were observed for individuals over 30 at CTS sites and individuals ≤30 at 
other types of clinics (30 days). The median time from infection to testing did not differ by the 
presence of an STI co-infection (22.5 days vs. 23.0 days, p=.33). 
The final multivariable model included testing site type, STI co-infection, gender, risk 
behavior (heterosexual man, MSM, female), and age. In the adjusted model, there was 
variation in the effect of testing site type on the time to testing by age. The hazard of being 
tested among patients ≤30 years at CTS sites was more than six times the hazard of those 
>30 at CTS sites (HR: 6.81, 95% CI: 2.10, 22.07). Similarly, patients of all ages tested at 
STD sites were more likely to be tested earlier than those >30 years who attended CTS 
sites. Patients >30 at other types of testing sites were more likely to be tested earlier than 
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those who attended CTS sites (HR: 1.70, 95% CI: 0.55, 5.24).  The presence of an STI co-
infection did not have an effect on the time to HIV testing. 
  
DISCUSSION 
Counter to our hypothesis, the presence of a concurrent STI infection at the time of HIV 
infection was not associated with shorter times between infection and testing. Due to the 
short incubation periods of many STIs, we expected that people with HIV and STI co-
infections would seek care earlier than those without co-infections, as they have a biological 
“cue” to seek testing. The lack of difference that we describe could be due to asymptomatic, 
unobserved STIs, or because the incubation periods of some STIs may be longer than 
average in an HIV infected host. Another feasible explanation is that our estimate of the date 
of infection is inaccurate, either by under- or over-estimating the time between HIV 
acquisition and seroconversion. Finally, our results could indicate that there is no effect of 
concurrent STIs on HIV testing behavior, although this is unlikely given the HIV testing 
recommendation for all people seeking care for STIs.49 
 The time from infection to testing varied by the type of HIV testing facility and age. 
Clients ≤30 at CTS sites had the shortest time from infection to testing. This finding could be 
explained by the risk perception of the clients at CTS sites. CTS sites may attract a more 
risk-aware clientele, which is a key factor associated with testing. 66, 67 In this case, anxiety 
over the risk of exposure may be a key factor that drives HIV testing shortly after infection. 
Similary, STD clinic clientele are routinely tested for HIV, which may account for the 
elevated hazards of testing we observe for this group.  
 The data presented in this analysis suggest that there is variation in the testing site 
where people who were recently infected with HIV seek VCT. Further research, including a 
study to elucidate reasons for testing during acute HIV, will help to explain testing behavior 
during this highly infectious time.  
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TABLE A.1. Unadjusted and adjusted hazard ratios (HR) comparing the estimated time from HIV acquisition to HIV testing by testing 
location and the presence of an STI co-infection at diagnosis among patients with acute HIV infection in North Carolina.  
 
Characteristic Median time to testing (days)1 p-value
2 Unadjusted HR  (95% CI) 
Adjusted HR3  
(95% CI) 
 
Testing Location and age 
 
HIV Counseling and Testing 
≤30 
>30 
 
STI Clinic 
≤30 
>30 
 
Other type of clinic 
≤30 
>30 
 
 
 
 
16.5  
30.0 
 
 
23.8 
21.5 
 
 
30.0 
23.0 
 
 
 
 
 
 
 
<0.01 
 
 
 
 
5.70 (1.87, 17.35) 
Referent 
 
 
1.98 (0.74, 5.31) 
3.00 (1.05, 8.63) 
 
 
1.04 (0.33, 3.29) 
1.63 (0.53, 4.98) 
 
 
 
 
6.81 (2.10, 22.07) 
Referent 
 
 
2.55 (0.89, 7.29) 
3.12 (1.05, 9.33) 
 
 
1.00 (0.31, 3.18) 
1.70 (0.55, 5.24) 
 
STI co-infection at diagnosis 
Yes 
No 
 
 
22.5 
23.0 
 
 
0.33 
 
 
1.32 (0.76, 2.27) 
Referent 
 
 
0.91 (0.49, 1.70) 
Referent 
 
1.  The date of infection was assumed to be 14 days prior to ARS symptom onset (symptomatic patients) or 35.5 days prior to the date of 
seroconversion (asymptomatic patients).  
 
2.  Log-rank test for equality of the survival curves. 
 
3.  Adjusted for gender, risk behavior and age. An interaction was found between testing location and age in the multivariable model, so the 
unadjusted results are presented stratified by age to facilitate comparison.  
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 APPENDIX B. Results of Linear Regression Model of log10(HIV RNA) Change 
 
 
TABLE B.1 Univariate linear regression models of serum HIV RNA (log10copies/ml) slope 
and selected demographic factors among 44 patients with acute HIV in NC.1 
Linear Regression 
Outcome: Difference in  
log10HIV RNA2 Characteristic 
Parameter Estimate P-value 
Gender and risk behavior 
Man who has sex with men 
Heterosexual man 
Female 
 
0.01 (-1.18, 1.20) 
0.23 (-1.19, 1.64) 
Referent 
0.94 
Age (years) 
≤ 25 
26-35  
≥36  
 
0.66 (-1.89, 0.48) 
0.03 (-1.41, 1.47) 
Referent 
0.46 
Race or ethnic background 
White, non-Hispanic 
White, Hispanic or Black 
 
Referent 
0.66 (-1.93, 0.18) 
 
 
0.27 
Testing Location 
HIV Counseling and Testing site 
STD Clinic 
Other type of clinic 
 
Referent 
-1.33 (-2.53, -0.13) 
-1.42 (-2.73, -0.11) 
 
0.06 
STI co-infection at diagnosis 
Yes  
No 
 
0.13 (-0.97, 1.22) 
Referent 
0.15 
Symptoms of acute retroviral syndrome at 
or before testing 
Yes  
No 
 
 
0.60 (-0.43, 1.63) 
Referent 
 
0.24 
 
1. Forty-four clients with AHI had both initial and confirmatory values available for analysis. 
Seventeen (38.6%) had increasing viral loads between the initial and confirmatory samples. 
 
2.  Positive parameter estimates indicate increasing HIV RNA slopes. 
 
 APPENDIX C. Results of Validation Sub-Study 
 
 
INTRODUCTION  
The date of HIV diagnosis is a critical measurement for many epidemiologic studies 
of health care access, quality of care, and clinical outcomes. However, measurement of the 
date of diagnosis can vary substantially. Some investigators rely on self-report, whereas 
other investigators use a confirmed laboratory testing date. Little is known about how 
different measures of HIV diagnosis date differ. The goal of this analysis was to compare the 
self-reported date of diagnosis to the date recorded in the UNC medical record and the date 
reported to the NC HIV/AIDS Reporting System (HARS) through routine name-based 
morbidity surveillance. 
 
METHODS 
Measurement of Self-Reported Date of HIV Diagnosis 
The study population was comprised of HIV positive patients who provided written informed 
consent to participate in the CSDS Survey. Consent to participate in the CSDS includes 
authorization to acquire medical information from the UNC medical record as well as other 
providers and facilities, including state health department records. The self-reported date of 
diagnosis was the answer to the question “When were you first told that you were HIV-
positive?” In the first version of the CSDS, patients were asked to identify the year of 
diagnosis. In subsequent versions of the questionnaire, patients were asked to identify the 
full date (month, day, year) of diagnosis. Due to this inconsistency, we will present the 
analysis by year of diagnosis only. 
 
Measurement HIV Diagnosis Date in the UNC Medical Record 
The date of diagnosis in the medical record was obtained by medical record abstraction by 
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trained personnel and was defined as the date of Western Blot confirmation or the first 
provider report of HIV. In cases where only the year was known, the date was considered to 
be the midpoint of the year (June 15th). Likewise, missing days were coded as 15 and 
missing months were coded as June. 
 
Measurement HIV Diagnosis Date in the NC HIV/AIDS Reporting System 
To obtain the earliest date of diagnosis in the HARS reporting system, patients who 
completed the CSDS were matched to HARS using a 4-step algorithm. First, patients were 
matched deterministically using the first four letters of the last name, first three letters of the 
first name, month and year of birth, and sex. In the second stage, single matches are 
removed and the remaining non-matched subjects were matched deterministically by social 
security number, if available. The remaining non-matched subjects were then manually 
matched by record lookup using an inexact matching algorithm and rotating the first name, 
last name, date of birth, and sex though the lookup system to identify changed names, 
gender errors, etc. Finally, multiple matches for a single patient were investigated and 
resolved and all matches were manually reviewed for error.  
 
Statistical Analysis 
We compared the self-reported year of diagnosis with earliest date reported in the UNC 
medical record or the HARS system. Data management and analysis was conducted with 
SAS software (version 9.1.2, Cary, North Carolina).  
 
RESULTS 
Since July 2000, 332 patients completed the CSDS interview and were eligible for the study. 
All but four reported a year of diagnosis (98.8%). Of the 328 with a self-reported date of 
diagnosis, 273 (83.2%) had been reported to the HARS system and 316 (96.3%) had a 
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diagnosis date in the UNC medical record. Overall, 322 (98.2%) matched to at least one 
system.  
 
Comparison of Medical Record and HARS Dates of Diagnosis 
In most cases (75.2%), the UNC medical record date of diagnosis was earlier than the date 
reported to the HARS system. For the 268 participants that had both the UNC medical 
record date and the HARS date available, the absolute difference between the two dates 
was on average 23.6 months, standard deviation 42.1 months (median difference 2.5 
months). Comparing year only, 166 (61.9%) had the same year of diagnosis. An additional 
32 (11.9%) were only discrepant by one year, and 70 cases (26.1%) were discrepant by two 
or more years (range: 2-16).  
 
Comparison of Self-Reported Date to HARS or UNC Medical Record 
We compared the earliest of the UNC medical record or HARS date to the self-reported date 
of diagnosis. Overall, 200 of the 322 participants (62.1%) with a self-reported date and 
either a UNC or HARS date reported concordant years of diagnosis. An additional 61 
(18.9%) were only discrepant by one year. The mean difference was 1.1 years. Sixty-one 
(18.9%) participants reported years of diagnosis two or more years different than that in the 
HARS or UNC system (range: 2-14). Of the 122 patients with non-matching years, 63 
(51.6%) reported years of diagnosis that were earlier than either the UNC or HARS system 
and 59 (48.4%) reported years that were later than the UNC or HARS system. Of the 265 
participants that had a self reported, HARS, and UNC medical record year of diagnosis, only 
45% of the time did all three years match. 
  
DISCUSSION 
In this study, we found variation in the year of diagnosis reported by patients, abstracted 
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from their medical record, and reported to the NC Department of Health and Human 
Services. While we did not have access to the true diagnosis date, our study should 
encourage other investigators to identify and describe the sources of bias that influence the 
date of diagnosis source used in their research endeavors.  
While name-based reporting of HIV has been mandated in North Carolina since 1990 
and AIDS reporting has been required since 1984, only 83% of cases had been reported to 
the state.162 As the source for the most comprehensive data on patterns of new diagnoses, 
morbidity reporting is essential for effective targeting of health resources. In addition to 
epidemiologic monitoring of the epidemic, HIV/AIDS reporting is used for Ryan White 
funding distribution to pay for medical care and treatment of un- and underinsured people 
living with HIV/AIDS. It is concerning that nearly 20% of patients were not located in the 
HARS system, despite all having received HIV primary care and all of them reporting that 
they were diagnosed in 2004 or earlier. In three-quarters of the cases that were reported to 
the HARS system, the year of diagnosis in the medical record was earlier than the year 
reported to the HIV/AIDS Reporting System, highlighting a disconnect between patient 
records and morbidity reporting. With the data available to us at the time of the analysis, it 
was impossible to know what the true date of diagnosis was for direct comparison. 
The self-reported year of diagnosis matched the earliest documented year of 
diagnosis in 62% of cases, and matched within a year in 81% of cases. This concordance is 
better than expected. Roughly 20% of participants reported a year of diagnosis that was 
earlier than either the UNC or HARS system. This is less than the 30% of people who 
reported earlier dates of diagnosis compared to a national analysis of 16 states in the HARS 
system.194 While this indicates that NC may be doing better than the national average, there 
is still room for improvement.  
Many epidemiologic studies of linkage to primary HIV care after diagnosis and health 
care outcomes after care and treatment initiation use the date of diagnosis as “time zero” for 
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HIV-related events. Our analysis has demonstrated that there is variation in each of these 
measurements. As a result, investigators should make efforts to identify the sources of bias 
for each measurement and when applicable, conduct sensitivity analyses to determine the 
impact of these biases on their results.  
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